



(86) Date de dépôt PCT/PCT Filing Date: 2015/11/05  
 (87) Date publication PCT/PCT Publication Date: 2016/05/12  
 (85) Entrée phase nationale/National Entry: 2017/05/02  
 (86) N° demande PCT/PCT Application No.: EP 2015/075800  
 (87) N° publication PCT/PCT Publication No.: 2016/071438  
 (30) Priorité/Priority: 2014/11/05 (EP14191959.7)

(51) Cl.Int./Int.Cl. *C12N 15/82* (2006.01),  
*A01H 5/00* (2006.01), *C07K 16/14* (2006.01)

(71) Demandeur/Applicant:  
AGROSAVFE NV, BE

(72) Inventeurs/Inventors:  
VERHEESEN, PETER, BE;  
GEERINCK, JAN, BE;  
VELOSO VIEIRA, JOAO FILIPE, GB;  
PEFEROEN, MARNIX, BE;  
VAN DAELE, INGE ELODIE, BE

(74) Agent: SMART & BIGGAR

(54) Titre : PLANTE TRANSGENIQUE COMPRENANT UN POLYNUCLEOTIDE CODANT UN DOMAINE VARIABLE D'ANTICORPS A CHAINE LOURDE

(54) Title: TRANSGENIC PLANT COMPRISING A POLYNUCLEOTIDE ENCODING A VARIABLE DOMAIN OF HEAVY-CHAIN ANTIBODY

(57) **Abrégé/Abstract:**

The present invention relates to a transgenic plant or plant tissue. In particular, the present invention relates to a transgenic plant or plant tissue or plant cell comprising at least one polynucleotide comprising at least one sequence encoding a variable domain of a heavy-chain antibody (VHH) specifically binding to a sphingolipid of a fungus. Advantageously, the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell (i) protects at least part of the transgenic plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, (ii) inhibits the growth of a plant pathogenic fungus on at least part of the transgenic plant or plant tissue or plant cell, or (iii) increases the resistance of at least part of the transgenic plant or plant tissue or plant cell against a plant pathogenic fungus. The present invention also relates to a method for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide encoding a VHH specifically binding to a pathogen.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau(43) International Publication Date  
12 May 2016 (12.05.2016)(10) International Publication Number  
**WO 2016/071438 A3**

## (51) International Patent Classification:

C12N 15/82 (2006.01) A01H 5/00 (2006.01)  
C07K 16/14 (2006.01)

## (21) International Application Number:

PCT/EP2015/075800

## (22) International Filing Date:

5 November 2015 (05.11.2015)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

14191959.7 5 November 2014 (05.11.2014) EP

(71) Applicant: AGROSAVFE NV [BE/BE]; Technologiepark  
4, B-9052 Gent (BE).(72) Inventors: VERHEESEN, Peter; Julienne De Vetterstraat  
19, B-9030 Mariakerke (BE). GEERINCK, Jan; Zonnes-  
straat 75, B-9100 Nieuwkerken-Waas (BE). VELOSO VIE-  
IRA, João Filipe; 12 Greenfinch road, Didcot Oxfordshire  
OX116BG (GB). PEFEROEN, Marnix; Stekelbeekstraat  
20/2A, B-9881 Bellem (BE). VAN DAELE, Inge Elodie;  
Gontrode Heirweg 171, B-9090 Melle (BE).(74) Agents: BOUNAGA, Sakina et al.; De Clercq & Partners,  
E. Gevaertdreef 10a, B-9830 Sint-Martens-Latem (BE).(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,  
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,  
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,  
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,  
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,  
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,  
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,  
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,  
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, KM, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

## Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))

— with sequence listing part of description (Rule 5.2(a))

## (88) Date of publication of the international search report:

23 June 2016

(54) Title: TRANSGENIC PLANT COMPRISING A POLYNUCLEOTIDE ENCODING A VARIABLE DOMAIN OF HEAVY-  
CHAIN ANTIBODY

(57) Abstract: The present invention relates to a transgenic plant or plant tissue. In particular, the present invention relates to a transgenic plant or plant tissue or plant cell comprising at least one polynucleotide comprising at least one sequence encoding a variable domain of a heavy-chain antibody (VHH) specifically binding to a sphingolipid of a fungus. Advantageously, the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell (i) protects at least part of the transgenic plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, (ii) inhibits the growth of a plant pathogenic fungus on at least part of the transgenic plant or plant tissue or plant cell, or (iii) increases the resistance of at least part of the transgenic plant or plant tissue or plant cell against a plant pathogenic fungus. The present invention also relates to a method for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide encoding a VHH specifically binding to a pathogen.



WO 2016/071438 A3

## TRANSGENIC PLANT COMPRISING A POLYNUCLEOTIDE ENCODING A VARIABLE DOMAIN OF HEAVY-CHAIN ANTIBODY

### FIELD OF THE INVENTION

The present invention relates to the field of transgenic plants. In particular the present invention relates to a transgenic plant or plant tissue or plant cell comprising at least one polynucleotide comprising at least one sequence encoding a variable domain of a heavy-chain antibody (VHH) specifically binding to a sphingolipid of a fungus. The present invention further relates to a method for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide encoding a VHH specifically binding to a pathogen.

### BACKGROUND

Crop protection, required for effective agriculture, relies heavily on the use of pesticides, which are applied to the crops by spraying them onto the crop, applying during watering of the crops or incorporating them into the soil. Pesticides are often organic chemical molecules and their repeated application to crops poses toxicity threats to both agricultural workers during handling and to the environment, due to spray drift, persistence in the soil or washing off into surface or ground water. It would be advantageous to be able to use alternative compounds that are less toxic to humans and the environment, but that at the same time provide effective control of plant pests. Proteinaceous pesticides with specificity against a certain plant pest target may be very advantageous in this respect, as they are expected to be short-lived in the environment and to have less toxic off-target effects. However, there are only a few proteinaceous or peptidergic pesticides known. Some examples are Bt toxins, lectins, defensins, fabatins, tachyplesin, magainin, harpin (see WO2010019442), pea albumin 1-subunit b (PA1b). However, these proteinaceous pesticides are either small peptides with compact structures, stabilized by several disulphide bridges, or are larger proteins (>300 amino acids) which occur in crystalline form (cry toxins). It is indeed known in the field of agriculture that biologicals, and in particular proteins, are challenging structures for developing pesticides, as they generally have far too little stability to maintain their pesticidal function in an agrochemical formulation, in particular for applications in the field.

### SUMMARY OF THE INVENTION

The present inventors have successfully developed transgenic plants comprising a polynucleotide encoding polypeptides with surprisingly high specificity, affinity and potency against targets of plant or crop pests, in particular plant pathogens, such as plant pathogenic fungi. Moreover, it is shown that these polypeptides retain their integrity, stability and activity upon *in planta* expression and that efficacious pest or pathogenic control can surprisingly be achieved.

The present inventors have realised a transgenic plant comprising a polynucleotide, wherein the expression of the polynucleotide in at least part of the transgenic plant (i.e., *in planta* expression of the polynucleotide) protects at least part of the transgenic plant from an infection or other biological interaction with a plant pathogenic fungus.

5 Hence, a first aspect of the present invention relates to a transgenic plant or plant tissue or plant cell comprising at least one polynucleotide comprising at least one sequence encoding a variable domain of a heavy-chain antibody (VHH) specifically binding to a sphingolipid of a fungus.

In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, a VHH as taught herein specifically binds to a sphingolipid of a fungus. In certain  
10 embodiments, a VHH as taught herein specifically binds to a ceramide of a fungus. In certain embodiments, a VHH as taught herein specifically binds to a glycosphingolipid of a fungus. In certain embodiments, a VHH as taught herein specifically binds to a cerebroside of a fungus. In certain preferred embodiments, a VHH as taught herein specifically binds to a glucocerebroside of a fungus.

The present inventors have found that a VHH as taught herein specifically binds to a sphingolipid of a  
15 fungus and binds to a sphingolipid of a plant pathogenic fungus.

Hence, in certain embodiments, the present invention relates to a transgenic plant or plant tissue or plant cell comprising at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a sphingolipid of a fungus, preferably to a ceramide of a fungus, preferably to a glycosphingolipid of a fungus, more preferably to a cerebroside of a fungus, even more preferably to a  
20 glucocerebroside of a fungus, and wherein the VHH binds to a sphingolipid of a plant pathogenic fungus, preferably to a ceramide of a plant pathogenic fungus, preferably to a glycosphingolipid of a plant pathogenic fungus, more preferably to a cerebroside of a plant pathogenic fungus, even more preferably to a glucocerebroside of a plant pathogenic fungus.

In certain embodiments, the present invention relates to a transgenic plant or plant tissue or plant cell  
25 comprising at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a sphingolipid of a fungus, and wherein the VHH binds to a sphingolipid of a plant pathogenic fungus, preferably to a ceramide of a plant pathogenic fungus, preferably to a glycosphingolipid of a plant pathogenic fungus, more preferably to a cerebroside of a plant pathogenic fungus, even more preferably to a glucocerebroside of a plant pathogenic fungus.

30 In certain embodiments, the present invention relates to a transgenic plant or plant tissue or plant cell comprising at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a ceramide of a fungus, and wherein the VHH binds to a sphingolipid of a plant pathogenic fungus, preferably to a ceramide of a plant pathogenic fungus, preferably to a glycosphingolipid of a plant pathogenic fungus, more preferably to a cerebroside of a plant pathogenic fungus, even more preferably  
35 to a glucocerebroside of a plant pathogenic fungus.

In certain embodiments, the present invention relates to a transgenic plant or plant tissue or plant cell comprising at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a glycosphingolipid of a fungus, and wherein the VHH binds to a sphingolipid of a plant

pathogenic fungus, preferably to a ceramide of a plant pathogenic fungus, preferably to a glycosphingolipid of a plant pathogenic fungus, more preferably to a cerebroside of a plant pathogenic fungus, even more preferably to a glucocerebroside of a plant pathogenic fungus.

5 In certain embodiments, the present invention relates to a transgenic plant or plant tissue or plant cell comprising at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a cerebroside of a fungus, and wherein the VHH binds to a sphingolipid of a plant pathogenic fungus, preferably to a ceramide of a plant pathogenic fungus, preferably to a glycosphingolipid of a plant pathogenic fungus, more preferably to a cerebroside of a plant pathogenic fungus, even more preferably to a glucocerebroside of a plant pathogenic fungus.

10 In certain embodiments, the present invention relates to a transgenic plant or plant tissue or plant cell comprising at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a glucocerebroside of a fungus, and wherein the VHH binds to a sphingolipid of a plant pathogenic fungus, preferably to a ceramide of a plant pathogenic fungus, preferably to a glycosphingolipid of a plant pathogenic fungus, more preferably to a cerebroside of a plant pathogenic fungus, even more preferably to a glucocerebroside of a plant pathogenic fungus.

15 In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, a VHH as taught herein binds to a sphingolipid of a plant pathogenic fungus. In certain embodiments, a VHH as taught herein binds to a ceramide of a plant pathogenic fungus. In certain embodiments, a VHH as taught herein specifically binds to a glycosphingolipid of a plant pathogenic fungus. In certain embodiments, a VHH as taught herein specifically binds to a cerebroside of a plant pathogenic fungus. In certain preferred embodiments, a VHH as taught herein specifically binds to a glucocerebroside of a plant pathogenic fungus.

20 In certain embodiments, the transgenic plant or plant tissue or plant cell may have an increased or enhanced level of a VHH as taught herein relative to (i.e., compared with) a non-modified (i.e., non-transformed or untransformed, such as wild type) plant or plant tissue.

25 In certain embodiments, the transgenic plant or plant tissue or plant cell may have a level of a VHH as taught herein which is at least 0,001 % of the amount of total soluble protein in the transgenic plant or plant tissue or plant cell, in particular in an extract of the transgenic plant or plant tissue. For example, the transgenic plant or plant tissue or plant cell may have a level of a VHH as taught herein which is at least 0,005 %, at least 0,01 %, at least 0,05 %, at least 0,1 %, at least 0,2 %, at least 0,3 %, at least 0,4 %, or at least 0,5% of the amount of total soluble protein in the transgenic plant or plant tissue or plant cell, in particular in an extract of the transgenic plant or plant tissue.

30 In certain embodiments, the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell may protect at least part of the transgenic plant or plant tissue or plant cell from an infection with a plant pathogenic fungus. For example, the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell may protect at least part of the transgenic plant or plant tissue or plant cell from an infection with a plant pathogenic fungus relative to (i.e., compared with) a non-modified (i.e., non-transformed or untransformed, such as wild type) plant or plant tissue.

In certain embodiments, the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell may inhibit the growth of a plant pathogenic fungus on at least part of the transgenic plant or plant tissue. For example, the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell may inhibit the growth of a plant pathogenic fungus on at least part of the transgenic plant or plant tissue or plant cell relative to (i.e., compared with) the growth of the plant pathogenic fungus on a non-modified (i.e., non-transformed or untransformed, such as wild type) plant or plant tissue.

In certain embodiments, the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell may increase the resistance of at least part of the transgenic plant or plant tissue or plant cell against a plant pathogenic fungus. For example, the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell may increase the resistance of at least part of the transgenic plant or plant tissue or plant cell against a plant pathogenic fungus relative to (i.e., compared with) the resistance of a non-modified (i.e., non-transformed or untransformed, such as wild type) plant or plant tissue or plant cell against the plant pathogenic fungus.

In certain embodiments, the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell may protect at least part of the transgenic plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, may inhibit the growth of a plant pathogenic fungus on at least part of the transgenic plant or plant tissue or plant cell, and/or may increase the resistance of at least part of the transgenic plant or plant tissue or plant cell against a plant pathogenic fungus.

In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise a promoter suitable for expression in plants, such as the 35S Cauliflower Mosaic Virus (CaMV) promoter, a plant tissue or plant cell specific promoter, or an inducible promoter.

In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise at least one sequence encoding a targeting signal for secretion, for location to the cytoplasm, or for location to cellular compartments or organelles, such as the ER lumen, the apoplast, the vacuole, or intra- and/or exterior membranes.

In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise at least one sequence encoding a tag, preferably a His6, c-myc, FLAG, C-tag, 3xFLAG, His5, His10, HA, T7, strep, HSV, and/or an E-tag.

In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may encode the VHH as such, as a combination with one or more identical or different VHHs, or as a combination with one or more identical or different VHHs with an antigen binding region (Fc region) of an antibody; optionally with a spacer.

In certain embodiments, the polynucleotide may encode the VHH as such, optionally with a spacer. In certain other embodiments, the polynucleotide may encode the VHH as a combination with one or more, such as two or more, identical or different VHHs, optionally with a spacer. In certain other embodiments, the polynucleotide may encode the VHH as a combination with one or more, such as two or more,

identical or different VHHs with a fragment crystallizable region (Fc region) of an antibody, optionally with a spacer. Such a spacer advantageously spatially extends two VHHs from each other, thereby enhancing the flexibility of the VHHs relative to each other and/or assuring optimal interaction between each VHH and its antigen.

5 In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the plant may be a plant selected from the group consisting of corn, rice, wheat, barley, sorghum, millet oats, rye, triticale or other cereals, soybean, alfalfa or other leguminous crops, sugar beet, fodder beet, papaya, banana and plantains or other fruits, grapevines, nuts, oilseed rape, sunflower or other oil crops, squash cucumber, melons or other cucurbits, cotton or other fiber plants, sugarcane, 10 palm, jatropha or other fuel crops, cabbages, tomato, pepper or other vegetables, ornamentals, shrubs, poplar, eucalyptus or other trees, evergreens, grasses, coffee plants, tea plants, tobacco plants, hop plants, rubber plants, and latex plants.

In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise a sequence encoding a VHH comprising:

15 (i) any one or more of SEQ ID NO 1 to 84, preferably SEQ ID NO 1, 2, and/or 70, more preferably SEQ ID NO 1 and/or 2, and/or

(ii) a CDR1, CDR2, and CDR3 region, wherein (i) the CDR1 region is selected from the group of SEQ ID NOs 85-168, and/or (ii) the CDR2 region is selected from the group of SEQ ID NOs 169-252, and/or (iii) the CDR3 region is selected from the group of SEQ ID NOs 253-335, or the CDR3 region has the amino acid sequence NRY. 20

In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise a sequence encoding a VHH comprising any one or more of SEQ ID NO 1 to 84, preferably SEQ ID NO 1 and/or 2. In certain embodiments, the polynucleotide may comprise a sequence encoding a VHH comprising SEQ ID NO 1, SEQ ID NO 2, and/or SEQ ID NO 70.

25 In certain embodiments, the polynucleotide may comprise a sequence encoding a VHH comprising SEQ ID NO 1 and/or SEQ ID NO 2. In certain embodiments, the polynucleotide may comprise a sequence encoding a VHH comprising SEQ ID NO 1. In certain embodiments, the polynucleotide may comprise a sequence encoding a VHH comprising SEQ ID NO 2. In certain embodiments, the polynucleotide may comprise a sequence encoding a VHH comprising SEQ ID NO 70.

30 In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise a sequence encoding a VHH comprising a CDR1, CDR2, and CDR3 region, wherein (i) the CDR1 region is selected from the group of SEQ ID NOs 85-168, and/or (ii) the CDR2 region is selected from the group of SEQ ID NOs 169-252, and/or (iii) the CDR3 region is selected from the group of SEQ ID NOs 253-335, or the CDR3 region has the amino acid sequence NRY.

35 In certain embodiments, the polynucleotide may comprise a sequence encoding a VHH comprising a CDR1, CDR2, and CDR3 region, wherein (i) the CDR1 region is selected from SEQ ID NOs 85 and/or 86, and/or (ii) the CDR2 region is selected from SEQ ID NOs 169 and/or 170, and/or (iii) the CDR3 region is selected from SEQ ID NOs 253 and/or 254. In certain embodiments, the polynucleotide may comprise a

sequence encoding a VHH comprising a CDR1, CDR2, and CDR3 region, wherein (i) the CDR1 region is SEQ ID NOs 85, and/or (ii) the CDR2 region is SEQ ID NOs 169, and/or (iii) the CDR3 region is SEQ ID NOs 253. In certain embodiments, the polynucleotide may comprise a sequence encoding a VHH comprising a CDR1, CDR2, and CDR3 region, wherein (i) the CDR1 region is SEQ ID NOs 86, and/or (ii) the CDR2 region is SEQ ID NOs 170, and/or (iii) the CDR3 region is SEQ ID NOs 254.

In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise a sequence encoding a VHH comprising, consisting of, or consisting essentially of four framework regions (FRs) and three complementary determining regions (CDRs), a CDR1, CDR2, and CDR3 region, wherein (i) the CDR1 region is selected from the group of SEQ ID NOs 85-168, and/or (ii) the CDR2 region is selected from the group of SEQ ID NOs 169-252, and/or (iii) the CDR3 region is selected from the group of SEQ ID NOs 253-335, or the CDR3 region has the amino acid sequence NRY.

In certain embodiments, the polynucleotide may comprise a sequence encoding a VHH comprising four framework regions and three CDRs, a CDR1, CDR2, and CDR3 region, wherein (i) the CDR1 region is selected from SEQ ID NOs 85 and/or 86, and/or (ii) the CDR2 region is selected from SEQ ID NOs 169 and/or 170, and/or (iii) the CDR3 region is selected from SEQ ID NOs 253 and/or 254. In certain embodiments, the polynucleotide may comprise a sequence encoding a VHH comprising four framework regions and three CDRs, a CDR1, CDR2, and CDR3 region, wherein (i) the CDR1 region is SEQ ID NOs 85, and/or (ii) the CDR2 region is SEQ ID NOs 169, and/or (iii) the CDR3 region is SEQ ID NOs 253. In certain embodiments, the polynucleotide may comprise a sequence encoding a VHH comprising four framework regions and three CDRs, a CDR1, CDR2, and CDR3 region, wherein (i) the CDR1 region is SEQ ID NOs 86, and/or (ii) the CDR2 region is SEQ ID NOs 170, and/or (iii) the CDR3 region is SEQ ID NOs 254.

In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise a sequence encoding a VHH comprising a CDR1, CDR2 and CDR3 region chosen from the list of comprising:

a CDR1 region having SEQ ID NO: 85, a CDR2 region having has SEQ ID NO: 169, and a CDR3 region having SEQ ID NO: 253, and/or

a CDR1 region having SEQ ID NO: 86, a CDR2 region having has SEQ ID NO: 170, and a CDR3 region having SEQ ID NO: 254, and/or

a CDR1 region having SEQ ID NO: 87, a CDR2 region having has SEQ ID NO: 171, and a CDR3 region having SEQ ID NO: 255, and/or

a CDR1 region having SEQ ID NO: 88, a CDR2 region having has SEQ ID NO: 172, and a CDR3 region having SEQ ID NO: 256, and/or

a CDR1 region having SEQ ID NO: 89, a CDR2 region having has SEQ ID NO: 173, and a CDR3 region having SEQ ID NO: 257, and/or

- a CDR1 region having SEQ ID NO: 90, a CDR2 region having has SEQ ID NO: 174, and a CDR3 region having SEQ ID NO: 258, and/or
- a CDR1 region having SEQ ID NO: 91, a CDR2 region having has SEQ ID NO: 175, and a CDR3 region having SEQ ID NO: 259, and/or
- 5 a CDR1 region having SEQ ID NO: 92, a CDR2 region having has SEQ ID NO: 176, and a CDR3 region having SEQ ID NO: 260, and/or
- a CDR1 region having SEQ ID NO: 93, a CDR2 region having has SEQ ID NO: 177, and a CDR3 region having SEQ ID NO: 261, and/or
- 10 a CDR1 region having SEQ ID NO: 94, a CDR2 region having has SEQ ID NO: 178, and a CDR3 region having SEQ ID NO: 262, and/or
- a CDR1 region having SEQ ID NO: 95, a CDR2 region having has SEQ ID NO: 179, and a CDR3 region having SEQ ID NO: 263, and/or
- a CDR1 region having SEQ ID NO: 96, a CDR2 region having has SEQ ID NO: 180, and a CDR3 region having SEQ ID NO: 264, and/or
- 15 a CDR1 region having SEQ ID NO: 97, a CDR2 region having has SEQ ID NO: 181, and a CDR3 region having SEQ ID NO: 265, and/or
- a CDR1 region having SEQ ID NO: 98, a CDR2 region having has SEQ ID NO: 182, and a CDR3 region having SEQ ID NO: 266, and/or
- a CDR1 region having SEQ ID NO: 99, a CDR2 region having has SEQ ID NO: 183, and a CDR3 region having SEQ ID NO: 267, and/or
- 20 a CDR1 region having SEQ ID NO: 100, a CDR2 region having has SEQ ID NO: 184, and a CDR3 region having SEQ ID NO: 268, and/or
- a CDR1 region having SEQ ID NO: 101, a CDR2 region having has SEQ ID NO: 185, and a CDR3 region having SEQ ID NO: 269, and/or
- 25 a CDR1 region having SEQ ID NO: 102, a CDR2 region having has SEQ ID NO: 186, and a CDR3 region having SEQ ID NO: 270, and/or
- a CDR1 region having SEQ ID NO: 103, a CDR2 region having has SEQ ID NO: 187, and a CDR3 region having SEQ ID NO: 271, and/or
- a CDR1 region having SEQ ID NO: 104, a CDR2 region having has SEQ ID NO: 188, and a CDR3 region having SEQ ID NO: 272, and/or
- 30 a CDR1 region having SEQ ID NO: 105, a CDR2 region having has SEQ ID NO: 189, and a CDR3 region having SEQ ID NO: 273, and/or
- a CDR1 region having SEQ ID NO: 106, a CDR2 region having has SEQ ID NO: 190, and a CDR3 region having SEQ ID NO: 274, and/or

- a CDR1 region having SEQ ID NO: 107, a CDR2 region having has SEQ ID NO: 191, and a CDR3 region having SEQ ID NO: 275, and/or
- a CDR1 region having SEQ ID NO: 108, a CDR2 region having has SEQ ID NO: 192, and a CDR3 region having SEQ ID NO: 276, and/or
- 5 a CDR1 region having SEQ ID NO: 109, a CDR2 region having has SEQ ID NO: 193, and a CDR3 region having SEQ ID NO: 277, and/or
- a CDR1 region having SEQ ID NO: 110, a CDR2 region having has SEQ ID NO: 194, and a CDR3 region having SEQ ID NO: 278, and/or
- 10 a CDR1 region having SEQ ID NO: 111, a CDR2 region having has SEQ ID NO: 195, and a CDR3 region having SEQ ID NO: 279, and/or
- a CDR1 region having SEQ ID NO: 112, a CDR2 region having has SEQ ID NO: 196, and a CDR3 region having SEQ ID NO: 280, and/or
- a CDR1 region having SEQ ID NO: 113, a CDR2 region having has SEQ ID NO: 197, and a CDR3 region having SEQ ID NO: 281, and/or
- 15 a CDR1 region having SEQ ID NO: 114, a CDR2 region having has SEQ ID NO: 198, and a CDR3 region having SEQ ID NO: 282, and/or
- a CDR1 region having SEQ ID NO: 115, a CDR2 region having has SEQ ID NO: 199, and a CDR3 region having SEQ ID NO: 283, and/or
- a CDR1 region having SEQ ID NO: 116, a CDR2 region having has SEQ ID NO: 200, and a CDR3 region having SEQ ID NO: 284, and/or
- 20 a CDR1 region having SEQ ID NO: 117, a CDR2 region having has SEQ ID NO: 201, and a CDR3 region having SEQ ID NO: 285, and/or
- a CDR1 region having SEQ ID NO: 118, a CDR2 region having has SEQ ID NO: 202, and a CDR3 region having SEQ ID NO: 286, and/or
- 25 a CDR1 region having SEQ ID NO: 119, a CDR2 region having has SEQ ID NO: 203, and a CDR3 region having SEQ ID NO: 287, and/or
- a CDR1 region having SEQ ID NO: 120, a CDR2 region having has SEQ ID NO: 204, and a CDR3 region having SEQ ID NO: 288, and/or
- a CDR1 region having SEQ ID NO: 121, a CDR2 region having has SEQ ID NO: 205, and a CDR3 region having SEQ ID NO: 289, and/or
- 30 a CDR1 region having SEQ ID NO: 122, a CDR2 region having has SEQ ID NO: 206, and a CDR3 region having SEQ ID NO: 290, and/or
- a CDR1 region having SEQ ID NO: 123, a CDR2 region having has SEQ ID NO: 207, and a CDR3 region having SEQ ID NO: 291, and/or

- a CDR1 region having SEQ ID NO: 124, a CDR2 region having has SEQ ID NO: 208, and a CDR3 region having SEQ ID NO: 292, and/or
- a CDR1 region having SEQ ID NO: 125, a CDR2 region having has SEQ ID NO: 209, and a CDR3 region having SEQ ID NO: 293, and/or
- 5 a CDR1 region having SEQ ID NO: 126, a CDR2 region having has SEQ ID NO: 210, and a CDR3 region having SEQ ID NO: 294, and/or
- a CDR1 region having SEQ ID NO: 127, a CDR2 region having has SEQ ID NO: 211, and a CDR3 region having SEQ ID NO: 295, and/or
- 10 a CDR1 region having SEQ ID NO: 128, a CDR2 region having has SEQ ID NO: 212, and a CDR3 region having SEQ ID NO: 296, and/or
- a CDR1 region having SEQ ID NO: 129, a CDR2 region having has SEQ ID NO: 213, and a CDR3 region having SEQ ID NO: 297, and/or
- a CDR1 region having SEQ ID NO: 130, a CDR2 region having has SEQ ID NO: 214, and a CDR3 region having SEQ ID NO: 298, and/or
- 15 a CDR1 region having SEQ ID NO: 131, a CDR2 region having has SEQ ID NO: 215, and a CDR3 region having SEQ ID NO: 299, and/or
- a CDR1 region having SEQ ID NO: 132, a CDR2 region having has SEQ ID NO: 216, and a CDR3 region having SEQ ID NO: 300, and/or
- a CDR1 region having SEQ ID NO: 133, a CDR2 region having has SEQ ID NO: 217, and a CDR3 region having SEQ ID NO: 301, and/or
- 20 a CDR1 region having SEQ ID NO: 134, a CDR2 region having has SEQ ID NO: 218, and a CDR3 region having SEQ ID NO: 302, and/or
- a CDR1 region having SEQ ID NO: 135, a CDR2 region having has SEQ ID NO: 219, and a CDR3 region having SEQ ID NO: 303, and/or
- 25 a CDR1 region having SEQ ID NO: 136, a CDR2 region having has SEQ ID NO: 220, and a CDR3 region having SEQ ID NO: 304, and/or
- a CDR1 region having SEQ ID NO: 137, a CDR2 region having has SEQ ID NO: 221, and a CDR3 region having SEQ ID NO: 305, and/or
- a CDR1 region having SEQ ID NO: 138, a CDR2 region having has SEQ ID NO: 222, and a CDR3 region having SEQ ID NO: 306, and/or
- 30 a CDR1 region having SEQ ID NO: 139, a CDR2 region having has SEQ ID NO: 223, and a CDR3 region having the amino acid sequence NRY, and/or
- a CDR1 region having SEQ ID NO: 140, a CDR2 region having has SEQ ID NO: 224, and a CDR3 region having SEQ ID NO: 307, and/or

- a CDR1 region having SEQ ID NO: 141, a CDR2 region having has SEQ ID NO: 225, and a CDR3 region having SEQ ID NO: 308, and/or
- a CDR1 region having SEQ ID NO: 142, a CDR2 region having has SEQ ID NO: 226, and a CDR3 region having SEQ ID NO: 309, and/or
- 5 a CDR1 region having SEQ ID NO: 143, a CDR2 region having has SEQ ID NO: 227, and a CDR3 region having SEQ ID NO: 310, and/or
- a CDR1 region having SEQ ID NO: 144, a CDR2 region having has SEQ ID NO: 228, and a CDR3 region having SEQ ID NO: 311, and/or
- 10 a CDR1 region having SEQ ID NO: 145, a CDR2 region having has SEQ ID NO: 229, and a CDR3 region having SEQ ID NO: 312, and/or
- a CDR1 region having SEQ ID NO: 146, a CDR2 region having has SEQ ID NO: 230, and a CDR3 region having SEQ ID NO: 313, and/or
- a CDR1 region having SEQ ID NO: 147, a CDR2 region having has SEQ ID NO: 231, and a CDR3 region having SEQ ID NO: 314, and/or
- 15 a CDR1 region having SEQ ID NO: 148, a CDR2 region having has SEQ ID NO: 232, and a CDR3 region having SEQ ID NO: 315, and/or
- a CDR1 region having SEQ ID NO: 149, a CDR2 region having has SEQ ID NO: 233, and a CDR3 region having SEQ ID NO: 316, and/or
- a CDR1 region having SEQ ID NO: 150, a CDR2 region having has SEQ ID NO: 234, and a CDR3 region having SEQ ID NO: 317, and/or
- 20 a CDR1 region having SEQ ID NO: 151, a CDR2 region having has SEQ ID NO: 235, and a CDR3 region having SEQ ID NO: 318, and/or
- a CDR1 region having SEQ ID NO: 152, a CDR2 region having has SEQ ID NO: 236, and a CDR3 region having SEQ ID NO: 319, and/or
- 25 a CDR1 region having SEQ ID NO: 153, a CDR2 region having has SEQ ID NO: 237, and a CDR3 region having SEQ ID NO: 320, and/or
- a CDR1 region having SEQ ID NO: 154, a CDR2 region having has SEQ ID NO: 238, and a CDR3 region having SEQ ID NO: 321, and/or
- a CDR1 region having SEQ ID NO: 155, a CDR2 region having has SEQ ID NO: 239, and a CDR3 region having SEQ ID NO: 322, and/or
- 30 a CDR1 region having SEQ ID NO: 156, a CDR2 region having has SEQ ID NO: 240, and a CDR3 region having SEQ ID NO: 323, and/or
- a CDR1 region having SEQ ID NO: 157, a CDR2 region having has SEQ ID NO: 241, and a CDR3 region having SEQ ID NO: 324, and/or

a CDR1 region having SEQ ID NO: 158, a CDR2 region having has SEQ ID NO: 242, and a CDR3 region having SEQ ID NO: 325, and/or

a CDR1 region having SEQ ID NO: 159, a CDR2 region having has SEQ ID NO: 243, and a CDR3 region having SEQ ID NO: 326, and/or

5 a CDR1 region having SEQ ID NO: 160, a CDR2 region having has SEQ ID NO: 244, and a CDR3 region having SEQ ID NO: 327, and/or

a CDR1 region having SEQ ID NO: 161, a CDR2 region having has SEQ ID NO: 245, and a CDR3 region having SEQ ID NO: 328, and/or

10 a CDR1 region having SEQ ID NO: 162, a CDR2 region having has SEQ ID NO: 246, and a CDR3 region having SEQ ID NO: 329, and/or

a CDR1 region having SEQ ID NO: 163, a CDR2 region having has SEQ ID NO: 247, and a CDR3 region having SEQ ID NO: 330, and/or

a CDR1 region having SEQ ID NO: 164, a CDR2 region having has SEQ ID NO: 248, and a CDR3 region having SEQ ID NO: 331, and/or

15 a CDR1 region having SEQ ID NO: 165, a CDR2 region having has SEQ ID NO: 249, and a CDR3 region having SEQ ID NO: 332, and/or

a CDR1 region having SEQ ID NO: 166, a CDR2 region having has SEQ ID NO: 250, and a CDR3 region having SEQ ID NO: 333, and/or

20 a CDR1 region having SEQ ID NO: 167, a CDR2 region having has SEQ ID NO: 251, and a CDR3 region having SEQ ID NO: 334, and/or

a CDR1 region having SEQ ID NO: 168, a CDR2 region having has SEQ ID NO: 252, and a CDR3 region having SEQ ID NO: 335.

25 In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise a sequence encoding a VHH comprising a CDR1, CDR2 and CDR3 region chosen from the list of comprising:

a CDR1 region having SEQ ID NO: 85, a CDR2 region having has SEQ ID NO: 169, and a CDR3 region having SEQ ID NO: 253, and/or

a CDR1 region having SEQ ID NO: 86, a CDR2 region having has SEQ ID NO: 170, and a CDR3 region having SEQ ID NO: 254.

30 In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise a sequence encoding a VHH comprising a CDR1 region having SEQ ID NO: 85, a CDR2 region having has SEQ ID NO: 169, and a CDR3 region having SEQ ID NO: 253.

35 In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise a sequence encoding a VHH comprising a CDR1 region

having SEQ ID NO: 86, a CDR2 region having has SEQ ID NO: 170, and a CDR3 region having SEQ ID NO: 254.

A further aspect relates to harvestable parts and propagation materials of a transgenic plant or plant tissue or plant cell as defined herein, comprising at least one polynucleotide as defined herein.

5 Accordingly, a further aspect provides harvestable parts and propagation materials of a transgenic plant or plant tissue or plant cell as defined herein, comprising at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a sphingolipid of a fungus, preferably to a ceramide of a fungus, preferably to a glycosphingolipid of a fungus, more preferably to a cerebroside of a fungus, even more preferably to a glucocerebroside of a fungus. In certain embodiments, the VHH binds to a  
10 sphingolipid of a plant pathogenic fungus, preferably to a ceramide of a plant pathogenic fungus, preferably to a glycosphingolipid of a plant pathogenic fungus, more preferably to a cerebroside of a plant pathogenic fungus, even more preferably to a glucocerebroside of a plant pathogenic fungus.

In certain embodiments, the harvestable parts and propagation materials of a transgenic plant or plant tissue or plant cell are selected from the group consisting of seeds, fruits, grains, bulbs, bolls, tubers,  
15 progeny, and hybrids.

A further aspect relates to an extract of a transgenic plant or plant tissue or plant cell as defined herein, comprising at least one polynucleotide as defined herein, said extract comprising said VHH. Accordingly, a further aspect provides an extract of a transgenic plant or plant tissue or plant cell as defined herein, comprising at least one VHH specifically binding to a sphingolipid of a fungus, preferably to a ceramide of  
20 a fungus, preferably to a glycosphingolipid of a fungus, more preferably to a cerebroside of a fungus, even more preferably to a glucocerebroside of a fungus. In certain embodiments, the VHH binds to a sphingolipid of a plant pathogenic fungus, preferably to a ceramide of a plant pathogenic fungus, preferably to a glycosphingolipid of a plant pathogenic fungus, more preferably to a cerebroside of a plant pathogenic fungus, even more preferably to a glucocerebroside of a plant pathogenic fungus.

25 A further aspect relates to compositions comprising an extract of a transgenic plant or plant tissue or plant cell as defined herein. Accordingly, a further aspect provides a composition comprising an extract of a transgenic plant or plant tissue or plant cell as defined herein, comprising at least one VHH specifically binding to a sphingolipid of a fungus, preferably to a ceramide of a fungus, preferably to a glycosphingolipid of a fungus, more preferably to a cerebroside of a fungus, even more preferably to a  
30 glucocerebroside of a fungus. In certain embodiments, the VHH binds to a sphingolipid of a plant pathogenic fungus, preferably to a ceramide of a plant pathogenic fungus, preferably to a glycosphingolipid of a plant pathogenic fungus, more preferably to a cerebroside of a plant pathogenic fungus, even more preferably to a glucocerebroside of a plant pathogenic fungus.

A further aspect relates to a method for the production of a transgenic plant or plant tissue or plant cell  
35 comprising the introduction of at least one polynucleotide as defined herein into the genome of a plant or plant tissue. Hence, a further aspect provides a method for the production of a transgenic plant or plant tissue or plant cell comprising the introduction of at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a sphingolipid of a fungus into the genome of a plant or

plant tissue. In certain embodiments, the present invention relates to a method for the production of a transgenic plant or plant tissue or plant cell comprising the introduction of at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a ceramide of a fungus into the genome of a plant or plant tissue. In certain embodiments, the present invention relates to a method for the production of a transgenic plant or plant tissue or plant cell comprising the introduction of at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a glycosphingolipid of a fungus into the genome of a plant or plant tissue. In certain embodiments, the present invention relates to a method for the production of a transgenic plant or plant tissue or plant cell comprising the introduction of at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a cerebroside of a fungus into the genome of a plant or plant tissue. In certain embodiments, the present invention relates to a method for the production of a transgenic plant or plant tissue or plant cell comprising the introduction of at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a glucocerebroside of a fungus into the genome of a plant or plant tissue. In certain embodiments, the VHH binds to a sphingolipid of a plant pathogenic fungus, preferably to a ceramide of a plant pathogenic fungus, preferably to a glycosphingolipid of a plant pathogenic fungus, more preferably to a cerebroside of a plant pathogenic fungus, even more preferably to a glucocerebroside of a plant pathogenic fungus.

A further aspect relates to the use of at least one polynucleotide as defined herein, for the production of a transgenic plant or plant tissue. A further aspect thus provides the use of at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a sphingolipid of a fungus, for the production of a transgenic plant or plant tissue. In certain embodiments, the invention relates to the use of at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a ceramide of a fungus, for the production of a transgenic plant or plant tissue. In certain embodiments, the invention relates to the use of at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a glycosphingolipid of a fungus, for the production of a transgenic plant or plant tissue. In certain embodiments, the invention relates to the use of at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a cerebroside of a fungus, for the production of a transgenic plant or plant tissue. In certain embodiments, the invention relates to the use of at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a glucocerebroside of a fungus, for the production of a transgenic plant or plant tissue. In certain embodiments, the VHH binds to a sphingolipid of a plant pathogenic fungus, preferably to a ceramide of a plant pathogenic fungus, preferably to a glycosphingolipid of a plant pathogenic fungus, more preferably to a cerebroside of a plant pathogenic fungus, even more preferably to a glucocerebroside of a plant pathogenic fungus.

The present inventors have found that a VHH specifically binding to a pathogen (and binding to a plant pathogen) which is produced in at least part of the transgenic plant (e.g., *in planta* expression of a polynucleotide encoding the VHH specifically binding to a pathogen) has antimicrobial effects *per se*, in particular microbiostatic effects, on the plant pathogen. The present inventors found that a VHH as taught herein does not act as a 'targeting agent' of an antimicrobial substance or composition to the plant

pathogen but as an antimicrobial agent *per se*, in particular as a microbiostatic agent *per se*, on the plant pathogen.

Accordingly, a further aspect of the present invention relates to a method for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide encoding a variable domain of a heavy-chain antibody (VHH) specifically binding to a pathogen. In certain embodiments, the VHH may specifically bind to a sphingolipid of a pathogen, preferably to a ceramide of a pathogen, preferably to a glycosphingolipid of a pathogen, more preferably to a cerebroside of a pathogen, even more preferably to a glucocerebroside of a pathogen.

In certain embodiments, the present invention relates to a method for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide encoding a VHH specifically binding to a pathogen, and wherein the VHH binds to a plant pathogen, preferably to a sphingolipid of a plant pathogen, preferably to a ceramide of a plant pathogen, preferably to a glycosphingolipid of a plant pathogen, more preferably to a cerebroside of a plant pathogen, even more preferably to a glucocerebroside of a plant pathogen.

A further aspect of the present invention relates to a method for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, comprising treating said at least part of a plant or plant tissue or plant cell with an extract of a transgenic plant or plant tissue or plant cell as defined herein, comprising at least one polynucleotide as defined herein, said extract comprising said VHH.

A further aspect of the present invention relates to a method for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, comprising treating said at least part of a plant or plant tissue or plant cell with a composition comprising an extract of a transgenic plant or plant tissue or plant cell as defined herein, comprising at least one polynucleotide as defined herein, said extract comprising said VHH.

A further aspect relates to the use of an extract of a transgenic plant or plant tissue or plant cell as defined herein, comprising at least one polynucleotide as defined herein, said extract comprising said VHH, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell.

A further aspect relates to the use of a composition comprising an extract of a transgenic plant or plant tissue or plant cell as defined herein, comprising at least one polynucleotide as defined herein, said extract comprising said VHH, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell.

In certain embodiments of the methods or uses, as taught herein, the VHH may specifically bind to a pathogen, and the VHH may bind to a plant pathogen, preferably to a sphingolipid of a plant pathogen, preferably to a ceramide of a plant pathogen, preferably to a glycosphingolipid of a plant pathogen, more preferably to a cerebroside of a plant pathogen, even more preferably to a glucocerebroside of a plant pathogen.

In certain embodiments of the methods or uses, as taught herein, the VHH may specifically bind to a sphingolipid of a pathogen, and the VHH may bind to a plant pathogen, preferably to a sphingolipid of a plant pathogen, preferably to a ceramide of a plant pathogen, preferably to a glycosphingolipid of a plant pathogen, more preferably to a cerebroside of a plant pathogen, even more preferably to a glucocerebroside of a plant pathogen.

In certain embodiments of the methods or uses, as taught herein, the VHH may specifically bind to a ceramide of a pathogen, and the VHH may bind to a plant pathogen, preferably to a sphingolipid of a plant pathogen, preferably to a ceramide of a plant pathogen, preferably to a glycosphingolipid of a plant pathogen, more preferably to a cerebroside of a plant pathogen, even more preferably to a glucocerebroside of a plant pathogen.

In certain embodiments of the methods or uses, as taught herein, the VHH may specifically bind to a glycosphingolipid of a pathogen, and the VHH may bind to a plant pathogen, preferably to a sphingolipid of a plant pathogen, preferably to a ceramide of a plant pathogen, preferably to a glycosphingolipid of a plant pathogen, more preferably to a cerebroside of a plant pathogen, even more preferably to a glucocerebroside of a plant pathogen.

In certain embodiments of the methods or uses, as taught herein, the VHH may specifically bind to a cerebroside of a pathogen, and the VHH may bind to a plant pathogen, preferably to a sphingolipid of a plant pathogen, preferably to a ceramide of a plant pathogen, preferably to a glycosphingolipid of a plant pathogen, more preferably to a cerebroside of a plant pathogen, even more preferably to a glucocerebroside of a plant pathogen.

In certain embodiments of the methods or uses, as taught herein, the VHH may specifically bind to a glucocerebroside of a pathogen, and the VHH may bind to a plant pathogen, preferably to a sphingolipid of a plant pathogen, preferably to a ceramide of a plant pathogen, preferably to a glycosphingolipid of a plant pathogen, more preferably to a cerebroside of a plant pathogen, even more preferably to a glucocerebroside of a plant pathogen.

In certain embodiments, the present invention relates to a method for protecting at least part of a plant or plant tissue or plant cell from an infection or other biological interaction with a plant pathogen, comprising

expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide encoding a VHH specifically binding to a pathogen.

In certain embodiments, the present invention relates to a method for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide encoding a VHH specifically binding to a pathogen.

In certain embodiments, the present invention relates to a method for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide encoding a VHH specifically binding to a pathogen. In certain embodiments, the present invention relates to a method for increasing resistance of at least part of a plant or plant tissue or plant cell against a plant pathogen, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide encoding a VHH specifically binding to a pathogen.

In certain embodiments, the present invention relates to a method as taught herein, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, for inhibiting the growth of a plant pathogenic fungus on at least part of a plant or plant tissue or plant cell, and/or for increasing resistance of at least part of a plant or plant tissue or plant cell against the plant pathogenic fungus, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide as defined herein. Hence, in certain embodiments, the present invention relates to a method as taught herein, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, for inhibiting the growth of a plant pathogenic fungus on at least part of a plant or plant tissue or plant cell, and/or for increasing resistance of at least part of a plant or plant tissue or plant cell against the plant pathogenic fungus, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a sphingolipid of a fungus. In certain embodiments, the present invention relates to a method as taught herein, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, for inhibiting the growth of a plant pathogenic fungus on at least part of a plant or plant tissue or plant cell, and/or for increasing resistance of at least part of a plant or plant tissue or plant cell against the plant pathogenic fungus, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a ceramide of a fungus. In certain embodiments, the present invention relates to a method as taught herein, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, for inhibiting the growth of a plant pathogenic fungus on at least part of a plant or plant tissue or plant cell, and/or for increasing resistance of at least part of a plant or plant tissue or plant cell against the plant pathogenic fungus, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a glycosphingolipid of a fungus. In certain embodiments, the present invention relates to a method as taught herein, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, for inhibiting the growth of a plant pathogenic fungus on at

least part of a plant or plant tissue or plant cell, and/or for increasing resistance of at least part of a plant or plant tissue or plant cell against the plant pathogenic fungus, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a cerebroside of a fungus. in certain embodiments, the present invention relates to a method as taught herein, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, for inhibiting the growth of a plant pathogenic fungus on at least part of a plant or plant tissue or plant cell, and/or for increasing resistance of at least part of a plant or plant tissue or plant cell against the plant pathogenic fungus, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a glucocerebroside of a fungus. In certain embodiments, the VHH binds to a sphingolipid of a plant pathogenic fungus, preferably to a ceramide of a plant pathogenic fungus, preferably to a glycosphingolipid of a plant pathogenic fungus, more preferably to a cerebroside of a plant pathogenic fungus, even more preferably to a glucocerebroside of a plant pathogenic fungus.

A further aspect relates to the use of at least one polynucleotide encoding a variable domain of a heavy-chain antibody (VHH) specifically binding to a pathogen, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, wherein the polynucleotide is expressed in at least part of the plant or plant tissue. In certain embodiments, the VHH may specifically bind to a sphingolipid of a pathogen, preferably to a ceramide of a pathogen, preferably to a glycosphingolipid of a pathogen, more preferably to a cerebroside of a pathogen, even more preferably to a glucocerebroside of a pathogen.

In certain embodiments, the present invention relates to the use of at least one polynucleotide encoding a VHH specifically binding to a pathogen, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, wherein the polynucleotide is expressed in at least part of the plant or plant tissue or plant cell, and wherein the VHH binds to a plant pathogen, preferably to a sphingolipid of a plant pathogen, preferably to a ceramide of a plant pathogen, preferably to a glycosphingolipid of a plant pathogen, more preferably to a cerebroside of a plant pathogen, even more preferably to a glucocerebroside of a plant pathogen.

In certain embodiments, the present invention relates to the use of at least one polynucleotide encoding a VHH specifically binding to a pathogen, for protecting at least part of a plant or plant tissue or plant cell from an infection or other biological interaction with a plant pathogen, wherein the polynucleotide is expressed in at least part of the plant or plant tissue.

In certain embodiments, the present invention relates to the use of at least one polynucleotide encoding a VHH specifically binding to a pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, wherein the polynucleotide is expressed in at least part of the plant or plant tissue.

In certain embodiments, the present invention relates to the use of at least one polynucleotide encoding a VHH specifically binding to a pathogen, for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, wherein the polynucleotide is expressed in at least part of the plant or plant tissue. In certain embodiments, the present invention relates to the use of at least one polynucleotide encoding a VHH specifically binding to a pathogen, for increasing resistance of at least part of a plant or plant tissue or plant cell against a plant pathogen, wherein the polynucleotide is expressed in at least part of the plant or plant tissue.

In certain embodiments, the present invention relates to the uses as taught herein, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, for inhibiting the growth of a plant pathogenic fungus on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, wherein the polynucleotide is as defined herein. In certain embodiments, the present invention relates to the uses as taught herein, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, for inhibiting the growth of a plant pathogenic fungus on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, wherein the polynucleotide comprises at least one sequence encoding a VHH specifically binding to a sphingolipid of a fungus. In certain embodiments, the polynucleotide may comprise at least one sequence encoding a VHH specifically binding to a ceramide of a fungus. In certain embodiments, the polynucleotide may comprise at least one sequence encoding a VHH specifically binding to a glycosphingolipid of a fungus. In certain embodiments, the polynucleotide may comprise at least one sequence encoding a VHH specifically binding to a cerebroside of a fungus. In certain embodiments, the polynucleotide may comprise at least one sequence encoding a VHH specifically binding to a glucocerebroside of a fungus. In certain embodiments, the VHH binds to a sphingolipid of a plant pathogenic fungus, preferably to a ceramide of a plant pathogenic fungus, preferably to a glycosphingolipid of a plant pathogenic fungus, more preferably to a cerebroside of a plant pathogenic fungus, even more preferably to a glucocerebroside of a plant pathogenic fungus.

The methods and uses embodying the principles of the present invention advantageously allow protecting a plant or plant tissue or plant cell from an infection or other interaction with a plant pathogen, inhibiting the growth of the plant pathogen on at least part of a plant or plant tissue or plant cell, or increasing pathogen resistance of at least part of a plant or plant tissue or plant cell by the *in planta* expression of a polynucleotide encoding a VHH specifically binding to a pathogen.

In certain embodiments of the methods or uses as taught herein, a VHH as taught herein may act as an antimicrobial agent. In certain embodiments of the methods or uses as taught herein, a VHH as taught herein may act as a microbiostatic agent.

The present inventors have found polynucleotides encoding a VHH specifically binding to a sphingolipid of a fungus, preferably to a ceramide of a fungus, more preferably to a glycosphingolipid of a fungus, even more preferably to a cerebroside of a fungus, yet more preferably to a glucocerebroside of a fungus. Accordingly, a further aspect of the invention relates to a transgenic plant or plant tissue or plant cell comprising at least one polynucleotide comprising at least one nucleic acid sequence selected from SEQ

ID NO: 336 and/or SEQ ID NO: 337. In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses as taught herein, the polynucleotide may comprise the nucleic acid sequence of SEQ ID NO: 336. In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses as taught herein, the polynucleotide may comprise the nucleic acid sequence of  
5 SEQ ID NO: 337.

The above and further aspects and preferred embodiments of the invention are described in the following sections and in the appended claims. The subject-matter of appended claims is hereby specifically incorporated in this specification.

### BRIEF DESCRIPTION OF FIGURES

10 **Figure 1:** Binding of VHH as crude VHH-containing periplasmic extracts to coated fungal GlcCer from *Pleurotus citrinopileatus*. Anti-GlcCer VHH bind to fungal GlcCer, no binding is observed for unrelated VHH.

**Figure 2:** Binding specificity of VHH 41D01. Binding of purified VHH 41D01 at 0.1 µg/ml to coated fungal GlcCer from *Fusarium oxysporum* or *Pleurotus citrinopileatus*, and non-fungal GlcCer from plant (soy), or  
15 mammal (pork). Bars represent average OD 405 nm values, error bars represent standard errors of the mean of n = 6. Anti-GlcCer VHH 41D01 specifically binds fungal GlcCer and not plant or mammalian GlcCer.

**Figure 3A-C:** Binding specificity of VHH. Binding of purified VHH at 1 µg/ml to coated fungal GlcCer from *Fusarium oxysporum* or *Pleurotus citrinopileatus*, non-fungal GlcCer from plant (soy), and non-fungal  
20 mammalian GlcCer (pig). Different anti-GlcCer VHH specifically bind to different fungal GlcCer, but do not bind to plant GlcCer or mammalian GlcCer.

**Figure 4:** Real-time measurement of the antibody-antigen interaction between VHH 41D01 and fungal GlcCer. VHH 41D01 binds fungal GlcCer. A slow dissociation of GlcCer from VHH 41D01 is observed. Unrelated VHH\_A does not bind fungal GlcCer.

25 **Figure 5:** Cross-reactivity and specificity of VHH 41D01 and VHH 56F11. Binding of purified VHH 41D01 at 0.1 µg/ml and VHH 56F11 at 1 µg/ml to coated fungal lipid extracts, GlcCer from *Pleurotus citrinopileatus*, and unrelated compounds: apple pectin, citrus pectin, or potato lectin. Bars represent average OD 405 nm values, error bars represent standard errors of the mean of n = 2. Anti-GlcCer VHH 41D01 and VHH 56F11 specifically bind each of the fungal lipid extracts tested. Anti-GlcCer VHH 41D01  
30 and VHH 56F11 do not show binding to unrelated coated compounds or non-coated wells.

**Figure 6:** Binding of VHH 41D01 in different compositions to fungal GlcCer from *Fusarium oxysporum*. Aqueous compositions containing anti-GlcCer VHH 41D01 at 0.1 µg/ml and protease inhibitors and/or non-ionic surfactant and/or preservative were tested for binding to fungal GlcCer. GlcCer-specific VHH 41D01 binds to fungal GlcCer in all compositions tested without adverse effects of any of the additives.

35 **Figure 7:** Schematic representation of localization and protein expression of VHH constructs as taught herein. VHH: variable domain of a heavy-chain antibody; His: His6 tag, consists of 6 His repeats (SEQ ID NO: 348); KDEL: ER retention signal (SEQ ID NO: 349); 2S2: seed storage protein gene signal peptide

(SEQ ID NO: 350); Fc: Fc from mouse IgG3 (SEQ ID NO: 351); linker: 9GS spacer (SEQ ID NO: 352); CW: cell wall; PM: plasma membrane; ER: endoplasmatic reticulum; TGN: trans-Golgi network; CCV: Clathrin-coated vesicle.

**Figure 8:** Binding of sec\_56F11\_hinge\_Fc\_HIS to coated fungal GlcCer. Specific binding to coated wells, but not to uncoated wells, was observed for sec\_56F11\_hinge\_Fc\_HIS in leaf extract of overexpressing plants.

**Figure 9A-B:** Increased resistance against *Botrytis cinerea* of plants expressing VHH specifically binding fungal GlcCer. Smaller lesions were observed on the leaves of VHH-overexpressing plants inoculated with *B. cinerea* spores.

10

### DETAILED DESCRIPTION OF THE INVENTION

The present invention will be described with respect to particular embodiments but the invention is not limited thereto.

Statements (features) and embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as disclosed herein are set herebelow. Each of the statements and embodiments of the invention so defined may be combined with any other statement and/or embodiment unless clearly indicated to the contrary. In particular, any feature or features or statements indicated as being preferred or advantageous may be combined with any other feature or features or statement indicated as being preferred or advantageous. Hereto, the present invention is in particular captured by any one or any combination of one or more of the below numbered aspects and embodiments 1 to 91, with any other statement and/or embodiments.

20


Numbered statements as disclosed in the present application are:

1. A transgenic plant or plant tissue or plant cell comprising at least one polynucleotide comprising at least one sequence encoding a variable domain of a heavy-chain antibody (VHH) specifically binding to a sphingolipid of a fungus.
2. The transgenic plant or plant tissue or plant cell according to statement 1, wherein the sphingolipid is a ceramide.
3. The transgenic plant or plant tissue or plant cell according to statement 1 or 2, wherein the sphingolipid is a glycosphingolipid.
4. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 3, wherein the sphingolipid is a cerebroside.
5. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 4, wherein the sphingolipid comprises a C19 sphingoid base with a C-9 methyl group, and two double bonds ( $\Delta 4$ ,  $\Delta 8$ ).
6. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 5, wherein the sphingolipid has, comprises, consists of, or is represented by the following structure:


25

30


35



7. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 6, wherein the sphingolipid has, comprises, consists of, or is represented by any of the following structures:



- 5 8. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 7, wherein the sphingolipid is a glucocerebroside.
9. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 8, wherein the sphingolipid has, comprises, consists of, or is represented by the following structure:



- 10 N-2'-hydroxyhexadecanoyl-1-β-D-glucopyranosyl-9-methyl-4,8-sphingadienine

10. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 9, wherein the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell (i) protects at least part of the transgenic plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, (ii) inhibits the growth of a plant pathogenic fungus on at least part of the transgenic plant or plant tissue or plant cell, and/or (iii) increases the resistance of at least part of the transgenic plant or plant tissue or plant cell against a plant pathogenic fungus.

11. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 10, wherein the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell protects at least part of the transgenic plant or plant tissue or plant cell from an infection with a plant pathogenic fungus.
- 5 12. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 11, wherein the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell protects at least part of the transgenic plant or plant tissue or plant cell from an infection or other biological interaction with a plant pathogenic fungus.
- 10 13. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 12, wherein the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell inhibits the growth of a plant pathogenic fungus on at least part of the transgenic plant or plant tissue.
- 15 14. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 13, wherein the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell increases the resistance of at least part of the transgenic plant or plant tissue or plant cell against a plant pathogenic fungus.
- 20 15. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 14, wherein the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell (i) protects at least part of the transgenic plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, (ii) inhibits the growth of a plant pathogenic fungus on at least part of the transgenic plant or plant tissue or plant cell, and (iii) increases the resistance of at least part of the transgenic plant or plant tissue or plant cell against a plant pathogenic fungus.
- 25 16. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 15, wherein the polynucleotide comprises a promoter suitable for expression in plants, a plant tissue or plant cell specific promoter, or an inducible promoter.
17. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 16, wherein the polynucleotide comprises a promoter suitable for expression in plants such as a the 35S Cauliflower Mosaic Virus (CaMV) promoter.
- 30 18. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 17, wherein the polynucleotide comprises at least one sequence encoding a targeting signal for secretion, for location to the cytoplasm, or for location to cellular compartments or organelles, such as the endoplasmic reticulum (ER) lumen, the apoplast, the vacuole, or intra- and/or exterior membranes.
- 35 19. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 18, wherein the polynucleotide comprises at least one sequence encoding a tag, preferably a His6, c-myc, FLAG, C-tag, 3xFLAG, His5, HA, T7, strep, HSV, and/or an E-tag.

20. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 19, wherein the polynucleotide encodes the VHH as such, as a combination with one or more identical or different VHHs, or as a combination with one or more identical or different VHHs with a fragment crystallizable region (Fc region); optionally with a spacer.
- 5 21. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 20, wherein the polynucleotide encodes the VHH as such, optionally with a spacer.
22. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 21, wherein the polynucleotide encodes the VHH as a combination with one or more identical or different VHHs, optionally with a spacer.
- 10 23. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 22, wherein the polynucleotide encodes the VHH as a combination with one or more identical or different VHHs with a fragment crystallizable region (Fc region), optionally with a spacer.
24. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 23, wherein the plant is a plant selected from the group consisting of corn, rice, wheat, barley, 15 sorghum, millet oats, rye, triticale or other cereals, soybean, alfalfa or other leguminous crops, sugar beet, fodder beet, papaya, banana and plantains or other fruits, grapevines, nuts, oilseed rape, sunflower or other oil crops, squash cucumber, melons or other cucurbits, cotton or other fiber plants, sugarcane, palm, jatropha or other fuel crops, cabbages, tomato, pepper or other vegetables, ornamentals, shrubs, poplar, eucalyptus or other trees, evergreens, grasses, coffee 20 plants, tea plants, tobacco plants, hop plants, rubber plants, and latex plants.
25. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 24, wherein the plant is selected from the group consisting of banana, barley oat rye, canola, corn, cotton, potato, rice, soybean, tobacco, and wheat, preferably wheat triticale.
26. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 25, 25 wherein the plant is selected from the group consisting of canola, corn, rice, soybean, and wheat.
27. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 26, wherein the plant is selected from the group consisting of rice, soybean, and wheat.
28. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 27, 30 wherein the polynucleotide comprises a sequence encoding a VHH comprising any one or more of SEQ ID NO 1 to 84.
29. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 28, wherein the polynucleotide comprises a sequence encoding a VHH comprising SEQ ID NO 1, SEQ ID NO 2, and/or SEQ ID NO 70.
30. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 29, 35 wherein the polynucleotide comprises a sequence encoding a VHH comprising SEQ ID NO 1 and/or 2.

31. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 30, wherein the polynucleotide comprises a sequence encoding a VHH comprising SEQ ID NO 1.
32. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 31, wherein the polynucleotide comprises a sequence encoding a VHH comprising SEQ ID NO 2.
- 5 33. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 32, wherein the polynucleotide comprises a sequence encoding a VHH comprising SEQ ID NO 70.
34. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 33, wherein the polynucleotide comprises a sequence encoding a VHH comprising: a CDR1, CDR2, and CDR3 region, wherein (i) the CDR1 region is selected from the group of SEQ ID NOs 85-168, and/or (ii) the CDR2 region is selected from the group of SEQ ID NOs 169-252, and/or (iii) the CDR3 region is selected from the group of SEQ ID NOs 253-335, or the CDR3 region has the amino acid sequence NRY.
- 10
35. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 34, wherein the polynucleotide comprises a sequence encoding a VHH comprising a CDR1, CDR2 and CDR3 region chosen from the list of comprising:
- 15
- a CDR1 region having SEQ ID NO: 85, a CDR2 region having has SEQ ID NO: 169, and a CDR3 region having SEQ ID NO: 253, and/or
- a CDR1 region having SEQ ID NO: 86, a CDR2 region having has SEQ ID NO: 170, and a CDR3 region having SEQ ID NO: 254, and/or
- 20
- a CDR1 region having SEQ ID NO: 87, a CDR2 region having has SEQ ID NO: 171, and a CDR3 region having SEQ ID NO: 255, and/or
- a CDR1 region having SEQ ID NO: 88, a CDR2 region having has SEQ ID NO: 172, and a CDR3 region having SEQ ID NO: 256, and/or
- 25
- a CDR1 region having SEQ ID NO: 89, a CDR2 region having has SEQ ID NO: 173, and a CDR3 region having SEQ ID NO: 257, and/or
- a CDR1 region having SEQ ID NO: 90, a CDR2 region having has SEQ ID NO: 174, and a CDR3 region having SEQ ID NO: 258, and/or
- a CDR1 region having SEQ ID NO: 91, a CDR2 region having has SEQ ID NO: 175, and a CDR3 region having SEQ ID NO: 259, and/or
- 30
- a CDR1 region having SEQ ID NO: 92, a CDR2 region having has SEQ ID NO: 176, and a CDR3 region having SEQ ID NO: 260, and/or
- a CDR1 region having SEQ ID NO: 93, a CDR2 region having has SEQ ID NO: 177, and a CDR3 region having SEQ ID NO: 261, and/or
- 35
- a CDR1 region having SEQ ID NO: 94, a CDR2 region having has SEQ ID NO: 178, and a CDR3 region having SEQ ID NO: 262, and/or

- a CDR1 region having SEQ ID NO: 95, a CDR2 region having has SEQ ID NO: 179, and a CDR3 region having SEQ ID NO: 263, and/or
- a CDR1 region having SEQ ID NO: 96, a CDR2 region having has SEQ ID NO: 180, and a CDR3 region having SEQ ID NO: 264, and/or
- 5 a CDR1 region having SEQ ID NO: 97, a CDR2 region having has SEQ ID NO: 181, and a CDR3 region having SEQ ID NO: 265, and/or
- a CDR1 region having SEQ ID NO: 98, a CDR2 region having has SEQ ID NO: 182, and a CDR3 region having SEQ ID NO: 266, and/or
- 10 a CDR1 region having SEQ ID NO: 99, a CDR2 region having has SEQ ID NO: 183, and a CDR3 region having SEQ ID NO: 267, and/or
- a CDR1 region having SEQ ID NO: 100, a CDR2 region having has SEQ ID NO: 184, and a CDR3 region having SEQ ID NO: 268, and/or
- a CDR1 region having SEQ ID NO: 101, a CDR2 region having has SEQ ID NO: 185, and a CDR3 region having SEQ ID NO: 269, and/or
- 15 a CDR1 region having SEQ ID NO: 102, a CDR2 region having has SEQ ID NO: 186, and a CDR3 region having SEQ ID NO: 270, and/or
- a CDR1 region having SEQ ID NO: 103, a CDR2 region having has SEQ ID NO: 187, and a CDR3 region having SEQ ID NO: 271, and/or
- a CDR1 region having SEQ ID NO: 104, a CDR2 region having has SEQ ID NO: 188, and a CDR3 region having SEQ ID NO: 272, and/or
- 20 a CDR1 region having SEQ ID NO: 105, a CDR2 region having has SEQ ID NO: 189, and a CDR3 region having SEQ ID NO: 273, and/or
- a CDR1 region having SEQ ID NO: 106, a CDR2 region having has SEQ ID NO: 190, and a CDR3 region having SEQ ID NO: 274, and/or
- 25 a CDR1 region having SEQ ID NO: 107, a CDR2 region having has SEQ ID NO: 191, and a CDR3 region having SEQ ID NO: 275, and/or
- a CDR1 region having SEQ ID NO: 108, a CDR2 region having has SEQ ID NO: 192, and a CDR3 region having SEQ ID NO: 276, and/or
- a CDR1 region having SEQ ID NO: 109, a CDR2 region having has SEQ ID NO: 193, and a CDR3 region having SEQ ID NO: 277, and/or
- 30 a CDR1 region having SEQ ID NO: 110, a CDR2 region having has SEQ ID NO: 194, and a CDR3 region having SEQ ID NO: 278, and/or
- a CDR1 region having SEQ ID NO: 111, a CDR2 region having has SEQ ID NO: 195, and a CDR3 region having SEQ ID NO: 279, and/or

- a CDR1 region having SEQ ID NO: 112, a CDR2 region having has SEQ ID NO: 196, and a CDR3 region having SEQ ID NO: 280, and/or
- a CDR1 region having SEQ ID NO: 113, a CDR2 region having has SEQ ID NO: 197, and a CDR3 region having SEQ ID NO: 281, and/or
- 5 a CDR1 region having SEQ ID NO: 114, a CDR2 region having has SEQ ID NO: 198, and a CDR3 region having SEQ ID NO: 282, and/or
- a CDR1 region having SEQ ID NO: 115, a CDR2 region having has SEQ ID NO: 199, and a CDR3 region having SEQ ID NO: 283, and/or
- 10 a CDR1 region having SEQ ID NO: 116, a CDR2 region having has SEQ ID NO: 200, and a CDR3 region having SEQ ID NO: 284, and/or
- a CDR1 region having SEQ ID NO: 117, a CDR2 region having has SEQ ID NO: 201, and a CDR3 region having SEQ ID NO: 285, and/or
- a CDR1 region having SEQ ID NO: 118, a CDR2 region having has SEQ ID NO: 202, and a CDR3 region having SEQ ID NO: 286, and/or
- 15 a CDR1 region having SEQ ID NO: 119, a CDR2 region having has SEQ ID NO: 203, and a CDR3 region having SEQ ID NO: 287, and/or
- a CDR1 region having SEQ ID NO: 120, a CDR2 region having has SEQ ID NO: 204, and a CDR3 region having SEQ ID NO: 288, and/or
- a CDR1 region having SEQ ID NO: 121, a CDR2 region having has SEQ ID NO: 205, and a CDR3 region having SEQ ID NO: 289, and/or
- 20 a CDR1 region having SEQ ID NO: 122, a CDR2 region having has SEQ ID NO: 206, and a CDR3 region having SEQ ID NO: 290, and/or
- a CDR1 region having SEQ ID NO: 123, a CDR2 region having has SEQ ID NO: 207, and a CDR3 region having SEQ ID NO: 291, and/or
- 25 a CDR1 region having SEQ ID NO: 124, a CDR2 region having has SEQ ID NO: 208, and a CDR3 region having SEQ ID NO: 292, and/or
- a CDR1 region having SEQ ID NO: 125, a CDR2 region having has SEQ ID NO: 209, and a CDR3 region having SEQ ID NO: 293, and/or
- a CDR1 region having SEQ ID NO: 126, a CDR2 region having has SEQ ID NO: 210, and a CDR3 region having SEQ ID NO: 294, and/or
- 30 a CDR1 region having SEQ ID NO: 127, a CDR2 region having has SEQ ID NO: 211, and a CDR3 region having SEQ ID NO: 295, and/or
- a CDR1 region having SEQ ID NO: 128, a CDR2 region having has SEQ ID NO: 212, and a CDR3 region having SEQ ID NO: 296, and/or

- a CDR1 region having SEQ ID NO: 129, a CDR2 region having has SEQ ID NO: 213, and a CDR3 region having SEQ ID NO: 297, and/or
- a CDR1 region having SEQ ID NO: 130, a CDR2 region having has SEQ ID NO: 214, and a CDR3 region having SEQ ID NO: 298, and/or
- 5 a CDR1 region having SEQ ID NO: 131, a CDR2 region having has SEQ ID NO: 215, and a CDR3 region having SEQ ID NO: 299, and/or
- a CDR1 region having SEQ ID NO: 132, a CDR2 region having has SEQ ID NO: 216, and a CDR3 region having SEQ ID NO: 300, and/or
- 10 a CDR1 region having SEQ ID NO: 133, a CDR2 region having has SEQ ID NO: 217, and a CDR3 region having SEQ ID NO: 301, and/or
- a CDR1 region having SEQ ID NO: 134, a CDR2 region having has SEQ ID NO: 218, and a CDR3 region having SEQ ID NO: 302, and/or
- a CDR1 region having SEQ ID NO: 135, a CDR2 region having has SEQ ID NO: 219, and a CDR3 region having SEQ ID NO: 303, and/or
- 15 a CDR1 region having SEQ ID NO: 136, a CDR2 region having has SEQ ID NO: 220, and a CDR3 region having SEQ ID NO: 304, and/or
- a CDR1 region having SEQ ID NO: 137, a CDR2 region having has SEQ ID NO: 221, and a CDR3 region having SEQ ID NO: 305, and/or
- 20 a CDR1 region having SEQ ID NO: 138, a CDR2 region having has SEQ ID NO: 222, and a CDR3 region having SEQ ID NO: 306, and/or
- a CDR1 region having SEQ ID NO: 139, a CDR2 region having has SEQ ID NO: 223, and a CDR3 region having the amino acid sequence NRY, and/or
- a CDR1 region having SEQ ID NO: 140, a CDR2 region having has SEQ ID NO: 224, and a CDR3 region having SEQ ID NO: 307, and/or
- 25 a CDR1 region having SEQ ID NO: 141, a CDR2 region having has SEQ ID NO: 225, and a CDR3 region having SEQ ID NO: 308, and/or
- a CDR1 region having SEQ ID NO: 142, a CDR2 region having has SEQ ID NO: 226, and a CDR3 region having SEQ ID NO: 309, and/or
- a CDR1 region having SEQ ID NO: 143, a CDR2 region having has SEQ ID NO: 227, and a CDR3 region having SEQ ID NO: 310, and/or
- 30 a CDR1 region having SEQ ID NO: 144, a CDR2 region having has SEQ ID NO: 228, and a CDR3 region having SEQ ID NO: 311, and/or
- a CDR1 region having SEQ ID NO: 145, a CDR2 region having has SEQ ID NO: 229, and a CDR3 region having SEQ ID NO: 312, and/or

- a CDR1 region having SEQ ID NO: 146, a CDR2 region having has SEQ ID NO: 230, and a CDR3 region having SEQ ID NO: 313, and/or
- a CDR1 region having SEQ ID NO: 147, a CDR2 region having has SEQ ID NO: 231, and a CDR3 region having SEQ ID NO: 314, and/or
- 5 a CDR1 region having SEQ ID NO: 148, a CDR2 region having has SEQ ID NO: 232, and a CDR3 region having SEQ ID NO: 315, and/or
- a CDR1 region having SEQ ID NO: 149, a CDR2 region having has SEQ ID NO: 233, and a CDR3 region having SEQ ID NO: 316, and/or
- 10 a CDR1 region having SEQ ID NO: 150, a CDR2 region having has SEQ ID NO: 234, and a CDR3 region having SEQ ID NO: 317, and/or
- a CDR1 region having SEQ ID NO: 151, a CDR2 region having has SEQ ID NO: 235, and a CDR3 region having SEQ ID NO: 318, and/or
- a CDR1 region having SEQ ID NO: 152, a CDR2 region having has SEQ ID NO: 236, and a CDR3 region having SEQ ID NO: 319, and/or
- 15 a CDR1 region having SEQ ID NO: 153, a CDR2 region having has SEQ ID NO: 237, and a CDR3 region having SEQ ID NO: 320, and/or
- a CDR1 region having SEQ ID NO: 154, a CDR2 region having has SEQ ID NO: 238, and a CDR3 region having SEQ ID NO: 321, and/or
- 20 a CDR1 region having SEQ ID NO: 155, a CDR2 region having has SEQ ID NO: 239, and a CDR3 region having SEQ ID NO: 322, and/or
- a CDR1 region having SEQ ID NO: 156, a CDR2 region having has SEQ ID NO: 240, and a CDR3 region having SEQ ID NO: 323, and/or
- a CDR1 region having SEQ ID NO: 157, a CDR2 region having has SEQ ID NO: 241, and a CDR3 region having SEQ ID NO: 324, and/or
- 25 a CDR1 region having SEQ ID NO: 158, a CDR2 region having has SEQ ID NO: 242, and a CDR3 region having SEQ ID NO: 325, and/or
- a CDR1 region having SEQ ID NO: 159, a CDR2 region having has SEQ ID NO: 243, and a CDR3 region having SEQ ID NO: 326, and/or
- a CDR1 region having SEQ ID NO: 160, a CDR2 region having has SEQ ID NO: 244, and a CDR3 region having SEQ ID NO: 327, and/or
- 30 a CDR1 region having SEQ ID NO: 161, a CDR2 region having has SEQ ID NO: 245, and a CDR3 region having SEQ ID NO: 328, and/or
- a CDR1 region having SEQ ID NO: 162, a CDR2 region having has SEQ ID NO: 246, and a CDR3 region having SEQ ID NO: 329, and/or

- a CDR1 region having SEQ ID NO: 163, a CDR2 region having has SEQ ID NO: 247, and a CDR3 region having SEQ ID NO: 330, and/or
- a CDR1 region having SEQ ID NO: 164, a CDR2 region having has SEQ ID NO: 248, and a CDR3 region having SEQ ID NO: 331, and/or
- 5 a CDR1 region having SEQ ID NO: 165, a CDR2 region having has SEQ ID NO: 249, and a CDR3 region having SEQ ID NO: 332, and/or
- a CDR1 region having SEQ ID NO: 166, a CDR2 region having has SEQ ID NO: 250, and a CDR3 region having SEQ ID NO: 333, and/or
- 10 a CDR1 region having SEQ ID NO: 167, a CDR2 region having has SEQ ID NO: 251, and a CDR3 region having SEQ ID NO: 334, and/or
- a CDR1 region having SEQ ID NO: 168, a CDR2 region having has SEQ ID NO: 252, and a CDR3 region having SEQ ID NO: 335.
36. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 35, wherein the polynucleotide comprises a sequence encoding a VHH comprising a CDR1 region having SEQ ID NO: 85, a CDR2 region having has SEQ ID NO: 169, and a CDR3 region having SEQ ID NO: 253.
- 15
37. The transgenic plant or plant tissue or plant cell according to any one of statements 1 to 35, wherein the polynucleotide comprises a sequence encoding a VHH comprising a CDR1 region having SEQ ID NO: 86, a CDR2 region having has SEQ ID NO: 170, and a CDR3 region having SEQ ID NO: 254.
- 20
38. Harvestable parts and propagation materials of a transgenic plant or plant tissue or plant cell according to any one of statements 1 to 37, comprising at least one polynucleotide as defined in any one of statements 1 to 37.
39. The harvestable parts and propagation materials according to statement 38, wherein the harvestable parts and propagation materials of a transgenic plant or plant tissue or plant cell are selected from the group consisting of seeds, fruits, grains, bulbs, bolls, tubers, progeny, and hybrids.
- 25
40. A method for the production of a transgenic plant or plant tissue or plant cell comprising the introduction of at least one polynucleotide as defined in any one of statements 1 to 37 into the genome of a plant or plant tissue.
- 30
41. The use of at least one polynucleotide as defined in any one of statements 1 to 37, for the production of a transgenic plant or plant tissue.
42. A method for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, comprising expressing in at least part of the plant or plant tissue or plant cell at
- 35

least one polynucleotide encoding a variable domain of a heavy-chain antibody (VHH) specifically binding to a pathogen.

- 5 43. The method according to statement 42, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, for inhibiting the growth of a plant pathogenic fungus on at least part of a plant or plant tissue or plant cell, and/or for increasing resistance of at least part of a plant or plant tissue or plant cell against the plant pathogenic fungus, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide as defined any one of statements 1 to 37.
- 10 44. The method according to statement 42 or 43, wherein the VHH specifically binds to a sphingolipid of a pathogen.
45. The method according to any one of statements 42 to 44, wherein the VHH specifically binds to a ceramide of a pathogen.
46. The method according to any one of statements 44 to 45, wherein the VHH specifically binds to a glycosphingolipid of a pathogen.
- 15 47. The method according to any one of statements 44 to 46, wherein the VHH specifically binds to a cerebroside of a pathogen.
48. The method according to any one of statements 44 to 47, wherein the VHH specifically binds to a glucocerebroside of a pathogen.
- 20 49. The method according to any one of statements 44 to 48, wherein the VHH binds to a plant pathogen.
50. The method according to any one of statements 44 to 49, wherein the VHH binds to a sphingolipid of a plant pathogen.
51. The method according to any one of statements 44 to 50, wherein the VHH binds to a ceramide of a plant pathogen.
- 25 52. The method according to any one of statements 44 to 51, wherein the VHH binds to a glycosphingolipid of a plant pathogen.
53. The method according to any one of statements 44 to 52, wherein the VHH binds to a cerebroside of a plant pathogen.
- 30 54. The method according to any one of statements 44 to 53, wherein the VHH binds to a glucocerebroside of a plant pathogenic fungus.
55. The method according to statements 44 to 54, wherein the VHH specifically binds to a fungus.
56. The method according to statements 44 to 55, wherein the VHH specifically binds to a sphingolipid of a fungus.
- 35 57. The method according to any one of statements 44 to 56, wherein the VHH specifically binds to a ceramide of a fungus.

58. The method according to any one of statements 44 to 57, wherein the VHH specifically binds to a glycosphingolipid of a fungus.
59. The method according to any one of statements 44 to 58, wherein the VHH specifically binds to a cerebroside of a fungus.
- 5 60. The method according to any one of statements 44 to 59, wherein the VHH specifically binds to a glucocerebroside of a fungus.
61. The method according to any one of statements 44 to 60, wherein the VHH binds to a plant pathogenic fungus.
62. The method according to any one of statements 44 to 61, wherein the VHH binds to a sphingolipid  
10 of a plant pathogenic fungus.
63. The method according to any one of statements 44 to 62, wherein the VHH binds to a ceramide of a plant pathogenic fungus.
64. The method according to any one of statements 44 to 63, wherein the VHH binds to a glycosphingolipid of a plant pathogenic fungus.
- 15 65. The method according to any one of statements 44 to 64, wherein the VHH binds to a cerebroside of a plant pathogenic fungus.
66. The method according to any one of statements 44 to 65, wherein the VHH binds to a glucocerebroside of a plant pathogenic fungus.
67. Use of at least one polynucleotide encoding a variable domain of a heavy-chain antibody (VHH)  
20 specifically binding to a pathogen, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, wherein the polynucleotide is expressed in at least part of the plant or plant tissue.
- 25 68. The use according to statement 67, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, for inhibiting the growth of a plant pathogenic fungus on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, wherein the polynucleotide is defined as in any one of statements 1 to 37.
- 30 69. The use according to statement 67 or 64, wherein the VHH specifically binds to a sphingolipid of a pathogen.
70. The use according to any one of statements 67 to 69, wherein the VHH specifically binds to a ceramide of a pathogen.
- 35 71. The use according to any one of statements 67 to 70, wherein the VHH specifically binds to a glycosphingolipid of a pathogen.

72. The use according to any one of statements 67 to 71, wherein the VHH specifically binds to a cerebroside of a pathogen.
73. The use according to any one of statements 67 to 72, wherein the VHH specifically binds to a glucocerebroside of a pathogen.
- 5 74. The use according to any one of statements 67 to 73, wherein the VHH binds to a plant pathogen.
75. The use according to any one of statements 67 to 74, wherein the VHH binds to a sphingolipid of a plant pathogen.
76. The use according to any one of statements 67 to 75, wherein the VHH binds to a ceramide of a plant pathogen.
- 10 77. The use according to any one of statements 67 to 76, wherein the VHH binds to a glycosphingolipid of a plant pathogen.
78. The use according to any one of statements 67 to 77, wherein the VHH binds to a cerebroside of a plant pathogen.
79. The use according to any one of statements 67 to 78, wherein the VHH binds to a glucocerebroside of a plant pathogenic fungus.
- 15
80. The use according to statements 67 to 79, wherein the VHH specifically binds to a fungus.
81. The use according to statements 67 to 80, wherein the VHH specifically binds to a sphingolipid of a fungus.
82. The use according to any one of statements 67 to 81, wherein the VHH specifically binds to a ceramide of a fungus.
- 20
83. The use according to any one of statements 67 to 82, wherein the VHH specifically binds to a glycosphingolipid of a fungus.
84. The use according to any one of statements 67 to 83, wherein the VHH specifically binds to a cerebroside of a fungus.
- 25 85. The use according to any one of statements 67 to 84, wherein the VHH specifically binds to a glucocerebroside of a fungus.
86. The use according to any one of statements 67 to 85, wherein the VHH binds to a plant pathogenic fungus.
87. The use according to any one of statements 67 to 86, wherein the VHH binds to a sphingolipid of a plant pathogenic fungus.
- 30
88. The use according to any one of statements 67 to 87, wherein the VHH binds to a ceramide of a plant pathogenic fungus.
89. The use according to any one of statements 67 to 88, wherein the VHH binds to a glycosphingolipid of a plant pathogenic fungus.

90. The use according to any one of statements 67 to 89, wherein the VHH binds to a cerebroside of a plant pathogenic fungus.
91. The use according to any one of statements 67 to 90, wherein the VHH binds to a glucocerebroside of a plant pathogenic fungus.
- 5 92. An extract of a transgenic plant or plant tissue or plant cell according to any one of statements 1 to 37, said extract comprising said VHH.
93. A composition comprising the extract of statement 92.
94. A method for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant  
10 tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, comprising treating said at least part of a plant or plant tissue or plant cell with the extract of statement 92 or the composition of statement 93.
95. Use of the extract of statement 92 or the composition of claim 93 for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of  
15 a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell.

#### DEFINITIONS

The present invention will be described with respect to particular embodiments but the invention is not  
20 limited thereto but only by the claims. Any reference signs in the claims shall not be construed as limiting the scope.

Where the term "comprising" is used in the present description and claims, it does not exclude other elements or steps.

Where an indefinite or definite article is used when referring to a singular noun e.g. "a" or "an", "the", this  
25 includes a plural of that noun unless something else is specifically stated.

The term "about" as used herein when referring to a measurable value such as a parameter, an amount, a temporal duration, and the like, is meant to encompass variations of +/- 10% or less, preferably +/- 5 % or less, more preferably +/- 1% or less, and still more preferably +/- 0.1% or less of and from the specified value, insofar such variations are appropriate to perform in the disclosed invention. It is to be understood  
30 that the value to which the modifier 'about' refers is itself also specifically, and preferably, disclosed.

The following terms or definitions are provided solely to aid in the understanding of the invention. Unless specifically defined herein, all terms used herein have the same meaning as they would to one skilled in the art of the present invention. Practitioners are particularly directed to Sambrook et al., Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., Cold Spring Harbor Press, Plainsview, New York (1989); and  
35 Ausubel et al., Current Protocols in Molecular Biology (Supplement 47), John Wiley & Sons, New York

(1999), for definitions and terms of the art. The definitions provided herein should not be construed to have a scope less than understood by a person of ordinary skill in the art.

Unless indicated otherwise, all methods, steps, techniques and manipulations that are not specifically described in detail can be performed and have been performed in a manner known per se, as will be clear to the skilled person. Reference is for example again made to the standard handbooks, to the  
5 general background art referred to above and to the further references cited therein.

As used herein, the terms "polypeptide", "protein", "peptide", and "amino acid sequence" are used interchangeably, and refer to a polymeric form of amino acids of any length, which can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and  
10 polypeptides having modified peptide backbones.

As used herein, amino acid residues will be indicated either by their full name or according to the standard three-letter or one-letter amino acid code.

As used herein, the terms "nucleic acid molecule", "polynucleotide", "polynucleic acid", "nucleic acid" are used interchangeably and refer to a polymeric form of nucleotides of any length, either  
15 deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function, known or unknown. Non-limiting examples of polynucleotides include a gene, a gene fragment, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, control regions, isolated RNA of any sequence, nucleic acid  
20 probes, and primers. The nucleic acid molecule may be linear or circular.

As used herein, the term "homology" denotes at least secondary structural similarity between two macromolecules, particularly between two polypeptides or polynucleotides, from same or different taxons, wherein said similarity is due to shared ancestry. Hence, the term "homologues" denotes so-related macromolecules having said secondary and optionally tertiary structural similarity.

25 For comparing two or more polynucleotide sequences, the '(percentage of) sequence identity' between a first polynucleotide sequence and a second polynucleotide sequence may be calculated using methods known by the person skilled in the art, e.g. by optimally aligning the polynucleotide sequences and introducing gaps, if necessary, followed by dividing the number of nucleotides in the first polynucleotide sequence that are identical to the nucleotides at the corresponding positions in the second polynucleotide  
30 sequence in a comparison window by the number of positions in the comparison window (the window size), and multiplying by 100%. Optimal sequence alignment of two or more polynucleotide sequences over a comparison window can be obtained by using a known computer algorithm for sequence alignment such as NCBI Blast (Altschul et al. J. Mol. Biol. 1990 Oct. 5; 215 (3): 403-410). Another example of an algorithm that is suitable for polynucleotide sequence alignments is the CLUSTALW program (Thompson,  
35 J. D. et al. Nucl. Acids Res. 1994 Nov. 11; 22 (22): 4673-4680). CLUSTALW performs multiple pairwise comparisons between groups of sequences and assembles them into a multiple alignment based on homology. For comparing two or more polypeptide sequences, the '(percentage of) sequence identity' between a first polypeptide sequence and a second polypeptide sequence may be calculated using

5 methods known by the person skilled in the art, e.g. by optimally aligning the polypeptide sequences and introducing gaps, if necessary, followed by dividing the number of amino acids in the first polypeptide sequence that are identical to the amino acids at the corresponding positions in the second polypeptide sequence in a comparison window by the number of positions in the comparison window (the window size), and multiplying by 100%. Optimal sequence alignment of two or more polypeptide sequences over a comparison window can be obtained by using a known computer algorithm for sequence alignment such as NCBI Blast (Altschul et al. J. Mol. Biol. 1990 Oct. 5; 215 (3): 403-410). Another example of an algorithm that is suitable for polypeptide sequence alignments is the CLUSTALW program (Thompson, J. D. et al. Nucl. Acids Res. 1994 Nov. 11; 22 (22): 4673-4680). CLUSTALW performs multiple pairwise comparisons between groups of sequences and assembles them into a multiple alignment based on homology. For amino acid alignments, the BLOSUM algorithm can be used as a protein weight matrix (Henikoff and Henikoff PNAS USA 1992 Nov. 15; 89 (22): 10915-10919). In determining the degree of sequence homology between two amino acid sequences, the skilled person may take into account so-called 'conservative' amino acid substitutions, which can generally be described as amino acid substitutions in which an amino acid residue is replaced with another amino acid residue of similar chemical structure and which has little or essentially no influence on the function, activity or other biological properties of the polypeptide. Conservative amino acid substitutions are counted as identities in order to calculate the percentage homology between two polypeptide sequences. Possible conservative amino acid substitutions will be clear to the person skilled in the art.

10 As used herein, "comparison window" makes reference to a contiguous and specified segment of an optimal alignment of polynucleotide or polypeptide sequences, wherein the sequences in the comparison window may comprise gaps for optimal alignment of the two sequences. The comparison window for determining sequence identity or homology may be as long as the longest of the aligned sequences, or as long as the shortest of the aligned sequences, or as long as the alignment including gaps in any of the sequences introduced to optimize the alignment. Comparison windows may be about 5000 positions long, or about 2000 positions, or about 1000 positions, or about 800 positions, or about 600 positions long, or about 500 positions long, or about 400 positions long, or about 300 positions long, or about 200 positions long, or about 100 positions long, or about 50 positions long, or about 40 positions long, or about 30 positions long, or about 20 positions long, or about 10 positions long. Amino acid sequences and nucleic acid sequences are said to be "exactly the same" if they have 100% sequence identity over their entire length.

15 As used herein, the terms "complementarity determining region" or "CDR" within the context of antibodies refer to variable regions of either the H (heavy) or the L (light) chains (also abbreviated as VH and VL, respectively) and contain the amino acid sequences capable of specifically binding to antigenic targets. These CDR regions account for the basic specificity of the antibody for a particular antigenic determinant structure. Such regions are also referred to as "hypervariable regions." The CDRs represent non-contiguous stretches of amino acids within the variable regions but, regardless of species, the positional locations of these critical amino acid sequences within the variable heavy and light chain regions have been found to have similar locations within the amino acid sequences of the variable chains. The variable

heavy and light chains of all canonical antibodies each have 3 CDR regions, each non-contiguous with the others (termed L1, L2, L3, H1, H2, H3) for the respective light (L) and heavy (H) chains.

The term "affinity", as used herein, refers to the degree to which a polypeptide, in particular an immunoglobulin, such as an antibody, or an immunoglobulin fragment, such as a VHH, binds to an antigen so as to shift the equilibrium of antigen and polypeptide toward the presence of a complex formed by their binding. Thus, for example, where an antigen and antibody (fragment) are combined in relatively equal concentration, an antibody (fragment) of high affinity will bind to the available antigen so as to shift the equilibrium toward high concentration of the resulting complex. The dissociation constant is commonly used to describe the affinity between the protein binding domain and the antigenic target. Typically, the dissociation constant is lower than  $10^{-5}$  M. Preferably, the dissociation constant is lower than  $10^{-6}$  M, and more preferably, lower than  $10^{-7}$  M. Most preferably, the dissociation constant is lower than  $10^{-8}$  M.

The terms "specifically bind" and "specific binding", as used herein, generally refers to the ability of a polypeptide, in particular an immunoglobulin, such as an antibody, or an immunoglobulin fragment, such as a VHH, to preferentially bind to a particular antigen that is present in a homogeneous mixture of different antigens. In certain embodiments, a specific binding interaction will discriminate between desirable and undesirable antigens in a sample, in some embodiments more than about 10 to 100-fold or more (e.g., more than about 1000- or 10,000-fold).

Accordingly, an amino acid sequence as disclosed herein is said to "specifically bind to" a particular target when that amino acid sequence has affinity for, specificity for and/or is specifically directed against that target (or for at least one part or fragment thereof).

The "specificity" of an amino acid sequence as disclosed herein can be determined based on affinity and/or avidity.

An amino acid sequence as disclosed herein is said to be "specific for a first target antigen of interest as opposed to a second target antigen of interest" when it binds to the first target antigen of interest with an affinity that is at least 5 times, such as at least 10 times, such as at least 100 times, and preferably at least 1000 times higher than the affinity with which that amino acid sequence as disclosed herein binds to the second target antigen of interest. Accordingly, in certain embodiments, when an amino acid sequence as disclosed herein is said to be "specific for" a first target antigen of interest as opposed to a second target antigen of interest, it may specifically bind to (as defined herein) the first target antigen of interest, but not to the second target antigen of interest.

As used herein, the terms "inhibiting", "reducing" and/or "preventing" may refer to (the use of) an amino acid sequence as disclosed herein that specifically binds to a target antigen of interest and inhibits, reduces and/or prevents the interaction between that target antigen of interest, and its natural binding partner. The terms "inhibiting", "reducing" and/or "preventing" may also refer to (the use of) an amino acid sequence as disclosed herein that specifically binds to a target antigen of interest and inhibits, reduces and/or prevents a biological activity of that target antigen of interest, as measured using a suitable in vitro, cellular or in vivo assay. Accordingly, "inhibiting", "reducing" and/or "preventing" may also refer to (the use of) an amino acid sequence as disclosed herein that specifically binds to a target antigen of interest and

inhibits, reduces and/or prevents one or more biological or physiological mechanisms, effects, responses, functions pathways or activities in which the target antigen of interest is involved. Such an action of the amino acid sequence as disclosed herein as an antagonist may be determined in any suitable manner and/or using any suitable (in vitro and usually cellular or in vivo) assay known in the art, depending on the target antigen of interest.

Thus, more particularly, "inhibiting", "reducing" and/or "preventing" using amino acid sequence as disclosed herein may mean either inhibiting, reducing and/or preventing the interaction between a target antigen of interest and its natural binding partner, or inhibiting, reducing and/or preventing the activity of a target antigen of interest, or inhibiting, reducing and/or preventing one or more biological or physiological mechanisms, effects, responses, functions pathways or activities in which the target antigen of interest is involved, such as by at least 10%, but preferably at least 20%, for example by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more, as measured using a suitable in vitro, cellular, or in vivo assay, compared to the activity of the target antigen of interest in the same assay under the same conditions but without using the amino acid sequence as disclosed herein. In addition, "inhibiting", "reducing" and/or "preventing" may also mean inducing a decrease in affinity, avidity, specificity and/or selectivity of a target antigen of interest for one or more of its natural binding partners and/or inducing a decrease in the sensitivity of the target antigen of interest for one or more conditions in the medium or surroundings in which the target antigen of interest is present (such as pH, ion strength, the presence of co-factors, etc.), compared to the same conditions but without the presence of the amino acid sequence as disclosed herein. In the context of the present invention, "inhibiting", "reducing" and/or "preventing" may also involve allosteric inhibition, reduction and/or prevention of the activity of a target antigen of interest.

The inhibiting or antagonizing activity or the enhancing or agonizing activity of an amino acid sequence as disclosed herein may be reversible or irreversible.

In respect of the amino acid sequences as disclosed herein, the terms "binding region", "binding site" or "interaction site" present on the amino acid sequences as disclosed herein shall herein have the meaning of a particular site, region, locus, part, or domain present on the target molecule, which particular site, region, locus, part, or domain is responsible for binding to that target molecule. Such binding region thus essentially consists of that particular site, region, locus, part, or domain of the target molecule, which is in contact with the amino acid sequence when bound to that target molecule.

"Plant" as used herein, means live plants and live plant parts, including fresh fruit, vegetables and seeds. Also, the term "plant" as used herein encompasses whole plants, ancestors and progeny of the plants and plant parts, including seeds, shoots, stems, leaves, roots (including tubers), flowers, and tissues and organs, wherein each of the aforementioned comprise the gene/nucleic acid of interest.

The term "plant" also encompasses plant cells, suspension cultures, callus tissue, embryos, meristematic regions, gametophytes, sporophytes, pollen and microspores, again wherein each of the aforementioned comprises the gene/nucleic acid of interest.

The choice of suitable control plants is a routine part of an experimental setup and may include corresponding wild type plants or corresponding plants without the gene of interest. The control plant is typically of the same plant species or even of the same variety as the plant to be assessed. The control plant may also be a nullizygote of the plant to be assessed. Nullizygotes are individuals missing the transgene by segregation. A "control plant" as used herein refers not only to whole plants, but also to plant parts, including seeds and seed parts.

The term "plant tissue" as used herein refers to a group of similar plant cells from the same origin that together carry out a specific function. Examples of plant tissues include meristematic tissue, protective tissue, parenchyma, sclerenchyma, collenchyma, xylem, and phloem.

"Crop" as used herein means a plant species or variety that is grown to be harvested as food, livestock fodder, fuel raw material, or for any other economic purpose. As a non-limiting example, said crops can be maize, cereals, such as wheat, rye, barley and oats, sorghum, rice, sugar beet and fodder beet, fruit, such as pome fruit (e.g. apples and pears), citrus fruit (e.g. oranges, lemons, limes, grapefruit, or mandarins), stone fruit (e. g. peaches, nectarines or plums), nuts (e.g. almonds or walnuts), soft fruit (e.g. cherries, strawberries, blackberries or raspberries), the plantain family or grapevines, leguminous crops, such as beans, lentils, peas and soya, oil crops, such as sunflower, safflower, rapeseed, canola, castor or olives, cucurbits, such as cucumbers, melons or pumpkins, fibre plants, such as cotton, flax or hemp, fuel crops, such as sugarcane, miscanthus or switchgrass, vegetables, such as potatoes, tomatoes, peppers, lettuce, spinach, onions, carrots, egg-plants, asparagus or cabbage, ornamentals, such as flowers (e.g. petunias, pelargoniums, roses, tulips, lilies, or chrysanthemums), shrubs, broad-leaved trees (e.g. poplars or willows) and evergreens (e.g. conifers), grasses, such as lawn, turf or forage grass or other useful plants, such as coffee, tea, tobacco, hops, pepper, rubber or latex plants.

A "plant pest", "plant pathogen" or "crop pest", as used herein interchangeably, refers to organisms that specifically cause damage to plants, plant parts or plant products, particularly plants, plant parts or plant products, used in agriculture. Note that the term "plant pest" or "crop pest" is used in the meaning that the pest targets and harms plants. Relevant crop pest examples include, but are not limited to pathogenic fungi (including Ascomycetes (such as *Fusarium* spp., *Thielaviopsis* spp., *Verticillium* spp., *Magnaporthe* spp.), Basidiomycetes (such as *Rhizoctonia* spp., *Phakospora* spp., *Puccinia* spp.), and fungal-like Oomycetes (such as *Pythium* spp. and *Phytophthora* spp.), aphids, caterpillars, flies, wasps, and the like, nematodes (living freely in soil or particularly species that parasitize plant roots, such as root-knot nematode and cyst nematodes such as soybean cyst nematode and potato cyst nematode), mites (such as spider mites, thread-footed mites and gall mites) and gastropods (including slugs such as *Deroceras* spp., *Milax* spp., *Tandonia* sp., *Limax* spp., *Arion* spp. and *Veronicella* spp. and snails such as *Helix* spp., *Cernuella* spp., *Theba* spp., *Cochlicella* spp., *Achatina* spp., *Succinea* spp., *Ovachlamys* spp., *Amphibulima* spp., *Zachrysia* spp., *Bradybaena* spp., and *Pomacea* spp.), bacteria (such as *Burkholderia* spp. and *Proteobacteria* such as *Xanthomonas* spp. and *Pseudomonas* spp.), *Phytoplasma*, *Spiroplasma*, viruses (such as tobacco mosaic virus and cauliflower mosaic virus), and protozoa.

"Microbe", as used herein, means fungus, yeast, bacterium, virus, and the like and "microbial" means derived from a microbe.

- “Fungus”, as used herein, means a eukaryotic organism, belonging to the group of Eumycota. The term fungus in the present invention also includes fungal-like organisms such as the Oomycota. Oomycota (or oomycetes) form a distinct phylogenetic lineage of fungus-like eukaryotic microorganisms. This group was originally classified among the fungi but modern insights support a relatively close relationship with the photosynthetic organisms such as brown algae and diatoms, within the group of heterokonts.
- The terms “plant pathogenic fungus” or “fungal plant pathogen”, as used herein interchangeably, refer to any fungus as defined herein capable of causing an infection or other biological reaction on a plant.
- The term “infection” as used herein refers to any inflammatory condition, disease or disorder in a plant which is caused by a plant pathogen.
- “Fungal infection” or “fungal disease” as used herein refers to any inflammatory condition, disease or disorder in a living organism, such as a plant, animal or human, which is caused by a fungus.
- The term “antimicrobial agent”, as used herein, refers to an agent that kills microorganisms or inhibits the growth of microorganisms. Antimicrobial agents encompass antibacterial, antifungal, antiviral, or antiparasitic agents.
- The term “microbicidal agent”, as used herein, refers to an agent that kills microorganisms.
- The term “microbiostatic agent”, as used herein, refers to an agent that inhibits the growth of microorganisms.
- The term “fungicidal agent”, as used herein, refers to an agent that kills a fungus.
- The term “fungistatic agent”, as used herein, refers to an agent that inhibits the growth of a fungus.
- “Antimicrobial (effect)” or “antimicrobial use”, as used herein, includes any effect or use of an agent, in particular of a VHH, for controlling, modulating or interfering with the harmful activity of a plant pathogen, including killing the plant pathogen, inhibiting the growth or activity of the plant pathogen, altering the behavior of the plant pathogen, and repelling or attracting the plant pathogen in plants, plant parts or in other agro-related settings, such as for example in soil.
- “Microbicidal (effect)” or “microbicidal use”, as used herein, includes any effect or use of an agent, in particular of a VHH, for controlling, modulating or interfering with the harmful activity of a plant pathogen, including killing the plant pathogen,
- “Microbiostatic (effect)” or “microbiostatic use”, as used herein, includes any effect or use of an agent, in particular of a VHH, for controlling, modulating or interfering with the harmful activity of a plant pathogen, including inhibiting the growth or activity of the plant pathogen, altering the behavior of the plant pathogen, and repelling or attracting the plant pathogen in plants, plant parts or in other agro-related settings, such as for example in soil.
- “Antifungal (effect)” or “antifungal use”, as used herein, includes any effect or use of an agent, in particular of a VHH, for controlling, modulating or interfering with the harmful activity of a fungus, including inhibiting the growth or activity of the fungus, altering the behavior of the fungus, and repelling or attracting the fungus in plants, plant parts or in other agro-related settings, such as in soil.

"Fungicidal (effect)" or "Fungicidal use", as used herein, includes any effect or use of an agent, in particular of a VHH, for controlling, modulating or interfering with the harmful activity of a fungus, including killing the fungus.

5 "Fungistatic (effect)" or "Fungistatic use", as used herein, includes any effect or use of an agent, in particular of a VHH, for controlling, modulating or interfering with the harmful activity of a fungus, including inhibiting the growth or activity of the fungus, altering the behavior of the fungus, and repelling or attracting the fungus in plants, plant parts or in other agro-related settings, such as for example in soil.

10 "Pesticidal activity" or "biocidal activity", as used interchangeably herein, means to interfere with the harmful activity of a plant pathogen, including but not limited to killing the plant pathogen, inhibiting the growth or activity of the plant pathogen, altering the behavior of the plant pathogen, repelling or attracting the plant pathogen.

"Biostatic activity", as used herein, means to interfere with the harmful activity of a plant pathogen, including but not limited to inhibiting the growth or activity of the plant pathogen, altering the behavior of the plant pathogen, repelling or attracting the plant pathogen.

15 Pesticidal, biocidal, or biostatic activity of an active ingredient, substance or principle or a composition or agent comprising a pesticidal, biocidal, or biostatic active ingredient, substance or principle, can be expressed as the minimum inhibitory activity (MIC) of an agent (expressed in units of concentration such as e.g. mg/mL), without however being restricted thereto.

20 "Fungicidal activity", as used herein, means to interfere with the harmful activity of a fungus, including but not limited to killing the fungus, inhibiting the growth or activity of the fungus, altering the behavior of the fungus, and repelling or attracting the fungus.

"Fungistatic activity", as used herein, means to interfere with the harmful activity of a fungus, including but not limited to inhibiting the growth or activity of the fungus, altering the behavior of the fungus, and repelling or attracting the fungus.

25 Fungicidal or fungistatic activity of an active ingredient, substance or principle or a composition or agent comprising a pesticidal, biocidal, or biostatic active ingredient, substance or principle, can be expressed as the minimum inhibitory activity (MIC) of an agent (expressed in units of concentration such as e.g. mg/mL), without however being restricted thereto.

30 As used herein, the term "antibody" refers to polyclonal antibodies, monoclonal antibodies, humanized antibodies, single-chain antibodies, and fragments thereof such as Fab, F(ab)<sub>2</sub>, Fv, and other fragments that retain the antigen binding function of the parent antibody. As such, an antibody may refer to an immunoglobulin or glycoprotein, or fragment or portion thereof, or to a construct comprising an antigen-binding portion comprised within a modified immunoglobulin-like framework, or to an antigen-binding portion comprised within a construct comprising a non- immunoglobulin-like framework or scaffold.

35 As used herein, the term "monoclonal antibody" refers to an antibody composition having a homogeneous antibody population. The term is not limited regarding the species or source of the antibody, nor is it intended to be limited by the manner in which it is made. The term encompasses whole immunoglobulins

as well as fragments such as Fab, F(ab)<sub>2</sub>, Fv, and others that retain the antigen binding function of the antibody. Monoclonal antibodies of any mammalian species can be used in this invention. In practice, however, the antibodies will typically be of rat or murine origin because of the availability of rat or murine cell lines for use in making the required hybrid cell lines or hybridomas to produce monoclonal antibodies.

5 As used herein, the term "polyclonal antibody" refers to an antibody composition having a heterogeneous antibody population. Polyclonal antibodies are often derived from the pooled serum from immunized animals or from selected humans.

The terms "variable domain of a heavy-chain antibody" or "VHH" or "heavy chain variable domain of an antibody", as used herein interchangeably, refer to the variable domain of the heavy chain of a heavy-  
10 chain antibody, which is naturally devoid of light chains, including but not limited to the variable domain of the heavy chain of heavy-chain antibodies of camelids or sharks.

The skilled person may understand that functional variants of VHH include any immunoglobulin single variable domain. Examples of immunoglobulin single variable domains include an immunoglobulin single variable domain selected from the group consisting of an immunoglobulin single variable domain derived  
15 from a heavy-chain antibody, an immunoglobulin single variable domain derived from a light chain variable domain sequence, an immunoglobulin single variable domain derived from a heavy chain variable domain sequence, an immunoglobulin single variable domain derived from a conventional four-chain antibody, a domain antibody, a single domain antibody, a "dAb" (Domantis/GSK), a VHH, or Nanobody (Ablynx).

20 As further described herein, the amino acid sequence and structure of a variable domain of a heavy-chain antibody can be considered, without however being limited thereto, to be comprised of four framework regions or "FR's", which are referred to in the art and herein as "framework region 1" or "FR1"; as "framework region 2" or "FR2"; as "framework region 3" or "FR3"; and as "framework region 4" or "FR4", respectively, which framework regions are interrupted by three complementary determining regions or  
25 "CDR's", which are referred to in the art as "complementarity determining region 1" or "CDR1"; as "complementarity determining region 2" or "CDR2"; and as "complementarity determining region 3" or "CDR3", respectively.

As also further described herein, the total number of amino acid residues in a variable domain of a heavy-chain antibody or VHH can be in the region of 110-130, preferably is 112-115, and most preferably  
30 is 113. It should however be noted that parts, fragments or analogs of a variable domain of a heavy-chain antibody are not particularly limited as to their length and/or size, as long as such parts, fragments or analogs retain (at least part of) the functional activity, such as the pesticidal, biocidal, biostatic activity, fungicidal or fungistatic activity (as defined herein) and/or retain (at least part of) the binding specificity of the original a variable domain of a heavy-chain antibody from which these parts, fragments or analogs are  
35 derived from. Parts, fragments or analogs retaining (at least part of) the functional activity, such as the pesticidal, biocidal, biostatic activity, fungicidal or fungistatic activity (as defined herein) and/or retaining (at least part of) the binding specificity of the original variable domain of a heavy-chain antibody from

which these parts, fragments or analogs are derived from are also further referred to herein as “functional fragments” of a variable domain of a heavy-chain antibody.

The amino acid residues of a variable domain of a heavy-chain antibody are numbered according to the general numbering for variable domains given by Kabat et al. (“*Sequence of proteins of immunological interest*”, US Public Health Services, NIH Bethesda, Md., Publication No. 91), as applied to V<sub>HH</sub> domains from Camelids in the article of Riechmann and Muyldermans, referred to above (see for example FIG. 2 of said reference). According to this numbering, FR1 of a variable domain of a heavy-chain antibody comprises the amino acid residues at positions 1-30, CDR1 of a variable domain of a heavy-chain antibody comprises the amino acid residues at positions 31-36, FR2 of a variable domain of a heavy-chain antibody comprises the amino acids at positions 36-49, CDR2 of a variable domain of a heavy-chain antibody comprises the amino acid residues at positions 50-65, FR3 of a variable domain of a heavy-chain antibody comprises the amino acid residues at positions 66-94, CDR3 of a variable domain of a heavy-chain antibody comprises the amino acid residues at positions 95-102, and FR4 of a variable domain of a heavy-chain antibody comprises the amino acid residues at positions 103-113. In this respect, it should be noted that – as is well known in the art for V<sub>HH</sub> domains – the total number of amino acid residues in each of the CDR's may vary and may not correspond to the total number of amino acid residues indicated by the Kabat numbering (that is, one or more positions according to the Kabat numbering may not be occupied in the actual sequence, or the actual sequence may contain more amino acid residues than the number allowed for by the Kabat numbering). This means that, generally, the numbering according to Kabat may or may not correspond to the actual numbering of the amino acid residues in the actual sequence. Generally, however, it can be said that, according to the numbering of Kabat and irrespective of the number of amino acid residues in the CDR's, position 1 according to the Kabat numbering corresponds to the start of FR1 and vice versa, position 36 according to the Kabat numbering corresponds to the start of FR2 and vice versa, position 66 according to the Kabat numbering corresponds to the start of FR3 and vice versa, and position 103 according to the Kabat numbering corresponds to the start of FR4 and vice versa.

Alternative methods for numbering the amino acid residues of a variable domain of a heavy-chain antibody are the method described by Chothia et al. (*Nature* 342, 877-883 (1989)), the so-called “AbM definition” and the so-called “contact definition”. However, in the present description, claims and figures, the numbering according to Kabat as applied to V<sub>HH</sub> domains by Riechmann and Muyldermans will be followed, unless indicated otherwise.

For a general description of heavy-chain antibodies and the variable domains thereof, reference is inter alia made to the following references, which are mentioned as general background art: WO 94/04678, WO 95/04079 and WO 96/34103 of the Vrije Universiteit Brussel; WO 94/25591, WO 99/37681, WO 00/40968, WO 00/43507, WO 00/65057, WO 01/40310, WO 01/44301, EP 1134231 and WO 02/48193 of Unilever; WO 97/49805, WO 01/21817, WO 03/035694, WO 03/054016 and WO 03/055527 of the Vlaams Instituut voor Biotechnologie (VIB); WO 03/050531 of Algonomics N.V. and Ablynx NV; WO 01/90190 by the National Research Council of Canada; WO 03/025020 (=EP 1 433 793) by the Institute of Antibodies; as well as WO 04/041867, WO 04/041862, WO 04/041865, WO 04/041863, WO

04/062551 by Ablynx NV and the further published patent applications by Ablynx NV; Hamers-Casterman et al., *Nature* 1993 Jun. 3; 363 (6428): 446-8; Davies and Riechmann, *FEBS Lett.* 1994 Feb. 21; 339(3): 285-90; Muyldermans et al., *Protein Eng.* 1994 September; 7(9): 1129-3; Davies and Riechmann, *Biotechnology (NY)* 1995 May; 13(5): 475-9; Gharoudi et al., 9th Forum of Applied Biotechnology, Med. Fac. Landbouw Univ. Gent. 1995; 60/4a part I: 2097-2100; Davies and Riechmann, *Protein Eng.* 1996 June; 9(6): 531-7; Desmyter et al., *Nat Struct Biol.* 1996 September; 3(9): 803-11; Sheriff et al., *Nat Struct Biol.* 1996 September; 3(9): 733-6; Spinelli et al., *Nat Struct Biol.* 1996 September; 3(9): 752-7; Arbabi Ghahroudi et al., *FEBS Lett.* 1997 Sep. 15; 414(3): 521-6; Vu et al., *Mol. Immunol.* 1997 November-December; 34(16-17): 1121-31; Atarhouch et al., *Journal of Carnel Practice and Research* 1997; 4: 177-182; Nguyen et al., *J. Mol. Biol.* 1998 Jan. 23; 275(3): 413-8; Lauwereys et al., *EMBO J.* 1998 Jul. 1; 17(13): 3512-20; Frenken et al., *Res Immunol.* 1998 July-August; 149(6):589-99; Transue et al., *Proteins* 1998 Sep. 1; 32(4): 515-22; Muyldermans and Lauwereys, *J. Mol. Recognit.* 1999 March-April; 12 (2): 131-40; van der Linden et al., *Biochim. Biophys. Acta* 1999 Apr. 12; 1431(1): 37-46; Decanniere et al., *Structure Fold. Des.* 1999 Apr. 15; 7(4): 361-70; Ngyuen et al., *Mol. Immunol.* 1999 June; 36(8): 515-24; Woolven et al., *Immunogenetics* 1999 October; 50 (1-2): 98-101; Riechmann and Muyldermans, *J. Immunol. Methods* 1999 Dec. 10; 231 (1-2): 25-38; Spinelli et al., *Biochemistry* 2000 Feb. 15; 39(6): 1217-22; Frenken et al., *J. Biotechnol.* 2000 Feb. 28; 78(1): 11-21; Nguyen et al., *EMBO J.* 2000 Mar. 1; 19(5): 921-30; van der Linden et al., *J. Immunol. Methods* 2000 Jun. 23; 240 (1-2): 185-95; Decanniere et al., *J. Mol. Biol.* 2000 Jun. 30; 300 (1): 83-91; van der Linden et al., *J. Biotechnol.* 2000 Jul. 14; 80(3): 261-70; Harmsen et al., *Mol. Immunol.* 2000 August; 37(10): 579-90; Perez et al., *Biochemistry* 2001 Jan. 9; 40(1): 74-83; Conrath et al., *J. Biol. Chem.* 2001 Mar. 9; 276 (10): 7346-50; Muyldermans et al., *Trends Biochem Sci.* 2001 April; 26(4):230-5; Muyldermans S., *J. Biotechnol.* 2001 June; 74 (4): 277-302; Desmyter et al., *J. Biol. Chem.* 2001 Jul. 13; 276 (28): 26285-90; Spinelli et al., *J. Mol. Biol.* 2001 Aug. 3; 311 (1): 123-9; Conrath et al., *Antimicrob Agents Chemother.* 2001 October; 45 (10): 2807-12; Decanniere et al., *J. Mol. Biol.* 2001 Oct. 26; 313(3): 473-8; Nguyen et al., *Adv Immunol.* 2001; 79: 261-96; Muruganandam et al., *FASEB J.* 2002 February; 16 (2): 240-2; Ewert et al., *Biochemistry* 2002 Mar. 19; 41 (11): 3628-36; Dumoulin et al., *Protein Sci.* 2002 March; 11 (3): 500-15; Cortez-Retamozo et al., *Int. J. Cancer.* 2002 Mar. 20; 98 (3): 456-62; Su et al., *Mol. Biol. Evol.* 2002 March; 19 (3): 205-15; van der Vaart J M., *Methods Mol. Biol.* 2002; 178: 359-66; Vranken et al., *Biochemistry* 2002 Jul. 9; 41 (27): 8570-9; Nguyen et al., *Immunogenetics* 2002 April; 54 (1): 39-47; Renisio et al., *Proteins* 2002 Jun. 1; 47 (4): 546-55; Desmyter et al., *J. Biol. Chem.* 2002 Jun. 28; 277 (26): 23645-50; Ledebouer et al., *J. Dairy Sci.* 2002 June; 85 (6): 1376-82; De Genst et al., *J. Biol. Chem.* 2002 Aug. 16; 277 (33): 29897-907; Ferrat et al., *Biochem. J.* 2002 Sep. 1; 366 (Pt 2): 415-22; Thomassen et al., *Enzyme and Microbial Technol.* 2002; 30: 273-8; Harmsen et al., *Appl. Microbiol. Biotechnol.* 2002 December; 60 (4): 449-54; Jobling et al., *Nat. Biotechnol.* 2003 January; 21 (1): 77-80; Conrath et al., *Dev. Comp. Immunol.* 2003 February; 27 (2): 87-103; Pleschberger et al., *Bioconjug. Chem.* 2003 March-April; 14 (2): 440-8; Lah et al., *J. Biol. Chem.* 2003 Apr. 18; 278 (16): 14101-11; Nguyen et al., *Immunology.* 2003 May; 109 (1): 93-101; Joosten et al., *Microb. Cell Fact.* 2003 Jan. 30; 2 (1): 1; Li et al., *Proteins* 2003 Jul. 1; 52 (1): 47-50; Loris et al., *Biol. Chem.* 2003 Jul. 25; 278 (30): 28252-7; van Koningsbruggen et al., *J. Immunol. Methods.* 2003 August; 279 (1-2): 149-61; Dumoulin et al., *Nature.* 2003 Aug. 14; 424 (6950): 783-8;

Bond et al., J. Mol. Biol. 2003 Sep. 19; 332 (3): 643-55; Yau et al., J. Immunol. Methods. 2003 Oct. 1; 281 (1-2): 161-75; Dekker et al., J. Virol. 2003 November; 77 (22): 12132-9; Meddeb-Mouelhi et al., Toxicol. 2003 December; 42 (7): 785-91; Verheesen et al., Biochim. Biophys. Acta 2003 Dec. 5; 1624 (1-3): 21-8; Zhang et al., J Mol Biol. 2004 Jan. 2; 335 (1): 49-56; Stijlemans et al., J Biol. Chem. 2004 Jan. 9; 279 (2): 1256-61; Cortez-Retamozo et al., Cancer Res. 2004 Apr. 15; 64 (8): 2853-7; Spinelli et al., FEBS Lett. 2004 Apr. 23; 564 (1-2): 35-40; Pleschberger et al., Bioconjug. Chem. 2004 May-June; 15 (3): 664-71; Nicaise et al., Protein Sci. 2004 July; 13 (7): 1882-91; Omidfar et al., Tumour Biol. 2004 July-August; 25 (4): 179-87; Omidfar et al., Tumour Biol. 2004 September-December; 25(5-6): 296-305; Szynol et al., Antimicrob Agents Chemother. 2004 September; 48(9):3390-5; Saerens et al., J. Biol. Chem. 2004 Dec. 10; 279 (50): 51965-72; De Genst et al., J. Biol. Chem. 2004 Dec. 17; 279 (51): 53593-601; Dolk et al., Appl. Environ. Microbiol. 2005 January; 71(1): 442-50; Joosten et al., Appl Microbiol Biotechnol. 2005 January; 66(4): 384-92; Dumoulin et al., J. Mol. Biol. 2005 Feb. 25; 346 (3): 773-88; Yau et al., J Immunol Methods. 2005 February; 297 (1-2): 213-24; De Genst et al., J. Biol. Chem. 2005 Apr. 8; 280 (14): 14114-21; Huang et al., Eur. J. Hum. Genet. 2005 Apr. 13; Dolk et al., Proteins. 2005 May 15; 59 (3): 555-64; Bond et al., J. Mol. Biol. 2005 May 6; 348(3):699-709; Zarebski et al., J. Mol. Biol. 2005 Apr. 21; [E-publication ahead of print].

Generally, it should be noted that the term "variable domain of a heavy-chain antibody", "variable domain" or "heavy chain variable domain" as used herein in its broadest sense is not limited to a specific biological source or to a specific method of preparation. For example, as will be discussed in more detail below, the VHHs as taught herein can be obtained by expression of a nucleotide sequence encoding a naturally occurring  $V_{HH}$  domain, or by preparing a nucleic acid encoding a  $V_{HH}$  using techniques for nucleic acid synthesis, followed by expression of the nucleic acid thus obtained, or by any combination of the foregoing. Suitable methods and techniques for performing the foregoing will be clear to the skilled person based on the disclosure herein and for example include the methods and techniques described in more detail herein.

However, according to a specific embodiment, the variable domain of a heavy-chain antibody as disclosed herein do not have an amino acid sequence that is exactly the same as (i.e. as a degree of sequence identity of 100% with) the amino acid sequence of a naturally occurring VHH domain, such as the amino acid sequence of a naturally occurring VHH domain from a camelid or shark.

As used herein, the terms "determining", "measuring", "assessing", "monitoring" and "assaying" are used interchangeably and include both quantitative and qualitative determinations.

All documents cited in the present specification are hereby incorporated by reference in their entirety. Unless otherwise defined, all terms used in disclosing the invention, including technical and scientific terms, have the meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. By means of further guidance, term definitions are included to better appreciate the teaching of the present invention.

TRANSGENIC PLANTS

The present invention relates to a transgenic plant or plant tissue or plant cell comprising at least one polynucleotide encoding a VHH specifically binding to a sphingolipid of a fungus.

As used herein, the wording "at least one polynucleotide comprising at least one sequence encoding a VHH" and "at least one polynucleotide encoding a VHH" may be used interchangeably.

The term "transgenic plant or plant tissue" generally refers to plants or plant tissues or plant cells that have been genetically engineered to create plants with new characteristics. A transgenic plant or plant tissue or plant cell can also be identified as a genetically modified organism (GMO).

The term "transgenic plant" also encompasses commodity products derived from the transgenic plant or plant tissue or plant cell, wherein the commodity product comprises a detectable amount of the transgenic or recombinant polynucleotide and wherein the commodity product is selected from the group consisting of plant biomass, oil, meal, food, animal feed, flour, flakes, bran, lint, fiber, paper, protein, starch, silage, hulls, and processed seed, and wherein optionally the commodity product is non-regenerable.

In certain embodiments, the plant may be selected from the group consisting of maize, soya bean, alfalfa, cotton, sunflower, Brassica oil seeds such as Brassica napus (e.g. canola, rape- seed), Brassica rapa, B. juncea (e.g. (field) mustard) and Brassica carinata, Arecaceae sp. (e.g. oilpalm, coconut), rice, wheat, sugar beet, sugar cane, oats, rye, barley, millet and sorghum, triticale, flax, nuts, grapes and vine and various fruit and vegetables from various botanic taxa, e.g. Rosaceae sp. (e.g. pome fruits such as apples and pears, but also stone fruits such as apricots, cherries, almonds, plums and peaches, and berry fruits such as strawberries, raspberries, red and black currant and gooseberry), Ribesioideae sp., Juglandaceae sp., Betulaceae sp., Anacardiaceae sp., Fagaceae sp., Moraceae sp., Oleaceae sp. (e.g. olive tree), Actinidaceae sp., Lauraceae sp. (e.g. avocado, cinnamon, camphor), Musaceae sp. (e.g. banana trees and plantations), Rubiaceae sp. (e.g. coffee), Theaceae sp. (e.g. tea), Sterculiaceae sp., Rutaceae sp. (e.g. lemons, oranges, mandarins and grapefruit); Solanaceae sp. (e.g. tomatoes, potatoes, peppers, capsicum, aubergines, tobacco), Liliaceae sp., Compositae sp. (e.g. lettuce, artichokes and chicory - including root chicory, endive or common chicory), Umbelliferae sp. (e.g. carrots, parsley, celery and celeriac), Cu- curbitaceae sp. (e.g. cucumbers - including gherkins, pumpkins, watermelons, calabashes and melons), Alliaceae sp. (e.g. leeks and onions), Cruciferae sp. (e.g. white cabbage, red cabbage, broccoli, cauliflower, Brussels sprouts, pak choi, kohlrabi, radishes, horseradish, cress and Chinese cabbage), Leguminosae sp. (e.g. peanuts, peas, lentils and beans - e.g. common beans and broad beans), Chenopodiaceae sp. (e.g. Swiss chard, fodder beet, spinach, beetroot), Linaceae sp. (e.g. hemp), Cannabaceae sp. (e.g. cannabis), Malvaceae sp. (e.g. okra, cocoa), Papaveraceae (e.g. poppy), Asparagaceae (e.g. asparagus); useful plants and ornamental plants in the garden and woods including turf, lawn, grass and Stevia rebaudiana, and genetically modified types of these plants.

In certain embodiments, the plant may be a crop selected from the group consisting of field crops, grasses, fruits, vegetables, lawns, trees, and ornamental plants.

In certain embodiments, the plant may be a harvestable part of the plant selected from the group consisting of a fruit, a flower, a nut, a vegetable, a fruit or vegetable with inedible peel, preferably selected

from avocados, bananas, plantains, lemons, grapefruits, melons, oranges, pineapples, kiwi fruits, guavas, mandarins, mangoes and pumpkin, is preferred, more preferably bananas, oranges, lemons and peaches, in particular bananas. In certain embodiments, the plant may be a cut flower of ornamental plants, preferably selected from Alstroemeria, Carnation, Chrysanthemum, Freesia, Gerbera, Gladiolus, baby's breath (*Gypsophila spec*), Helianthus, Hydrangea, Liliium, Lisianthus, roses and summer flowers. In certain embodiments, the plant may be cut grass or wood.

In certain embodiments, the plant may be a plant used for research purposes such as Arabidopsis, corn, tobacco, or poplar.

In certain embodiments, the plant may be a plant selected from the group consisting of corn, rice, wheat, barley, sorghum, millet oats, rye, triticale or other cereals, soybean, alfalfa or other leguminous crops, sugar beet, fodder beet, papaya, banana and plantains or other fruits, grapevines, nuts, oilseed rape, sunflower or other oil crops, squash cucumber, melons or other cucurbits, cotton or other fiber plants, sugarcane, palm, jatropha or other fuel crops, cabbages, tomato, pepper or other vegetables, ornamentals, shrubs, poplar, eucalyptus or other trees, evergreens, grasses, coffee plants, tea plants, tobacco plants, hop plants, rubber plants, and latex plants.

In certain preferred embodiments, the plant may be selected from the group consisting of banana, barley oat rye, canola, corn, cotton, potato, rice, soybean, tobacco, and wheat.

In certain more preferred embodiments, the plant may be selected from the group consisting of canola, corn, rice, soybean, and wheat.

In certain even more preferred embodiments, the plant may be selected from the group consisting of rice, soybean, and wheat.

Methods for the generation of transgenic plant including recombinant DNA techniques are well-known in the art.

Specifically recombinant methodologies generally involve inserting a DNA molecule expressing an amino acid sequence, protein or polypeptide of interest into an expression system to which the DNA molecule is heterologous (i.e. not normally present in the host). The heterologous DNA molecule is inserted into the expression system or vector in proper sense orientation and correct reading frame. The vector contains the necessary elements for the transcription and translation of the inserted protein-coding sequences. Transcription of DNA is dependent upon the presence of a promoter. Similarly, translation of mRNA in prokaryotes depends upon the presence of the proper prokaryotic signals which differ from those of eukaryotes. For a review on maximizing gene expression, see Roberts and Lauer, *Methods in Enzymology* 68:473 (1979). Regardless of the specific regulatory sequences employed, the DNA molecule is cloned into the vector using standard cloning procedures in the art, as described by Sambrook et al, *Molecular Cloning: A Laboratory Manual*, Cold Springs Laboratory, Cold Springs Harbor, N.Y. (1989). Once the isolated DNA molecule encoding the protein has been cloned into an expression system, it is ready to be incorporated into a host cell. Such incorporation can be carried out by the various forms of transformation, depending upon the vector/host cell system.

In certain embodiments, the present invention provides nucleic acid sequences capable of encoding a VHH in a transgenic plant or plant tissue or plant cell as defined herein. These nucleic acid sequences can also be in the form of a vector or a genetic construct or polynucleotide. As used herein, the terms "genetic construct" and "nucleic acid construct" are used interchangeably. The nucleic acid sequences as disclosed herein may be synthetic or semi-synthetic sequences, nucleotide sequences that have been isolated from a library (and in particular, an expression library), nucleotide sequences that have been prepared by PCR using overlapping primers, or nucleotide sequences that have been prepared using techniques for DNA synthesis known per se. In certain embodiments, the polynucleotide may comprise nucleic acid sequence of SEQ ID NO: 336 and/or SEQ ID NO: 337.

5 The genetic constructs as disclosed herein may be DNA or RNA, and are preferably double-stranded DNA. The genetic constructs of the invention may also be in a form suitable for transformation of the intended host cell or host organism in a form suitable for integration into the genomic DNA of the intended host cell or in a form suitable for independent replication, maintenance and/or inheritance in the intended host organism. For instance, the genetic constructs of the invention may be in the form of a vector, such as for example a plasmid, cosmid, YAC, a viral vector or transposon. In particular, the vector may be an expression vector, i.e., a vector that can provide for expression in vitro and/or in vivo (e.g. in a suitable host cell, host organism and/or expression system).

Accordingly, in another further aspect, the present invention also provides vectors comprising one or more nucleic acid sequences of the invention.

20 Also disclosed are chimeric genes comprising the following operably linked DNA elements: a) a plant expressible promoter, b) a DNA region which when transcribed yields a mRNA molecule capable of being translated into a polypeptide and c) a 3' end region comprising transcription termination and polyadenylation signals functioning in cells of said plant.

A "chimeric gene" or "chimeric construct" is a recombinant nucleic acid sequence in which a promoter (e.g. a plant expressible promoter) or regulatory nucleic acid sequence is operatively linked to, or associated with, a nucleic acid sequence that codes for an mRNA, such that the regulatory nucleic acid sequence is able to regulate transcription or expression of the associated nucleic acid coding sequence when introduced into a cell such as a plant cell. The regulatory nucleic acid sequence of the chimeric gene is not normally operatively linked to the associated nucleic acid sequence as found in nature.

30 In certain embodiments, the polynucleotide may comprise a promoter suitable for expression in plants, a plant tissue or plant cell specific promoter, or an inducible promoter.

The terms "plant promoter" or "promoter suitable for expression in plants" as used herein refers to a nucleic acid sequence comprising regulatory elements, which mediate the expression of a coding sequence in plant cells. For expression in plants, the nucleic acid molecule must be linked operably to or comprise a suitable promoter which expresses the gene at the right point in time and with the required spatial expression pattern.

The term “operably linked” as used herein refers to a functional linkage between the promoter sequence and the gene of interest, such that the promoter sequence is able to initiate transcription of the gene of interest.

5 Plant expressible promoters comprise nucleic acid sequences which are able to direct the expression of a transgene in a plant. Examples of plant expressible promoters are constitutive promoters which are transcriptionally active during most, but not necessarily all, phases of growth and development and under most environmental conditions, in at least one cell, tissue or organ, other promoters are inducible promoters, other examples are tissue specific promoters, still other examples are abiotic stress inducible promoters.

10 The term “plant tissue or plant cell specific promoter” refers to promoters which are transcriptionally active in a specific type of plant cells or plant tissues.

The term “inducible promoter” refers to promoters which allow regulating gene expression levels at particular stages of plant development and in particular tissues of interest. Examples of inducible systems include AlcR/AlcA (ethanol inducible); GR fusions, GVG, and pOp/LhGR (dexamethasone inducible); 15 XVE/OlexA (beta-estradiol inducible); and heat shock induction.

The chimeric gene (or the expression cassette) when transformed in a plant expresses a nucleic acid which results in expression of a protein.

Also disclosed is a recombinant vector which comprises an expression cassette (or a chimeric gene) as herein described before.

20 The term “terminator” encompasses a control sequence which is a DNA sequence at the end of a transcriptional unit which signals 3' processing and polyadenylation of a primary transcript and termination of transcription. The terminator can be derived from the natural gene, from a variety of other plant genes, or from T-DNA. The terminator to be added may be derived from, for example, the nopaline synthase or octopine synthase genes, or alternatively from another plant gene, or less preferably from any other 25 eukaryotic gene.

In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise at least one sequence encoding an antibody fragment consisting of a variable domain of a heavy-chain antibody (VHH). In certain embodiments, the polynucleotide may encode an antibody fragment consisting of a variable domain of a heavy-chain 30 antibody (VHH).

In certain embodiments, the polynucleotide may not comprise a sequence encoding a light chain of an antibody, such as an immunoglobulin light chain. In certain embodiments, the polynucleotide may not encode an immunoglobulin.

35 In certain embodiments, the transgenic plant or plant tissue or plant cell may not comprise any polynucleotide (comprising at least one sequence) encoding a light chain of an antibody, such as an immunoglobulin light chain. In certain embodiments, the transgenic plant or plant tissue or plant cell may not comprise any polynucleotide (comprising at least one sequence) encoding an immunoglobulin.

In certain embodiments, the polynucleotide may comprise at least one sequence encoding a targeting signal for secretion, for location to the cytoplasm, or for location to cellular compartments or organelles, such as the ER lumen, the apoplast, the vacuole, or intra- and/or exterior membranes.

5 Examples of a targeting signal for secretion include the 2S2 signal peptide. Examples of a targeting signal for location to cellular compartments or organelles, such as the ER lumen include the ER retention signal (KDEL).

In certain embodiments, the polynucleotide may comprise an ATG start codon for location to the cytoplasm.

10 In certain embodiments, the polynucleotide may encode the VHH as such, as a combination with one or more identical or different VHHs, or as a combination with one or more identical or different VHHs with a fragment crystallizable region (Fc region); optionally with a spacer.

15 The term "fragment crystallizable region" or "Fc region" refers to the tail region of an antibody. The Fc region may interact with cell surface receptors called Fc receptors and some proteins of the complement system. The Fc region of IgG, IgA and IgD antibody isotypes is composed of two identical protein fragments, derived from the second and third constant domains of the antibody's two heavy chains. The Fc region of IgM and IgE contains three heavy chain constant domains (CH domains 2 to 4) in each polypeptide chain.

Such an Fc region may advantageously enhance the stability of the VHH and/or may increase the expression of the VHH.

20 In certain embodiments, the Fc region may be an Fc region of an IgG antibody, an IgA antibody, an IgD antibody, an IgM antibody, or an IgE antibody. In certain preferred embodiments, the Fc region may be an Fc region of an IgG antibody, an IgA antibody, or an IgD antibody. In certain more preferred embodiments, the Fc region may be an Fc region of an IgG antibody.

25 In certain embodiments, the Fc region may be an Fc region of a mouse antibody (i.e., mouse Fc region). In certain preferred embodiments, the Fc region may be an Fc region of a human antibody (i.e., human Fc region).

In certain preferred embodiments, the Fc region may be the Fc region of mouse IgG3 antibody. In certain preferred embodiments, the Fc region may be the Fc region of the human IgG1 antibody (hGFc; Van Droogenbroeck et al., 2007, Proc Natl Acad Sci U S A, 104(4):1430-5).

30 The term "monovalent" as used herein refers to an antibody or antibody fragment comprising one binding site.

The term "bivalent" as used herein refers to an antibody or antibody fragment comprising two or more binding sites.

35 The terms "spacer" or "linker", as used herein interchangeably, refer to at least one amino acid spatially separating at least two VHHs. An exemplary spacer includes the 9GS spacer consisting of GGGGSGGGGS (SEQ ID NO: 352).

In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the VHHs as disclosed herein may be optionally linked to one or more further groups, moieties, or residues via one or more linkers. These one or more further groups, moieties or residues can serve for binding to other targets of interest. It should be clear that such further groups, residues, moieties and/or binding sites may or may not provide further functionality to the VHH as disclosed herein and may or may not modify the properties of the VHH as disclosed herein. Such groups, residues, moieties or binding units may also for example be chemical groups which can be biologically active.

These groups, moieties or residues are, in particular embodiments, linked N- or C-terminally to the VHH as disclosed herein.

For example, the introduction or linkage of such functional groups to a variable domain heavy-chain antibody can result in an increase in the solubility and/or the stability of the variable domain heavy-chain antibody, in a reduction of the toxicity of the variable domain heavy-chain antibody, or in the elimination or attenuation of any undesirable side effects of the variable domain heavy-chain antibody, and/or in other advantageous properties.

In particular embodiments, the one or more groups, residues, moieties are linked to the variable domain heavy-chain antibody via one or more suitable linkers or spacers.

In further particular embodiments, two or more target-specific variable domain heavy-chain antibodies disclosed herein may be linked to each other or may be interconnected. In particular embodiments, the two or more variable domain heavy-chain antibodies may be linked to each other via one or more suitable linkers or spacers. Suitable spacers or linkers for use in the coupling of different variable domain heavy-chain antibodies as disclosed herein will be clear to the skilled person and may generally be any linker or spacer used in the art to link peptides and/or proteins.

Some particularly suitable linkers or spacers include for example, but are not limited to, polypeptide linkers such as glycine linkers, serine linkers, mixed glycine/serine linkers, glycine- and serine-rich linkers or linkers composed of largely polar polypeptide fragments, or homo- or heterobifunctional chemical crosslinking compounds such as glutaraldehyde or, optionally PEG-spaced, maleimides or NHS esters.

For example, a polypeptide linker or spacer may be a suitable amino acid sequence having a length between 1 and 50 amino acids, such as between 1 and 30, and in particular between 1 and 10 amino acid residues. It should be clear that the length, the degree of flexibility and/or other properties of the linker(s) may have some influence on the properties of the VHHs, including but not limited to the affinity, specificity or avidity for the fungal target. It should be clear that when two or more linkers are used, these linkers may be the same or different. In the context and disclosure of the present invention, the person skilled in the art will be able to determine the optimal linkers for the purpose of coupling VHHs as disclosed herein without any undue experimental burden.

“Selectable marker”, “selectable marker gene” or “reporter gene” includes any gene that confers a phenotype on a cell in which it is expressed to facilitate the identification and/or selection of cells that are transfected or transformed with a nucleic acid construct of the invention. These marker genes enable the identification of a successful transfer of the nucleic acid molecules via a series of different principles.

Suitable markers may be selected from markers that confer antibiotic or herbicide resistance, that introduce a new metabolic trait or that allow visual selection. Examples of selectable marker genes include genes conferring resistance to antibiotics (such as nptII that phosphorylates neomycin and kanamycin, or hpt, phosphorylating hygromycin, or genes conferring resistance to, for example, bleomycin, streptomycin, tetracyclin, chloramphenicol, ampicillin, gentamycin, geneticin (G418), spectinomycin or blasticidin), to herbicides (for example bar which provides resistance to Basta®; aroA or gox providing resistance against glyphosate, or the genes conferring resistance to, for example, imidazolinone, phosphinothricin or sulfonylurea), or genes that provide a metabolic trait (such as manA that allows plants to use mannose as sole carbon source or xylose isomerase for the utilisation of xylose, or antinutritive markers such as the resistance to 2-deoxyglucose). Expression of visual marker genes results in the formation of colour (for example  $\beta$ -glucuronidase, GUS or  $\beta$ -galactosidase with its coloured substrates, for example X-Gal), luminescence (such as the luciferin/luciferase system) or fluorescence (Green Fluorescent Protein, GFP, and derivatives thereof). This list represents only a small number of possible markers. The skilled worker is familiar with such markers.

It is known that upon stable or transient integration of nucleic acids into plant cells, only a minority of the cells takes up the foreign DNA and, if desired, integrates it into its genome, depending on the expression vector used and the transfection technique used. To identify and select these integrants, a gene coding for a selectable marker (such as the ones described above) is usually introduced into the host cells together with the gene of interest. These markers can for example be used in mutants, in which these genes are not functional by, for example, deletion by conventional methods. Furthermore, nucleic acid molecules encoding a selectable marker can be introduced into a host cell on the same vector that comprises the sequence encoding the polypeptides of the invention or used in the methods of the invention, or else in a separate vector. Cells which have been stably transfected with the introduced nucleic acid can be identified for example by selection (for example, cells which have integrated the selectable marker survive whereas the other cells die).

Since the marker genes, particularly genes for resistance to antibiotics and herbicides, are no longer required or are undesired in the transgenic host cell once the nucleic acids have been introduced successfully, the process according to the invention for introducing the nucleic acids advantageously employs techniques which enable the removal or excision of these marker genes. One such a method is what is known as co-transformation. The co-transformation method employs two vectors simultaneously for the transformation, one vector bearing the nucleic acid according to the invention and a second bearing the marker gene(s). A large proportion of transformants receives or, in the case of plants, comprises (up to 40% or more of the transformants), both vectors. In case of transformation with *Agrobacteria*, the transformants usually receive only a part of the vector, i.e. the sequence flanked by the T-DNA, which usually represents the expression cassette. The marker genes can subsequently be removed from the transformed plant by performing crosses. In another method, marker genes integrated into a transposon are used for the transformation together with desired nucleic acid (known as the Ac/Ds technology). The transformants can be crossed with a transposase source or the transformants are transformed with a nucleic acid construct conferring expression of a transposase, transiently or stable. In

some cases (approx. 10%), the transposon jumps out of the genome of the host cell once transformation has taken place successfully and is lost. In a further number of cases, the transposon jumps to a different location. In these cases the marker gene must be eliminated by performing crosses. In microbiology, techniques were developed which make possible, or facilitate, the detection of such events. A further  
5 advantageous method relies on what is known as recombination systems; whose advantage is that elimination by crossing can be dispensed with. The best-known system of this type is what is known as the Cre/lox system. Cre1 is a recombinase that removes the sequences located between the loxP sequences. If the marker gene is integrated between the loxP sequences, it is removed once transformation has taken place successfully, by expression of the recombinase. Further recombination  
10 systems are the HIN/HIX, FLP/FRT and REP/STB system (Tribble et al., J. Biol. Chem., 275, 2000: 22255-22267; Velmurugan et al., J. Cell Biol., 149, 2000: 553-566). A site-specific integration into the plant genome of the nucleic acid sequences according to the invention is possible.

A transgenic plant for the purposes of the invention is thus understood as meaning, as above, that the nucleic acids used in the method of the invention are not present in, or originating from, the genome of  
15 said plant, or are present in the genome of said plant but not at their natural locus in the genome of said plant, it being possible for the nucleic acids to be expressed homologously or heterologously. However, as mentioned, transgenic also means that, while the nucleic acids according to the invention or used in the inventive method are at their natural position in the genome of a plant, the sequence has been modified with regard to the natural sequence, and/or that the regulatory sequences of the natural  
20 sequences have been modified. Transgenic is preferably understood as meaning the expression of the nucleic acids according to the invention at an unnatural locus in the genome, i.e. homologous or, heterologous expression of the nucleic acids takes place. Preferred transgenic plants are mentioned herein.

The term "expression" or "gene expression" means the transcription of a specific gene or specific genes  
25 or specific genetic construct. The term "expression" or "gene expression", as used herein, refers to transcription of a polynucleotide or gene or genetic construct into structural RNA (rRNA, tRNA) or mRNA with or without subsequent translation of the latter into a protein. The process includes transcription of DNA and processing of the resulting mRNA product.

The term "increased expression" or "overexpression" as used herein means any form of expression that is  
30 additional to the original wild-type expression level. For the purposes of this invention, the original wild-type expression level might also be zero, i.e. absence of expression or immeasurable expression.

Methods for increasing expression of genes or gene products are well documented in the art and include, for example, overexpression driven by appropriate promoters (as described herein before), the use of transcription enhancers or translation enhancers. Isolated nucleic acids which serve as promoter or  
35 enhancer elements may be introduced in an appropriate position (typically upstream) of a non-heterologous form of a polynucleotide so as to upregulate expression of a nucleic acid encoding the polypeptide of interest. If polypeptide expression is desired, it is generally desirable to include a polyadenylation region at the 3'-end of a polynucleotide coding region. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA. The 3' end sequence

to be added may be derived from, for example, the nopaline synthase or octopine synthase genes, or alternatively from another plant gene, or less preferably from any other eukaryotic gene.

An intron sequence may also be added to the 5' untranslated region (UTR) or the coding sequence of the partial coding sequence to increase the amount of the mature message that accumulates in the cytosol.

5 Inclusion of a spliceable intron in the transcription unit in both plant and animal expression constructs has been shown to increase gene expression at both the mRNA and protein levels up to 1000-fold (Buchman and Berg (1988) *Mol. Cell Biol.* 8: 4395-4405; Callis et al. (1987) *Genes Dev*, 1:1, 183-1200). Such intron enhancement of gene expression is typically greatest when placed near the 5' end of the transcription unit. Use of the maize introns Adh1-S intron 1, 2, and 6, the Bronze-1 intron are known in the art. For  
10 general information see: *The Maize Handbook*, Chapter 1 16, Freeling and Walbot, Eds., Springer, N.Y. (1994).

The term "encoding", as used herein, refers to the transcription of a polynucleotide or gene or genetic construct into structural RNA (rRNA, tRNA) or mRNA with the subsequent translation of the latter into a protein.

15 The term "introduction" or "transformation" as referred to herein encompass the transfer of an exogenous polynucleotide or chimeric gene (or expression cassette) into a host cell, irrespective of the method used for transfer. Plant tissue or plant cells capable of subsequent clonal propagation, whether by organogenesis or embryogenesis, may be transformed with a genetic construct of the present invention and a whole plant regenerated there from. The particular tissue chosen will vary depending on the clonal  
20 propagation systems available for, and best suited to, the particular species being transformed. Exemplary tissue targets include leaf disks, pollen, embryos, cotyledons, hypocotyls, megagametophytes, callus tissue, existing meristematic tissue (e.g., apical meristem, axillary buds, and root meristems), and induced meristem tissue (e.g., cotyledon meristem and hypocotyl meristem). The polynucleotide may be transiently or stably introduced into a host cell and may be maintained non-integrated, for example, as a  
25 plasmid. Alternatively, it may be integrated into the host genome. The resulting transformed plant cell may then be used to regenerate a transformed plant in a manner known to persons skilled in the art.

The transfer of foreign genes into the genome of a plant is called transformation. Transformation of plant species is now a fairly routine technique. Advantageously, any of several transformation methods may be used to introduce the gene of interest into a suitable ancestor cell. The methods described for the  
30 transformation and regeneration of plants from plant tissues or plant cells may be utilized for transient or for stable transformation. Transformation methods include the use of liposomes, electroporation, chemicals that increase free DNA uptake, injection of the DNA directly into the plant, particle gun bombardment, transformation using viruses or pollen, and microprojection. Methods may be selected from the calcium/polyethylene glycol method for protoplasts (Krens, F.A. et al., (1982) *Nature* 296, 72-74;  
35 Negrutiu I et al. (1987) *Plant Mol Biol* 8: 363- 373); electroporation of protoplasts (Shillito R.D. et al. (1985) *Bio/Technol* 3, 1099-1 102); microinjection into plant material (Crossway A et al., (1986) *Mol. Gen Genet* 202: 179-185); DNA or RNA-coated particle bombardment (Klein TM et al., (1987) *Nature* 327: 70) infection with (non-integrative) viruses and the like.

Transgenic plants, including transgenic crop plants, are preferably produced via Agrobacterium-mediated transformation. An advantageous transformation method is the transformation in planta. To this end, it is possible, for example, to allow the agrobacteria to act on plant seeds or to inoculate the plant meristem with agrobacteria. It has proved particularly expedient in accordance with the invention to allow a suspension of transformed agrobacteria to act on the intact plant or at least on the flower primordia. The plant is subsequently grown on until the seeds of the treated plant are obtained (Clough and Bent, *Plant J.* (1998) 16, 735-743). Methods for Agrobacterium-mediated transformation of rice include well known methods for rice transformation, such as those described in any of the following: European patent application EP1198985, Aldemita and Hodges (*Planta* 199: 612-617, 1996); Chan et al. (*Plant Mol Biol* 22 (3): 491 -506, 1993), Hiei et al. (*Plant J* 6 (2): 271 -282, 1994), which disclosures are incorporated by reference herein as if fully set forth. In the case of corn transformation, the preferred method is as described in either Ishida et al. (*Nat. Biotechnol* 14(6): 745-50, 1996) or Frame et al. (*Plant Physiol* 129(1): 13-22, 2002), which disclosures are incorporated by reference herein as if fully set forth. Said methods are further described by way of example in B. Jenes et al., *Techniques for Gene Transfer*, in: *Transgenic Plants, Vol. 1 , Engineering and Utilization*, eds. S.D. Kung and R. Wu, Academic Press (1993) 128-143 and in Potrykus *Annu. Rev. Plant Physiol. Plant Molec. Biol.* 42 (1991) 205-225). The nucleic acids or the construct to be expressed is preferably cloned into a vector, which is suitable for transforming *Agrobacterium tumefaciens*, for example pBin19 (Bevan et al (1984) *Nucl. Acids Res.* 12-8711) or pMP90 (Koncz and Schell (1986) *Mol. Gen. Genet.* 204, 383-396). Agrobacteria transformed by such a vector can then be used in known manner for the transformation of plants, such as plants used as a model, like *Arabidopsis* (*Arabidopsis thaliana* is within the scope of the present invention not considered as a crop plant), or crop plants such as, by way of example, tobacco plants, for example by immersing bruised leaves or chopped leaves in an agrobacterial solution and then culturing them in suitable media. The transformation of plants by means of *Agrobacterium tumefaciens* is described, for example, by Hofgen and Willmitzer in *Nucl. Acid Res.* (1988) 16, 9877 or is known inter alia from F.F. White, *Vectors for Gene Transfer in Higher Plants*; in *Transgenic Plants, Vol. 1 , Engineering and Utilization*, eds. S.D. Kung and R. Wu, Academic Press, 1993, pp. 15-38.

In addition to the transformation of somatic cells, which then have to be regenerated into intact plants, it is also possible to transform the cells of plant meristems and in particular those cells which develop into gametes. In this case, the transformed gametes follow the natural plant development, giving rise to transgenic plants. Thus, for example, seeds of *Arabidopsis* are treated with agrobacteria and seeds are obtained from the developing plants of which a certain proportion is transformed and thus transgenic [Feldman, KA and Marks MD (1987). *Mol Gen Genet* 208:1 -9; Feldmann K (1992). In: C Koncz, N-H Chua and J Shell, eds, *Methods in Arabidopsis Research*. Word Scientific, Singapore, pp. 274-289]. Alternative methods are based on the repeated removal of the inflorescences and incubation of the excision site in the center of the rosette with transformed agrobacteria, whereby transformed seeds can likewise be obtained at a later point in time (Chang (1994). *Plant J.* 5: 551 -558; Katavic (1994). *Mol Gen Genet*, 245: 363-370). However, an especially effective method is the vacuum infiltration method with its modifications such as the "floral dip" method. In the case of vacuum infiltration of *Arabidopsis*, intact plants under reduced pressure are treated with an agrobacterial suspension [Bechthold, N (1993). CR

Acad Sci Paris Life Sci, 316: 1 194-1 199], while in the case of the "floral dip" method the developing floral tissue is incubated briefly with a surfactant-treated agrobacterial suspension [Clough, SJ and Bent AF (1998) *The Plant J.* 16, 735-743]. A certain proportion of transgenic seeds are harvested in both cases, and these seeds can be distinguished from non-transgenic seeds by growing under the above-

5 described selective conditions. In addition the stable transformation of plastids is of advantages because plastids are inherited maternally in most crops reducing or eliminating the risk of transgene flow through pollen. The transformation of the chloroplast genome is generally achieved by a process which has been schematically displayed in Klaus et al., 2004 [*Nature Biotechnology* 22 (2), 225-229]. Briefly the sequences to be transformed are cloned together with a selectable marker gene between flanking

10 sequences homologous to the chloroplast genome. These homologous flanking sequences direct site specific integration into the plastome. Plastidal transformation has been described for many different plant species and an overview is given in Bock (2001) *Transgenic plastids in basic research and plant biotechnology.* *J Mol Biol.* 2001 Sep 21; 312 (3):425-38 or Maliga, P (2003) *Progress towards commercialization of plastid transformation technology.* *Trends Biotechnol.* 21, 20-28. Further

15 biotechnological progress has recently been reported in form of marker free plastid transformants, which can be produced by a transient co-integrated marker gene (Klaus et al., 2004, *Nature Biotechnology* 22(2), 225-229).

The genetically modified plant cells can be regenerated via all methods with which the skilled worker is familiar. Suitable methods can be found in the abovementioned publications by S.D. Kung and R. Wu,

20 Potrykus or Hofgen and Willmitzer.

Generally after transformation, plant cells or cell groupings are selected for the presence of one or more markers which are encoded by plant-expressible genes co-transferred with the gene of interest, following which the transformed material is regenerated into a whole plant. To select transformed plants, the plant material obtained in the transformation is, as a rule, subjected to selective conditions so that transformed

25 plants can be distinguished from untransformed plants. For example, the seeds obtained in the above-described manner can be planted and, after an initial growing period, subjected to a suitable selection by spraying. A further possibility consists in growing the seeds, if appropriate after sterilization, on agar plates using a suitable selection agent so that only the transformed seeds can grow into plants. Alternatively, the transformed plants are screened for the presence of a selectable marker such as the

30 ones described above.

Following DNA transfer and regeneration, putatively transformed plants may also be evaluated, for instance using Southern analysis, for the presence of the gene of interest, copy number and/or genomic organisation. Alternatively or additionally, expression levels of the newly introduced DNA may be monitored using Northern and/or Western analysis, both techniques being well known to persons having

35 ordinary skill in the art.

The generated transformed plants may be propagated by a variety of means, such as by clonal propagation or classical breeding techniques. For example, a first generation (or T1) transformed plant may be selfed and homozygous second-generation (or T2) transformants selected, and the T2 plants may then further be propagated through classical breeding techniques. The generated transformed

organisms may take a variety of forms. For example, they may be chimeras of transformed cells and non-transformed cells; clonal transformants (e.g., all cells transformed to contain the expression cassette); grafts of transformed and untransformed tissues (e.g., in plants, a transformed rootstock grafted to an untransformed scion).

- 5 In certain embodiments, the transgenic plant or plant tissue or plant cell may have an increased or enhanced level of a VHH as taught herein relative to (i.e., compared with) a non-modified (i.e., non-transformed or untransformed, such as wild type) plant or plant tissue.

The level of a VHH as taught herein can be determined by any method known in the art for measuring the concentration of a protein. For instance, the level of a VHH as taught herein can be determined by an enzyme-linked immunosorbent assay (ELISA). The level of a VHH can be expressed as a percentage of  
10 the amount of VHH relative to the total protein amount.

The terms "quantity", "amount" and "level" are synonymous and generally well-understood in the art. With respect to proteins, the terms may particularly refer to an absolute quantification of the protein in a sample, or to a relative quantification of the protein in the sample, i.e., relative to another value such as  
15 relative to a reference value (e.g., the total protein content).

In certain embodiments, the transgenic plant or plant tissue or plant cell may have a level of a VHH as taught herein, which is at least 0,001 % of the amount of total soluble protein in the transgenic plant or plant tissue or plant cell, in particular in an extract of the transgenic plant or plant tissue. For example, the transgenic plant or plant tissue or plant cell may have a level of a VHH as taught herein which is at least  
20 0,005 %, at least 0,01 %, at least 0,05 %, at least 0,1 %, at least 0,2 %, at least 0,3 %, at least 0,4 %, or at least 0,5% of the amount of total soluble protein in the transgenic plant or plant tissue or plant cell, in particular in an extract of the transgenic plant or plant tissue.

Total soluble proteins of plants or plant tissues or plant cells can be extracted. Routine procedures can be used to determine the amount of total soluble protein in extracts of plants or plant tissues. Preferably, the  
25 protein concentration is determined by a colorimetric method, such as Bradford analysis known in the art. A Western blot using anti-VHH antibody fragment antibodies can be used to verify that VHH antibody fragments are expressed in transgenic plants. Preferably, anti-histidine antibodies are used to detect VHH that carry a hexahistidine tag. Preferably, anti-Fc antibodies are used to detect VHH fused to antibody Fc fragments. The concentration of VHH in a sample can be calculated comparing samples with a standard  
30 series of VHH in known amounts. The level of VHH expression can be calculated from the VHH and total soluble protein concentration.

In one aspect, the present inventors have identified transgenic plants or plant tissues or plant cells comprising at least one VHH which can specifically bind to a sphingolipid of a fungus and bind to a sphingolipid of a plant pathogenic fungus. Importantly, through this interaction with a specific molecular  
35 structure of the plant pathogenic fungus, the transgenic plant or plant tissue or plant cell disclosed herein is capable of controlling, modulating, inhibiting, preventing or reducing one or more biological activities of the plant pathogen, such that the growth of the plant pathogen is controlled, modulated, inhibited, prevented or reduced. In certain embodiments, the transgenic plants or plant tissues or plant cells as

taught herein are capable of killing a plant pathogenic fungus through the specific interaction of at least one VHH, which can specifically bind to a sphingolipid of a fungus and which is expressed in the plant or plant tissue.

5 Accordingly, the transgenic plants or plant tissues or plant cells as disclosed herein can be used to modulate, such as to change, decrease or inhibit, the biological function of a plant pathogenic fungus by binding to a binding site present on a sphingolipid target of that plant pathogenic fungus thereby affecting the natural biological activities (such as, but not limited to, growth) of the plant pathogenic fungus and/or one or more biological pathways in which the structural target of that plant pathogenic fungus is involved.

10 In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the VHHs as taught herein may be capable of specific binding (as defined herein) to a plant pathogen target or a plant pathogen antigen; and more preferably capable of binding to a plant pathogen target or a plant pest antigen or plant pathogen antigen with an affinity as defined herein (suitably measured and/or expressed as a  $K_D$ -value (actual or apparent), a  $K_A$ -value (actual or apparent), a  $k_{on}$ -rate and/or a  $k_{off}$ -rate, or alternatively as an  $IC_{50}$  value, as further described herein).

15 In particular embodiments, the invention provides a transgenic plant or plant tissue or plant cell, for combating plant pests, more particularly a plant fungus, which comprises at least one polypeptide or amino acid sequence of between 80 and 200 amino acids as the active substance.

20 In certain embodiments, the invention provides a transgenic plant or plant tissue or plant cell, for combating plant pests, which comprises at least two polypeptides or at least two amino acid sequences of between 80 and 200 amino acids as the active substance.

In certain embodiments, the invention provides a transgenic plant or plant tissue or plant cell, for combating plant pests, which comprises at least three polypeptides or at least three amino acid sequences of between 80 and 200 amino acids as the active substance.

25 The transgenic plant or plant tissue or plant cell according to the invention for combating plant pests, as defined before, means that the transgenic plant or plant tissue or plant cell, more in particular the VHH as defined before, encoded in the transgenic plant or plant tissue or plant cell, is able to interfere with, preferably to reduce or to arrest, the harmful effects of one or more plant pests on one or more plants, preferably crops.

30 Thus, in one embodiment, the transgenic plant or plant tissue or plant cell comprises a polypeptide of between 80 and 200 amino acids as the active substance.

In more specific embodiments the transgenic plant or plant tissue or plant cell comprises a polypeptide of between 80-100 amino acids, 800-120 amino acids, 80-140 amino acids, 80-160 amino acids or 80-180 amino acids.

35 In yet another embodiment the transgenic plant or plant tissue or plant cell comprises a polypeptide of between 100-200 amino acids, 100-180 amino acids, 100-160 amino acids, 100-150 amino acids, 100-140 amino acids or 100-120 amino acids.

In yet another embodiment the transgenic plant or plant tissue or plant cell comprises a polypeptide of between 110-200 amino acids, 110-180 amino acids, 110-160 amino acids, 110-140 amino acids or 110-130 amino acids.

5 In yet another embodiment, the transgenic plant or plant tissue or plant cell comprises a polypeptide of between 120-200 amino acids, 120-180 amino acids, 120-160 amino acids, or 120-140 amino acids.

In yet another embodiment, the transgenic plant or plant tissue or plant cell comprises a polypeptide of between 140-200 amino acids, 140-180 amino acids, or 140-160 amino acids.

In yet another embodiment, the transgenic plant or plant tissue or plant cell comprises a polypeptide of between 160-200 amino acids or 160-180 amino acids.

10 The at least one variable domain of a heavy-chain antibody (VHH) comprised in the transgenic plant or plant tissue or plant cell disclosed herein can be a naturally occurring polypeptide, or alternatively can be entirely artificially designed. Non-limiting examples of such naturally occurring polypeptides include heavy chain antibodies (hcAb).

15 According to particular embodiments, the invention provides a number of stretches of amino acid residues (i.e. small peptides) that are particularly suited for binding to a sphingolipid antigen or a sphingolipid target, such as but not limited to a fungal sphingolipid antigen or a fungal sphingolipid target.

20 These stretches of amino acid residues may be present in, and/or may be incorporated into, the VHH as disclosed herein, in particular in such a way that they form (part of) the antigen binding site of that VHH. As these stretches of amino acid residues were first generated as CDR sequences of antibodies, such as heavy chain antibodies, or of  $V_H$  or  $V_{HH}$  sequences that were raised against a sphingolipid target (or may be based on and/or derived from such CDR sequences, as further described herein), they will also generally be referred to herein as "*CDR sequences*" (i.e. as CDR1 sequences, CDR2 sequences and CDR3 sequences, respectively). It should however be noted that the invention in its broadest sense is not limited to a specific structural role or function that these stretches of amino acid residues may have in the VHH as disclosed herein, as long as these stretches of amino acid residues allow the VHHs as disclosed herein to specifically bind to a sphingolipid target. Thus, generally, the invention in its broadest sense relates to transgenic plant or plant tissues or plant cells comprising at least one polynucleotide encoding a variable domain of a heavy-chain antibody (VHH) that is capable of binding to a sphingolipid target and that comprises a combination of CDR sequences as described herein.

30 Thus, in certain embodiments, the VHHs as disclosed herein may be variable domains that comprise at least one amino acid sequence that is chosen from the group consisting of the CDR1 sequences, CDR2 sequences and CDR3 sequences that are described herein. In particular, a heavy chain variable domain as disclosed herein may comprise at least one antigen binding site, wherein said antigen binding site comprises at least one combination of a CDR1 sequence, a CDR2 sequence and a CDR3 sequence that are described herein.

35 Any variable domain of a heavy-chain antibody as taught herein and having one these CDR sequence combinations is preferably such that it can specifically bind (as defined herein) to a sphingolipid target or

a sphingolipid antigen, and more in particular such that it specifically binds to a sphingolipid of a plant pathogen, in particular with dissociation constant (Kd) of  $10^{-8}$  moles/liter or less of said variable domain in solution.

5 Specific binding of a variable domain of a heavy-chain antibody to a sphingolipid target can be determined in any suitable manner known per se, including, for example biopanning, Scatchard analysis and/or competitive binding assays, such as radioimmunoassays (RIA), enzyme immunoassays (EIA) and sandwich competition assays, and the different variants thereof known in the art.

10 In a preferred embodiment, the polypeptide of between 80 and 200 amino acids, is obtained by affinity selection against a particular pest target molecule and said polypeptide has a high affinity for said pest target molecule: typically, the dissociation constant of the binding between the polypeptide and its pest target molecule is lower than  $10^{-5}$  M, more preferably, the dissociation constant is lower than  $10^{-6}$  M, even more preferably, the dissociation constant is lower than  $10^{-7}$  M, most preferably, the dissociation constant is lower than  $10^{-8}$  M.

15 In particular embodiments, the at least one variable domain of a heavy-chain antibody as taught herein has a minimum inhibitory concentration (MIC) value for said plant pathogenic fungus of 1.0  $\mu\text{g/mL}$  or less of said variable domain in solution.

20 Also disclosed herein are polypeptides of between 80 and 200 amino acids or a sub-range as disclosed herein before, obtained by affinity selection to a specific plant pest target, which is able to inhibit the growth and/or the activity of a crop pest at a minimum inhibitory concentration of about 0.00001 to 1  $\mu\text{M}$ . In specific embodiments the minimum inhibitory concentrations are between 0.0001 to 1  $\mu\text{M}$ , are between 0.001 to 1  $\mu\text{M}$ , between 0.01 to 1  $\mu\text{M}$ , between 0.1 to 1  $\mu\text{M}$ , between 0.0001 to 0.1  $\mu\text{M}$ , between 0.001 to 0.1  $\mu\text{M}$ , between 0.01 to 0.1  $\mu\text{M}$ , between 0.00001 to 0.01  $\mu\text{M}$ , between 0.0001 to 0.01  $\mu\text{M}$ , between 0.001 to 0.01  $\mu\text{M}$ .

25 The Minimal Inhibitory Concentration or the MIC value is the lowest concentration of an agent such as a polypeptide that inhibits the visible growth of the crop or plant pest after incubation. For example the minimum fungicidal concentration (MFC) is considered as the lowest concentration of polypeptide which prevents growth and reduces the fungal inoculum by a 99.90% within 24 h. MFCs (Minimal Fungal Concentrations) can be determined on agar plates but can also be conveniently determined in fluids (e.g. in microwell plates) depending on the type of the fungus and the assay conditions.

30 In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise a sequence encoding a VHH comprising, consisting of, or consisting essentially of a CDR1, CDR2 and CDR3 region chosen from the list of comprising:

a CDR1 region having SEQ ID NO: 85, a CDR2 region having has SEQ ID NO: 169, and a CDR3 region having SEQ ID NO: 253, and/or

35 a CDR1 region having SEQ ID NO: 86, a CDR2 region having has SEQ ID NO: 170, and a CDR3 region having SEQ ID NO: 254, and/or

- a CDR1 region having SEQ ID NO: 87, a CDR2 region having has SEQ ID NO: 171, and a CDR3 region having SEQ ID NO: 255, and/or
- a CDR1 region having SEQ ID NO: 88, a CDR2 region having has SEQ ID NO: 172, and a CDR3 region having SEQ ID NO: 256, and/or
- 5 a CDR1 region having SEQ ID NO: 89, a CDR2 region having has SEQ ID NO: 173, and a CDR3 region having SEQ ID NO: 257, and/or
- a CDR1 region having SEQ ID NO: 90, a CDR2 region having has SEQ ID NO: 174, and a CDR3 region having SEQ ID NO: 258, and/or
- 10 a CDR1 region having SEQ ID NO: 91, a CDR2 region having has SEQ ID NO: 175, and a CDR3 region having SEQ ID NO: 259, and/or
- a CDR1 region having SEQ ID NO: 92, a CDR2 region having has SEQ ID NO: 176, and a CDR3 region having SEQ ID NO: 260, and/or
- a CDR1 region having SEQ ID NO: 93, a CDR2 region having has SEQ ID NO: 177, and a CDR3 region having SEQ ID NO: 261, and/or
- 15 a CDR1 region having SEQ ID NO: 94, a CDR2 region having has SEQ ID NO: 178, and a CDR3 region having SEQ ID NO: 262, and/or
- a CDR1 region having SEQ ID NO: 95, a CDR2 region having has SEQ ID NO: 179, and a CDR3 region having SEQ ID NO: 263, and/or
- a CDR1 region having SEQ ID NO: 96, a CDR2 region having has SEQ ID NO: 180, and a CDR3 region having SEQ ID NO: 264, and/or
- 20 a CDR1 region having SEQ ID NO: 97, a CDR2 region having has SEQ ID NO: 181, and a CDR3 region having SEQ ID NO: 265, and/or
- a CDR1 region having SEQ ID NO: 98, a CDR2 region having has SEQ ID NO: 182, and a CDR3 region having SEQ ID NO: 266, and/or
- 25 a CDR1 region having SEQ ID NO: 99, a CDR2 region having has SEQ ID NO: 183, and a CDR3 region having SEQ ID NO: 267, and/or
- a CDR1 region having SEQ ID NO: 100, a CDR2 region having has SEQ ID NO: 184, and a CDR3 region having SEQ ID NO: 268, and/or
- a CDR1 region having SEQ ID NO: 101, a CDR2 region having has SEQ ID NO: 185, and a CDR3 region having SEQ ID NO: 269, and/or
- 30 a CDR1 region having SEQ ID NO: 102, a CDR2 region having has SEQ ID NO: 186, and a CDR3 region having SEQ ID NO: 270, and/or
- a CDR1 region having SEQ ID NO: 103, a CDR2 region having has SEQ ID NO: 187, and a CDR3 region having SEQ ID NO: 271, and/or

- a CDR1 region having SEQ ID NO: 104, a CDR2 region having has SEQ ID NO: 188, and a CDR3 region having SEQ ID NO: 272, and/or
- a CDR1 region having SEQ ID NO: 105, a CDR2 region having has SEQ ID NO: 189, and a CDR3 region having SEQ ID NO: 273, and/or
- 5 a CDR1 region having SEQ ID NO: 106, a CDR2 region having has SEQ ID NO: 190, and a CDR3 region having SEQ ID NO: 274, and/or
- a CDR1 region having SEQ ID NO: 107, a CDR2 region having has SEQ ID NO: 191, and a CDR3 region having SEQ ID NO: 275, and/or
- 10 a CDR1 region having SEQ ID NO: 108, a CDR2 region having has SEQ ID NO: 192, and a CDR3 region having SEQ ID NO: 276, and/or
- a CDR1 region having SEQ ID NO: 109, a CDR2 region having has SEQ ID NO: 193, and a CDR3 region having SEQ ID NO: 277, and/or
- a CDR1 region having SEQ ID NO: 110, a CDR2 region having has SEQ ID NO: 194, and a CDR3 region having SEQ ID NO: 278, and/or
- 15 a CDR1 region having SEQ ID NO: 111, a CDR2 region having has SEQ ID NO: 195, and a CDR3 region having SEQ ID NO: 279, and/or
- a CDR1 region having SEQ ID NO: 112, a CDR2 region having has SEQ ID NO: 196, and a CDR3 region having SEQ ID NO: 280, and/or
- a CDR1 region having SEQ ID NO: 113, a CDR2 region having has SEQ ID NO: 197, and a CDR3 region having SEQ ID NO: 281, and/or
- 20 a CDR1 region having SEQ ID NO: 114, a CDR2 region having has SEQ ID NO: 198, and a CDR3 region having SEQ ID NO: 282, and/or
- a CDR1 region having SEQ ID NO: 115, a CDR2 region having has SEQ ID NO: 199, and a CDR3 region having SEQ ID NO: 283, and/or
- 25 a CDR1 region having SEQ ID NO: 116, a CDR2 region having has SEQ ID NO: 200, and a CDR3 region having SEQ ID NO: 284, and/or
- a CDR1 region having SEQ ID NO: 117, a CDR2 region having has SEQ ID NO: 201, and a CDR3 region having SEQ ID NO: 285, and/or
- a CDR1 region having SEQ ID NO: 118, a CDR2 region having has SEQ ID NO: 202, and a CDR3 region having SEQ ID NO: 286, and/or
- 30 a CDR1 region having SEQ ID NO: 119, a CDR2 region having has SEQ ID NO: 203, and a CDR3 region having SEQ ID NO: 287, and/or
- a CDR1 region having SEQ ID NO: 120, a CDR2 region having has SEQ ID NO: 204, and a CDR3 region having SEQ ID NO: 288, and/or

- a CDR1 region having SEQ ID NO: 121, a CDR2 region having has SEQ ID NO: 205, and a CDR3 region having SEQ ID NO: 289, and/or
- a CDR1 region having SEQ ID NO: 122, a CDR2 region having has SEQ ID NO: 206, and a CDR3 region having SEQ ID NO: 290, and/or
- 5 a CDR1 region having SEQ ID NO: 123, a CDR2 region having has SEQ ID NO: 207, and a CDR3 region having SEQ ID NO: 291, and/or
- a CDR1 region having SEQ ID NO: 124, a CDR2 region having has SEQ ID NO: 208, and a CDR3 region having SEQ ID NO: 292, and/or
- 10 a CDR1 region having SEQ ID NO: 125, a CDR2 region having has SEQ ID NO: 209, and a CDR3 region having SEQ ID NO: 293, and/or
- a CDR1 region having SEQ ID NO: 126, a CDR2 region having has SEQ ID NO: 210, and a CDR3 region having SEQ ID NO: 294, and/or
- a CDR1 region having SEQ ID NO: 127, a CDR2 region having has SEQ ID NO: 211, and a CDR3 region having SEQ ID NO: 295, and/or
- 15 a CDR1 region having SEQ ID NO: 128, a CDR2 region having has SEQ ID NO: 212, and a CDR3 region having SEQ ID NO: 296, and/or
- a CDR1 region having SEQ ID NO: 129, a CDR2 region having has SEQ ID NO: 213, and a CDR3 region having SEQ ID NO: 297, and/or
- a CDR1 region having SEQ ID NO: 130, a CDR2 region having has SEQ ID NO: 214, and a CDR3 region having SEQ ID NO: 298, and/or
- 20 a CDR1 region having SEQ ID NO: 131, a CDR2 region having has SEQ ID NO: 215, and a CDR3 region having SEQ ID NO: 299, and/or
- a CDR1 region having SEQ ID NO: 132, a CDR2 region having has SEQ ID NO: 216, and a CDR3 region having SEQ ID NO: 300, and/or
- 25 a CDR1 region having SEQ ID NO: 133, a CDR2 region having has SEQ ID NO: 217, and a CDR3 region having SEQ ID NO: 301, and/or
- a CDR1 region having SEQ ID NO: 134, a CDR2 region having has SEQ ID NO: 218, and a CDR3 region having SEQ ID NO: 302, and/or
- a CDR1 region having SEQ ID NO: 135, a CDR2 region having has SEQ ID NO: 219, and a CDR3 region having SEQ ID NO: 303, and/or
- 30 a CDR1 region having SEQ ID NO: 136, a CDR2 region having has SEQ ID NO: 220, and a CDR3 region having SEQ ID NO: 304, and/or
- a CDR1 region having SEQ ID NO: 137, a CDR2 region having has SEQ ID NO: 221, and a CDR3 region having SEQ ID NO: 305, and/or

- a CDR1 region having SEQ ID NO: 138, a CDR2 region having has SEQ ID NO: 222, and a CDR3 region having SEQ ID NO: 306, and/or
- a CDR1 region having SEQ ID NO: 139, a CDR2 region having has SEQ ID NO: 223, and a CDR3 region having the amino acid sequence NRY, and/or
- 5 a CDR1 region having SEQ ID NO: 140, a CDR2 region having has SEQ ID NO: 224, and a CDR3 region having SEQ ID NO: 307, and/or
- a CDR1 region having SEQ ID NO: 141, a CDR2 region having has SEQ ID NO: 225, and a CDR3 region having SEQ ID NO: 308, and/or
- 10 a CDR1 region having SEQ ID NO: 142, a CDR2 region having has SEQ ID NO: 226, and a CDR3 region having SEQ ID NO: 309, and/or
- a CDR1 region having SEQ ID NO: 143, a CDR2 region having has SEQ ID NO: 227, and a CDR3 region having SEQ ID NO: 310, and/or
- a CDR1 region having SEQ ID NO: 144, a CDR2 region having has SEQ ID NO: 228, and a CDR3 region having SEQ ID NO: 311, and/or
- 15 a CDR1 region having SEQ ID NO: 145, a CDR2 region having has SEQ ID NO: 229, and a CDR3 region having SEQ ID NO: 312, and/or
- a CDR1 region having SEQ ID NO: 146, a CDR2 region having has SEQ ID NO: 230, and a CDR3 region having SEQ ID NO: 313, and/or
- a CDR1 region having SEQ ID NO: 147, a CDR2 region having has SEQ ID NO: 231, and a CDR3 region having SEQ ID NO: 314, and/or
- 20 a CDR1 region having SEQ ID NO: 148, a CDR2 region having has SEQ ID NO: 232, and a CDR3 region having SEQ ID NO: 315, and/or
- a CDR1 region having SEQ ID NO: 149, a CDR2 region having has SEQ ID NO: 233, and a CDR3 region having SEQ ID NO: 316, and/or
- 25 a CDR1 region having SEQ ID NO: 150, a CDR2 region having has SEQ ID NO: 234, and a CDR3 region having SEQ ID NO: 317, and/or
- a CDR1 region having SEQ ID NO: 151, a CDR2 region having has SEQ ID NO: 235, and a CDR3 region having SEQ ID NO: 318, and/or
- a CDR1 region having SEQ ID NO: 152, a CDR2 region having has SEQ ID NO: 236, and a CDR3 region having SEQ ID NO: 319, and/or
- 30 a CDR1 region having SEQ ID NO: 153, a CDR2 region having has SEQ ID NO: 237, and a CDR3 region having SEQ ID NO: 320, and/or
- a CDR1 region having SEQ ID NO: 154, a CDR2 region having has SEQ ID NO: 238, and a CDR3 region having SEQ ID NO: 321, and/or

a CDR1 region having SEQ ID NO: 155, a CDR2 region having has SEQ ID NO: 239, and a CDR3 region having SEQ ID NO: 322, and/or

a CDR1 region having SEQ ID NO: 156, a CDR2 region having has SEQ ID NO: 240, and a CDR3 region having SEQ ID NO: 323, and/or

5 a CDR1 region having SEQ ID NO: 157, a CDR2 region having has SEQ ID NO: 241, and a CDR3 region having SEQ ID NO: 324, and/or

a CDR1 region having SEQ ID NO: 158, a CDR2 region having has SEQ ID NO: 242, and a CDR3 region having SEQ ID NO: 325, and/or

10 a CDR1 region having SEQ ID NO: 159, a CDR2 region having has SEQ ID NO: 243, and a CDR3 region having SEQ ID NO: 326, and/or

a CDR1 region having SEQ ID NO: 160, a CDR2 region having has SEQ ID NO: 244, and a CDR3 region having SEQ ID NO: 327, and/or

a CDR1 region having SEQ ID NO: 161, a CDR2 region having has SEQ ID NO: 245, and a CDR3 region having SEQ ID NO: 328, and/or

15 a CDR1 region having SEQ ID NO: 162, a CDR2 region having has SEQ ID NO: 246, and a CDR3 region having SEQ ID NO: 329, and/or

a CDR1 region having SEQ ID NO: 163, a CDR2 region having has SEQ ID NO: 247, and a CDR3 region having SEQ ID NO: 330, and/or

20 a CDR1 region having SEQ ID NO: 164, a CDR2 region having has SEQ ID NO: 248, and a CDR3 region having SEQ ID NO: 331, and/or

a CDR1 region having SEQ ID NO: 165, a CDR2 region having has SEQ ID NO: 249, and a CDR3 region having SEQ ID NO: 332, and/or

a CDR1 region having SEQ ID NO: 166, a CDR2 region having has SEQ ID NO: 250, and a CDR3 region having SEQ ID NO: 333, and/or

25 a CDR1 region having SEQ ID NO: 167, a CDR2 region having has SEQ ID NO: 251, and a CDR3 region having SEQ ID NO: 334, and/or

a CDR1 region having SEQ ID NO: 168, a CDR2 region having has SEQ ID NO: 252, and a CDR3 region having SEQ ID NO: 335.

30 In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise a sequence encoding a VHH comprising a CDR1, CDR2 and CDR3 region chosen from the list of comprising:

a CDR1 region having SEQ ID NO: 85, a CDR2 region having has SEQ ID NO: 169, and a CDR3 region having SEQ ID NO: 253, and/or

35 a CDR1 region having SEQ ID NO: 86, a CDR2 region having has SEQ ID NO: 170, and a CDR3 region having SEQ ID NO: 254.

In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise a sequence encoding a VHH comprising a CDR1 region having SEQ ID NO: 85, a CDR2 region having has SEQ ID NO: 169, and a CDR3 region having SEQ ID NO: 253.

- 5 In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the polynucleotide may comprise a sequence encoding a VHH comprising a CDR1 region having SEQ ID NO: 86, a CDR2 region having has SEQ ID NO: 170, and a CDR3 region having SEQ ID NO: 254.

- 10 In particular embodiments, the VHH as taught herein are heavy chain variable domains that essentially consist of four framework regions (FR1 to FR4 respectively) and three complementarity determining regions (CDR1 to CDR3 respectively); or any suitable fragment of such an heavy chain variable domain (which will then usually contain at least some of the amino acid residues that form at least one of the CDR's, as further described herein).

- 15 Functional variants of the VHH as taught herein may in particular be a domain antibody (or an heavy chain variable domain that is suitable for use as a domain antibody), a single domain antibody (or an heavy chain variable domain that is suitable for use as a single domain antibody), or a "dAb" (or an heavy chain variable domain that is suitable for use as a dAb); other single variable domains, or any suitable fragment of any one thereof. For a general description of (single) domain antibodies, reference is also made to the prior art cited above, as well as to EP 0 368 684. For the term "dAb's", reference is for  
20 example made to Ward et al. (Nature 1989 Oct 12; 341 (6242): 544-6), to Holt et al., Trends Biotechnol., 2003, 21(11):484-490; as well as to for example WO 06/030220, WO 06/003388 and other published patent applications of Domantis Ltd.

Thus, in particular embodiments, the present invention provides a variable domain of a heavy-chain antibody with the (general) structure

- 25 FR1 - CDR1 - FR2 - CDR2 - FR3 - CDR3 - FR4

in which FR1 to FR4 refer to framework regions 1 to 4, respectively, and in which CDR1 to CDR3 refer to the complementarity determining regions 1 to 3, respectively, and are as further defined herein.

- 30 SEQ ID NO's: 1 to 84 (see Table 1) give the amino acid sequences of a number of variable domains of a heavy-chain antibody that have been raised against a sphingolipid target, in particular against glucosylceramide.

Table 1: VHH sequences

Name	SEQ ID	VHH Amino acid sequence
41D01	1	QVQLQESGGGLVQAGGSLRLSCAASGRTF SRYGMGWFRLPGKQRELVTSITRGGTTTYADSVKG RFTISRDNAKNTVY LQMNSLKPEDTAVYYCNARS IWRDYWGQGTQVTVSS
56F11	2	QVQLQESGGGLVQSGGSLRLSCVHSKTTFTRNAMGWYRQALGKERELVATITSGGTTNYADSVKG RFTISMDSAKNTVY LQMNSLKPEDTAVYYCNVNTRRIFGGTVREYWGQGTQVTVSS
40F07	3	QVQLQESGGGLVQAGGSLRLSCVASGTTTFSSYTMGWYRQAPGKQRELLASIEGGNTDYADSVKG RFTISRDNARNTVY LQMNSLKTEDTAVYYCNAARTWSIFRNYWGQGTQVTVSS
41D06	4	QVQLQESGGGLVQAGGSLRLSCAASGGIFGINAMRWYRQAPGKQRELVASISSGGNTNYSESVKG RFTISRDDANYTVY LQMNSLKPEDTAVYYCNFVRLWFPDYWGQGTQVTVSS

Name	SEQ ID	VHH Amino acid sequence
41G10	5	QVQLQESGGGLVQPGGSLTLSCAATKTGFSINAMGWYRQAPGKQREMVATIITSGGTTNYADSVKGRFAISRDNKNTVSLQMNTLKPEDTALYYCNTEARRYFTRASQVYWGQGTQVTVSS
41H05	6	QVQLQESGGGLVQPGGSLRLSCAASGGIF SINAMGWYRQDPGKQREMVATIITSGANTNYTDSVKG RFTISRDNKNTVY LQMNSLKPEDTAVYYCNAVGRRWYGGYVELWGQGTQVTVSS
42C11	7	QVQLQESGGGLVQPGGSLRLSCAASGSIFSTYVMGWYRQAIGKQRELVATIITSSGKTNYAASVKG RFTVSRDITKNTMYLQMNLSLKPEDTAVYYCGADRWVLRWSNYWGQGTQVTVSS
42C12	8	QVQLQESGGGLVQPGGSLRLSCAASGSISSLGWYRQAPGKQREFVASATSGGDTTYADSVKGRFTISRDNKNTVY LQMNSLKPEDTAVYYCKGQGRVAVTRKEYWGQGTQVTVSS
50D03	9	QVQLQESGGGLVQPGGSLRLSCAASGSIFSTYAMGWYRQAIGKQRELVATIITSSGKTNYAASVKG RFTISRDIITKNTMYLQMNLSLKPEDTAVYYCGADRWVLRWSNYWGQGTQVTVSS
50D07	10	QVQLQESGGGLVQPGGSLRLSCTASGNIVNIRDMGWYRQVPGKQRELVATIITSDQSTNYADSVKGRFTTTRDNKKTVY LQMDSLKPEDTAGYYCNARVRTVLRGWRDYWGQGTQVTVSS
50E02	11	QVQLQESGGGLVQPGGSLRLSCAASGSIF SINAMGWYRQAPGKQRELVAAITSDGSTNYADSVKGRFTISRDNKNTAYLQMNLSLKPEDTAVYYCNLRRRTFLKSSDYWGQGTQVTVSS
51B08	12	QVQLQESGGGLVQAGDSLRLSCAASGRREFSYAMGWFRQVPGKERELVAGISSGGSTKYADSVRGRFTISRDNKNTVSLQMKSLKPEDTAVYYCNAKYGRWYTYGRPEYDSWGQGTQVTVSS
51C06	13	QVQLQESGGGLVQPGGSLRLSCAASGSIFSSDTMGWYRRAPGKQRELVAAITGGNTNYADSVKGRFTISRDNKNTVY LQMNSLQPEDTAVYYCNCRRRWSRDFWGQGTQVTVSS
51C08	14	QVQLQESGGGLVQPGGSLRLSCAASGTIFSIKTMGWYRQAPGKQRELVATIISNGGSTNYADSVKGRFTISRDNKNTVY LQMNSLKPEDTAVYYCNARQQF IGAPYEYWGQGTQVTVSS
52A01	15	QVQLQESGGGLVQAGGSLRLSCTASGAIITFSLGTMGWYRQAPGKQRELVASISTGSTNYADSVKGRFTISRDI IKNILYLQMNLSLKPEDTAVYYSCNARLLWSNYWGQGTQVTVSS
52B01	16	QVQLQESGGGLVQAGESLRLSCAASGSTF SINVMGWYRQAPGEQRELVATIISRGGSTNYADSVKGRFTISRDNKNTVY LQMDSLKPEDTAVYYCNAAGWVGVNTNYWGQGTQVTVSS
52G05	17	QVQLQESGGGLVQAGGSLRLSCAASGSTGSI SAMGWYRQAPGKQRELVASITRRGSTNYADSVKDRFTISRDNANTVY LQMNSLKPEDTAVYYCNARRYTRNDYWGQGTQVTVSS
53A01	18	QVQLQESGGGLVQAGGSLRLSCEVSGTTF SINTMGWHYRQAPGKQRELVASISSGGWTNYADSVKGRFTISRDNKKTVY LQMNNLKPEDTAVYYCRWGAIGNWYWGQGTQVTVSS
53F05	19	QVQLQESGGGLVQPGGSLRLSCAASVRI FGLNAMGWYRQGPQKQRELVASITGGSTNYAEPVKG RFTISRDNANTVY LQMNNLKPEDTAVYYCNAERRWGLPNYWGQGTQVTVSS
54A02	20	QVQLQESGGGLVEAGGSLRLSCAASGRTF SRYGMGWFRQAPGKEREFVAANRWSSGGSTYYADSVRGRFTISRDNKNTVY LQMNSLKPEDTAVYYCAAYAHITAWGMRNDYEYDYWGQGTQVTVSS
54B01	21	QVQLQESGGGLVQAGGSLRLSCAATGRTF SRYTMGWFRQAPGKERDFVAGITWTGGSTDYADSVKGRFTISRDNKNTVY LQMNSLKPEDTAVYYCAAGNLLRLAGQLRRGYDSWGQGTQVTVSS
54C01	22	QVQLQESGGGLVQAGGSLRLSCAASGRTG SRYAMGWFRQAPGKEREFVAAISWSSGGSTYYADSVKDRFTISRDNKNTVY LQMNSLKPEDTAVYYCATRNRAGPHYSRGYTAGQEYDYWGQGTQVTVSS
54C04	23	QVQLQESGGGLVQPGGSLRLSCAASGRIF SINAMGWYRQGPQKQRELVVDMTSGGSINYADSVSG RFTISRDNKNTVY LQMNSLKPEDTAVYYCHANLRTAFWRNGNDYWGQGTQVTVSS
54C08	24	QVQLQESGGGLVQPGGSLRLSCAASGSISSINAMGWYRQAPGKQRELVASITSGGSTNYADSVKGRFTISRDNKNTVNLQMNLSLKPEDTAVYYCSAGPWYRRSWGRGTQVTVSS
54C10	25	QVQLQESGGGLVQPGESLRLSCAASASIFWVNDMGWYRQAPGKQRELVAQITRRGSTNYADSVKGRFTISRDNKDEVY LQMNSLKPEDTAVYYCNADLAVRGRYWGQGTQVTVSS
54C11	26	QVQLQESGGGLVQPGGSLRLSCAASGSFFPVNDMAWYRQALGNERELVANI TRGGSTNYADSVKGRFTISRDNKNTVY LQMNTLKPEDTAVYYCNVRIGFGWTAKAYWGQGTQVTVSS
54D03	27	QVQLQESGGGLVQPGGSLRLSCAASGGIFGINAMRWYRQAPGKQRELVASISSGGNTNYSESVKGRFTISRDDANYTVY LQMNSLKPEDTAVYYCNFVRLWFPDYWGQGTQVTVSS
54D06	28	QVQLQESGGGLVQPGGSLRLSCAASGSTIRINAMGWYRQAPGKQRELVATI TRGGITNYADSVKGRFTISRDNKFTVY LQMNSLKPEDTAVYYCNARSWVGPPEYWGQGTQVTVSS
54D10	29	QVQLQESGGGLVQPGGSLRLSCAASGMTYSIHAMGWYRQAPGKERELVAITSTSGTDDYTDYADSVKGRFTISR DGANNNTVY LQMNSLKSEDTAVYYCHVKTRTWYNGKYDYWGQGTQVTVSS
54E01	30	QVQLQESGGGLVQPGGSLRLSCTASGSIF SINPMGWYRQAPGKQRELVAAITSGGSTNYADYVKG RFTISRDNKNTVY LQMNSLKPEDTAVYYCNGRSTLWRRDYWGQGTQVTVSS
54E05	31	QVQLQESGGGLVQPGGSLRLSCAASGSIF SINTMGWYRQAPGKQRELVAAITNRGSTNYADYVKG RFTISRDNKNTVY LQMNSLKPDDTAVYYCNAHRSWPRYDSWGQGTQVTVSS
54E10	32	QVQLQESGGGLVQPGGSLRLSCAASGSIF SFNAMGWYRQAPGKQRELVAAITRRGGSTNYADSVKGRFTISRDNANTVY LQMNSLKPEDTAVYYCNAESRIFRRYDYWGPGTQVTVSS
54F01	33	QVQLQESGGGLVQPGGSLRLSCVTSGSIFGLNLMGWYRQAPGKQRELVATI TRGGSTNYADSVKGRFTISRDNKKTVY LQMNSLKPEDTAVYYCNVDRGWSSYWGQGTQVTVSS

Name	SEQ ID	VHH Amino acid sequence
54F02	34	QVQLQESGGGLVQPGGSLRLSCVTSIGSIRSIINTMGWYRQAPGNERELVATITSGGTNYADSVKN RFTISRDNKNTVYLYQMNSLKPEDTAVYYCNLHQRAWARSYVYWGQGTQVTVSS
54G01	35	QVQLQESGGGSVQPGGSLRLSCAASGSIFAVNAMGWYRQAPGHQRELVAIISNSTSNYADSVKG RFTISRDNKNTVYLYQMNSLKPEDTAVYFCYAKRSWFSQEYWGQGTQVTVSS
54G08	36	QVQLQESGGGLVQPGGSLRLSCAASGSIFSFNLMGWYRQAPGKQRELVAAITSSSNTNYADSVKG RFTISRDNKNTVYLYQMNSLKPEDTAVYYCNAQYTIITPWGIKKDYWGQGTQVTVSS
54G09	37	QVQLQESGGGLMVPGGSLRLSCTASGNIVNIRDMGWYRQVPGKQRELVATITSDQSTNYADSVKG RFTTTRDNKNTVYLYQMNSLKPEDTAGYYCNARVRTVLRGWRDYWGQGTQVTVSS
55B02	38	QVQLQESGGGLVQPGESLRLSCVSGSIFNINSMNWYRQASGKQRELVADMRS DGSTNYADSVKG RFTISRDNARKTVYLYQMNSLKPEDTAVYYCHANSIFRSRDYWGQGTQVTVSS
55B05	39	QVQLQESGGGVVQAGDSLRLSCAASGRTFGGYTVAWFRQAPGKEREFFVARIISWSGIMAYYAESVK GRFTISRDNKNTVYLYQMNSLKPEDTAVYYCASRSQIRSPWSSLDDYDRWGQGTQVTVSS
55C05	40	QVQLQESGGGLVQPGGSLRLSCVVSIGSISMKAMGWHRQAPGKERELVAQITRGDSTNYADSVKG RFTISRDNKNTVYLYQMNSLKPDDTGVYYCNADREFFGRDYWGKGTQVTVSS
55D08	41	QVQLQESGGGLVQPGGSLRLSCAASRSILSISAMGWYRQGGPKQREPVATITTSAGSSNYSDSVKG RFTISRDNKNTAYLYQMNSLKPEDTAVYYCKTVYSRPLLGPLEVWGQGTQVTVSS
55E02	42	QVQLQESGGGLVQTTGGSLRLSCVASGSMFSSNAMAWYRQAPGKQRELVARILSGGSTNYADSVKG RFTISRGNKNTVYLYQMNSLKPEDTAVYYCNAVRYLVNYWGQGTQVTVSS
55E07	43	QVQLQESGGGSVQVGDSTLSCVASGRSLDIYMGWFRQAPGKEREFFVARIITSGGSTYYADSVKG RFTLSRDNAKNTVYLYQMNSLKPEDTAVYYCAAGVVVATSPKFYAYWGQGTQVTVSS
55E09	44	QVQLQESGGGLVQAGGSLRLSCAASKRIFSTYTMGWFRQAPGKEREFFVAIISWGGRTYADSVK GRFTISRDNARNTVHLYQMNSLEPEDTAVYYCYTRRLGTGYWGQGTQVTVSS
55E10	45	QVQLQESGGGLVQAGGSLRLSCAASGSTFSIQITIGWYRQAPGKQDRVATISSGGSTNYADSVKG RFTISRDNKNTVYLYQMNSLKPEDTAVYYCNLRYWFRDYWGQGTQVTVSS
55F04	46	QVQLQESGGGLVQPGGSLRLSCAASGSTFSINVRGWYRQAPGKQRELVATITSDGSTNYADSVKG RFTISRDNKNTAYLYQMNSLKPEDTAVYYCNAVRLFRQYWGQGTQVTVSS
55F09	47	QVQLQESGGGLVQPGGSLRLSCAASGSIFRLNAMGWYRQAPGKQRELVAIITPGGGNTTYADSVK GRFTISRDNALNTIYLYQMNSLKPEDTAVYYCNAGGSSRWYSSRYYPGGYWGQGTQVTVSS
55F10	48	QVQLQESGGGLVQAGGSLRLSCATSGGTFSRYAMGWFRQAPGKERELVATIRRSGSSTYYLDSTK GRFTISRDNKNTVYLYQMNSLKLKEDTAVYYCAADSSARALVGGPGNRWDYWGQGTQVTVSS
55G02	49	QVQLQESGGGLVQPGGSLRLSCAASGSIGSINVMGWYRQYPGKQRELVAFITSGGITNYTDSVKG RFAISRDNQAQNTVYLYQMNSLTPEDTAVYYCHLKNKKNRPGYWGQGTQVTVSS
55G08	50	QVQLQESGGGLVQPGGSLRLSCRASGGIFGINAMRWYRQAPGKQRELVASISSGGTTDYVESVK RFTISRDNATNTVDLQMSALKPEDTAVYYCNFVRFVFPDYWGQGTQVTVSS
56A05	51	QVQLQESGGGLVQAGGSLRLSCAASGITFMSNTMGWYRQAPGKQRELVASISSGGSTNYADSVKG RFTISRDNKNTVYLYQMNSLKPEDTAVYYCNARRNVFISSWGQGTQVTVSS
56A06	52	QVQLQESGGGLVQPGGSLRLSCVASGSISVYGMGWYRQAPGKQRELVARITNIGTTNYADSVKGR FTISRDNKNTVYLYQMNSLQPEDTAVYYCNLRLRGRDYWGQGTQVTVSS
56A09	53	QVQLQESGGGLVQPGGSLRLSCAASRTALRLNSMGWYRQAPGSQRELVATITRGGTTNYADSVKG RFTISRDIIGNNTVYLYQMNSLEPEDTAVYYCNANFGILVGREYWGKGTQVTVSS
56C09	54	QVQLQESGGGLVQAGGSLRLSCAVSISFISLSMAWYRQTPGKQRELVANITSVGSTNYADSVKG RFTISRDIKKTLYLYQMNSLKPEDTAIYYCNTRMPFLGDSWGQGTQVTVSS
56C12	55	QVQLQESGGGLVQAGGSLRLSCAVSAFSSFNRAVSWYRQAPGKSREWVASISGIRITTYTNSVK RFIISRDNKNTVYLYQMNSLQPEDTGVYRCYMNRYSGQGTQVTVSS
56D06	56	QVQLQESGGGSVQPGGSLRLSCAASGTVFFSISAMGWYRQAPGKQRELVAGISRGGSTKYGDFVK GRFTISRDNKKTIVLYQMNSLQPEDTAIYYCRLTITGTYLWGQGTQVTVSS
56D07	57	QVQLQESGGGLVQPGGSLRLSCAASGSIFSMKVMGWYRQGGPKLRELVAVITSGGRTNYAESVK RFTISRDNKNTVSLQMNLSLQPEDTAVYYCYKTIIRPYWGQGTQVTVSS
56D10	58	QVQLQESGGGLVQAGGSLRLSCAASGITFRITTMGWYRQAPGKQRELVAISSSGGTNYASSVK RFTISRDNKNTVYLYQMNSLRPEDTAVYYCNARKEITTPWSTDYWGQGTQVTVSS
56E04	59	QVQLQESGGGLVQPGDSLRLSCTPSGSIFNHKATGWYRQAPGSQRELVAKITTGGTTNYADSVKG RFTISRDNKNTVYLYQMNSLKPEDTAVYYCNAERYFATTLWGQGTQVTVSS
56E05	60	QVQLQESGGGLVQAGGSLRLSCAASGITFSNAGGWYRQAPGQQRELVARISSGGNTNYTDSVK RFTISRDIITKNTLSLQMNLSLQPEDSAVYYCNAQRVILGPRNYWGQGTQVTVSS
56E08	61	QVQLQESGGGLVQAGGSLRLSCAASGNIFRINDMGWYRQAPGNQRELVATITSANITNYADSVKG RFTISRDNKNTVYLYQMNSLNPEDTAVYYCTAQAKKWRI GPWSDYWGQGTQVTVSS
56F07	62	QVQLQESGGGLVQPGGSLRLSCAASGRIFSIINDMAWYRQAPGKQRELVAIITNDDSTTYADSVK RFTISRDNKNTVYLYQMNSLKPEDTAVYYCNADINTAIWRRKYWGQGTQVTVSS

Name	SEQ ID	VHH Amino acid sequence
56G07	63	QVQLQESGGGLVQPGGSLRLSCAVSGSRIFIHDMGWHRQAPGEPRELVATITPFGRRNYSEYVKG RFTVSRDIARNTMSLQMSNLKAEDTGMYYCNVRVNGVDYWGQGTQVTVSS
56G08	64	QVQLQESGGGLVQAGGSLRLSCAISGITFRPFGRISRMGWYRQAPGKERELVATLSRAGTSRYVD SVKGRFTISRDDAKNTLYLQMVSLNPEDTAVYYCYIAQLGTDYWGQGTQVTVSS
56G10	65	QVQLQESGGGLVQAGGSLRLSCVASGITLRMYQVGWYRQAPGKQRELVAEISSRGTMYADSVKG RFTISRDKAKNIVYLYLQMNLEPEDTAVYYCNARAFAGFRNSWGQGTQVTVSS
56H04	66	QVQLQESGGGSVQAGGSLRLSCAVSGGTF SNKAMGWYRQSSGKQRALVARI STVGTAHYADSVKG RFTVSKDNAGNTLYLQMNLSKPEDTAVYYCNAQAGRLYL RNYWGQGTQVTVSS
56H05	67	QVQLQESGGGLVQPGESLRLSCVAAASTSITTFNTMAWYRQAPGKQRELVAQINNRDNT EYADSV KGRFII SRGNAKNTSNLQMNLDKSEDTGIYYCNAKRWSWSTGFWGQGTQVTVSS
56H07	68	QVQLQESGGGLVQAGGSLRLSCTASGLTFALGTMGWYRQAPGKQRELVASISTGSTNYADSVKGR FTISRDI IKNILYLYLQMNLSKPEDTAVYSCNARLWWSNYWGQGTQVTVSS
56H08	69	QVQLQESGGGLVQAGGSLRLSCTASGRTSSVNPMGWYRQAPGKQRELVAVISSDGSTNYADSVKG RFTVSRDNAKNTLYLQMNLSKPEDTAVYYCNANRRWSWGSEYWGQGTQVTVSS
57A06	70	QVQLQESGGGLVQAGGSLRLSCAASGITFTNNAGGWYRQAPGQRELVARISSGGNTNYTDSVKG RFTISRDIITKNTLSLQMNLSKPEDSAVYYCNAQRRVILGPRNYWGQGTQVTVSS
57B01	71	QVQLQESGGGLVQAGGSLRLSCEAPVSTFNINAMAWYRQAPGKSRELVARISSGGSTNYADSVKG RFTISRDNKNTVYLYLQMNLSKPEDTAVYICYVNRHWGWDYWGQGTQVTVSS
57B07	72	QVQLQESGGGLVQPGGTLRLSCVASGSRFSINAMGWYRQAPGKQRELVA TVDSGGYTNYADSVKG RFTISRDNKNTVYLYLQMSLTPEDTAVYYCYAGIYKWPWSVDARDYWGQGTQVTVSS
57B11	73	QVQLQESGGGLVQAGGSLRLSCAASGSSISMNSMGWYRQAPGKERERVALIRSSGGTYADSVKG RFTISRDNKNTVYLYLQMNLSKPEDTAVYYCQARRTWLSSESWGQGTQVTVSS
57C07	74	QVQLQESGGGLVQAGGSLRLSCAVSGSTFGINTMGWYRQAPEKQRELVASISRGGMTNYADSVKG RFIISRDNKNTVYLYLQMNLSKPEDTAVYVCNAGIRSRWYGGPITTYWGQGTQVTVSS
57C09	75	QVQLQESGGGLVQAGGSLRLSCAASGSTGSINAMGWYRQGPQKQDLVASISSGGATNYADSVKG RFTISRDNKNTVYLYLQMSLTPEDTAVYYCNAKKSRSWSWSIVHDYWGQGTQVTVSS
57D02	76	QVQLQESGGGSVQTGGSLTSLCTTSGSIFGRSDMGWYRQAPGKQRELVAITRRSRTNYAEFVKG RFTISRDSAKNLVTLQMNLSKPEDTNVYYCNARWGAGGIFSTWGQGTQVTVSS
57D09	77	QVQLQESGGGLVQPGESLRLSCAASGSMSIDAMGWYRQAPGDQRELVASITGGSTNYADSVKGR FTISRDNKNTVWLQMNLSKPEDTAVYYCNAKVRRLRWRPSPDYWGQGTQVTVSS
57D10	78	QVQLQESGGGLVQPGGSLRLSCAASGRLLSISTMGWYRRTPEDQREMVASITKDGTNYADSVKG RLTISRDNKNTVYLYLQMNLSKPDDETAVYVCNARATTWVPYRRDAEFWGQGTQVTVSS
57E07	79	QVQLQESGGGLVQAGGSLRLSCAASGSIFGINDMGWYRQAPGKQKQDLVADITRSGSTHYVDSVKG RFTISRDNKNTVYLYLQMNLSKPEDTAVYYCNADSGSHWNNRRDYWGQGTQVTVSS
57E11	80	QVQLQESGGGLVQPGGSLKLSCAASGFTFSINTMGWYRQAPGKQRELVARISRLRVTNYADSVKG RFTISRDNKNTVYLYLQMNLSKPEDTAVYYCNAANWGLAGNEYWGQGTQVTVSS
57G01	81	QVQLQESGGGLVQAGGSLRPSCTASGSTLLINSMGWYRQAPGKQRELVAITSNSGTNYVDAVKG RFAISRDNANHTVYLYLQMNLEPEDTAVYYCNAQTFWRRNYWGQGTQVTVSS
57G07	82	QVQLQESGGGLVQAGGSLRLSCAVSGSTSRINAMGWYRQAPGKKRESVATIRRGNTKYADSVKG RFTISRDNANNTVYLYLQNLNSKPEDTAVYYCNAHSWLDYDYWGRGTQVTVSS
57G08	83	QVQLQESGGGLVQAGGSLRLSCASRRRINGITMGWYRQAPGKQRELVAITDIHNSTKYADSVKGR FIISRDNKNSMLYLYLQMNLSKPEDTAVYYCNRIPTFGRYWGQGTQVTVSS
57H08	84	QVQLQESGGGLVQAGGSLRLSCVASGSTFYTFSTKNVWYRQAPGKQRELVAQQRYDGSTNYADS LQGRFTISRDNKRTVYLYLQMNLSKPEDTAVYICNVNRGFI SYWGQGTQVTVSS

In particular, the invention in some specific embodiments provides transgenic plants or plant tissues or plant cells comprising a polynucleotide encoding at least one VHH that is directed against a sphingolipid target and that has at least 80%, preferably at least 85%, such as 90% or 95% or more sequence identity with at least one of the heavy chain variable domains of SEQ ID NO's: 1 to 84 (see Table 1), and nucleic acid sequences that encode such heavy chain variable domains.

Some particularly preferred VHH as disclosed herein are those which can bind to and/or are directed against a sphingolipid of a plant pathogen and which have at least 90% amino acid identity with at least

one of the VHH of SEQ ID NO's: 1 to 84 (see Table 1), in which for the purposes of determining the degree of amino acid identity, the amino acid residues that form the CDR sequences are disregarded.

In these heavy chain variable domains, the CDR sequences (see Table 2) are generally as further defined herein.

5 Table 2: CDR sequences

Name	CDR1 sequence	SEQ ID	CDR2 sequence	SEQ ID	CDR3 sequence	SEQ ID
41D01	RYGMG	85	SITRGGTTYADSVKG	169	RSIWRDY	253
56F11	RNAMG	86	TITSGGTTNYADSVKG	170	NTRRIFGGTVREY	254
40F07	SYTMG	87	SIEGGGNTDYADSVKG	171	ARTWSIFRNY	255
41D06	INAMR	88	SISSGGNTNYSESVKG	172	VRLWFPDY	256
41G10	INAMG	89	TITSGGTTNYADSVKG	173	EARRYFTRASQVY	257
41H05	INAMG	90	TITSGANTNYTDSVKG	174	VGRRWYGGYVEL	258
42C11	TYVMG	91	TITSSGKTNYAASVKG	175	DRWVLTRWSNY	259
42C12	ISSLG	92	SATSGGDTTYADSVKG	176	QRGVAWTRKEY	260
50D03	TYAMG	93	TITSSGKTNYAASVKG	177	DRWVLTRWSNY	261
50D07	IRDMG	94	TITSDQSTNYADSVKG	178	RVRTVLRGWRDY	262
50E02	INAMG	95	AITSDGSTNYADSVKG	179	RRRTFLKSSDY	263
51B08	SYAMG	96	GISSGGSTKYADSVRG	180	KYGRWYTYGRPEYDS	264
51C06	SDTMG	97	AITTGNTNYADSVKG	181	RRRWSRDF	265
51C08	IKTMG	98	TISNGGSTNYADSVKG	182	RQQFIGAPYDY	266
52A01	LGTMG	99	SISTGSTNYADSVKG	183	RLLSNY	267
52B01	INVMG	100	TISRGGSTNYADSVKG	184	AGWVGVTNY	268
52G05	ISAMG	101	SITRRGSTNYADSVKD	185	RRYYTRNDY	269
53A01	INTMG	102	SISSGGWTNYADSVKG	186	GAIGNW	270
53F05	LNAMG	103	SITTGSTNYAEPVKG	187	ERRWGLPNY	271
54A02	RYGMG	104	ANRWSGGSTYYADSVRG	188	YAHITAWGMRNDYEYDY	272
54B01	RYTMG	105	GITWTGGSTDYADSVKG	189	GNNLRLAGQLRRGYDS	273
54C01	RYAMG	106	AISWSGGSTYYADSVKD	190	RNRAGPHYSRGTAGQDY	274
54C04	INAMG	107	DMTSGGSINYADSVSG	191	NLRTAFWRNGNDY	275
54C08	INAMG	108	SITSGGSTNYADSVKG	192	GPWYRRS	276
54C10	VNDMG	109	QITRRGSTNYADSVKG	193	DLAVRGRY	277
54C11	VNDMA	110	NITRGGSTNYADSVKG	194	RIGFGWTAKAY	278
54D03	INAMR	111	SISSGGNTNYSESVKG	195	VRLWFPDY	279
54D06	INAMG	112	TITRGGITNYADSVKG	196	RSWVGPEY	280
54D10	IHAMG	113	ITSTSGTDDYADSVKG	197	KTRTWYNGKYDY	281
54E01	INPMG	114	AITSGGSTNYADYVKG	198	RSTLWRRDY	282
54E05	INTMG	115	AITNRGSTNYADYVKG	199	HRSWPRYDS	283
54E10	FNAMG	116	AITRGGSTNYADSVKG	200	ESRIFRRYDY	284
54F01	LNLMG	117	TITRGGSTNYADSVKG	201	DRGWSSY	285
54F02	INTMG	118	TITSGGTTNYADSVKN	202	HQRAWARSYVY	286
54G01	VNAMG	119	IISNSTSNYADSVKG	203	KRSWFSQY	287
54G08	FNLMG	120	AITSSNTNYADSVKG	204	QYTITPWGIKKDY	288
54G09	IRDMG	121	TITSDQSTNYADSVKG	205	RVRTVLRGWRDY	289
55B02	INSMN	122	DMRSDGSTNYADSVKG	206	NSIFRSRDY	290
55B05	GYTVA	123	RISWSGIMAYYAESVKG	207	RSQIRSPWSSLDDYDR	291
55C05	MKAMG	124	QITRGDSTNYADSVKG	208	DRFFGRDY	292
55D08	ISAMG	126	TITSAGSSNYSDSVKG	210	VYSRPLLGPLEV	294
55E07	IYGMG	127	RITSGGSTYYADSVKG	211	GVVATSPKFYAY	295
55E09	TYTMG	128	AIIWSGGRTRYADSVKG	212	RRLGTGY	296
55E10	IQTIG	129	TISSGGSTNYADSVKG	213	RYWFRDY	297
55F04	INVRG	130	TITSDGSTNYADSVKG	214	VRLFRQY	298
55F09	LNAMG	131	AITPGGNTTYADSVKG	215	GGSSRWYSSRYPPGGY	299
55F10	RYAMG	132	TIRRSSTYYLDSTKG	216	DSSARALVGGPGNRWDY	300

Name	CDR1 sequence	SEQ ID	CDR2 sequence	SEQ ID	CDR3 sequence	SEQ ID
55G02	INVMG	133	FITSGGITNYTDSVKG	217	KNAKNVRPGY	301
55G08	INAMR	134	SISSGGTTDYVESVKG	218	VRFWFPDY	302
56A05	SNTMG	135	SISSGGSTNYADSVKG	219	RRNVFISS	303
56A06	VYGMG	136	RITNIGTTNYADSVKG	220	RRLGRDY	304
56A09	LNSMG	137	TITRGGTTNYADSVKG	221	NFGILVGREY	305
56C09	ILSMA	138	NITSVGSTNYADSVKG	222	RMPFLGDS	306
56C12	NRAVS	139	SISGIRITTYTNSVKG	223	NRY	
56D06	ISAMG	140	GISRGGSTKYGDFVKG	224	TSITGTYL	307
56D07	MKVMG	141	VITSGGRTNYAESVKG	225	KTIRPY	308
56D10	ITTMG	142	SSSSGGTTNYASSVKG	226	RKFITTPWSTDY	309
56E04	HKATG	143	KITTTGGTTNYADSVKG	227	ERYFATTL	310
56E05	NNAGG	144	RISGGNTNYTDSVKG	228	QRRVILGPRNY	311
56E08	INDMG	145	TITSANITNYADSVKG	229	QAKKWRIGPWSY	312
56F07	INDMA	146	IITNDSTTYADSVKG	230	DINTAIWRRKY	313
56G07	IHDMG	147	TITPFGRNYSEYVKG	231	RVNGVDY	314
56G08	ISRMG	148	TLSRAGTSRYVDSVKG	232	AQLGTDY	315
56G10	MYQVG	149	EISSRGTTMYADSVKG	233	RAFAFGRNS	316
56H04	NKAMG	150	RISTVGTAHYADSVKG	234	QAGRLYLRNY	317
56H05	FNTMA	151	QINNRDNTEYADSVKG	235	KRWSWSTGF	318
56H07	LGTMG	152	SISTGSTNYADSVKG	236	RLWWSNY	319
56H08	VNPMG	153	VISSDGSTNYADSVKG	237	NRRWSWGSEY	320
57A06	NNAGG	154	RISGGNTNYTDSVKG	238	QRRVILGPRNY	321
57B01	INAMA	155	RISGGSTNYADSVKG	239	NRHWGWDY	322
57B07	INAMG	156	TVDSGGYTYADSVKG	240	GIYKWPWSVDARDY	323
57B11	MNSMG	157	LIRSSGGTYADSVKG	241	RRTWLSSES	324
57C07	INTMG	158	SISRGGMTNYADSVKG	242	GIRSRWYGGPITTY	325
57C09	INAMG	159	SISSGGATNYADSVKG	243	KKSRWSWSIVHDY	326
57D02	RSDMG	160	TITRRSRTNYAEFVKG	244	RWGAGGIFST	327
57D09	IDAMG	161	SITTTGGSTNYADSVKG	245	KVRLRWFRPPSDY	328
57D10	ISTMG	162	SITKDGTTNYADSVKG	246	RATTWVPYRRDAEF	329
57E07	INDMG	163	DITRSGSTHYVDSVKG	247	DSGSHWWNRRDY	330
57E11	INTMG	164	RISRLRVTNYADSVKG	248	ANWGLAGNEY	331
57G01	INSMG	165	TISNSGTTNYVDAVKG	249	QTFWRRNY	332
57G07	INAMG	166	TIRRGNTKYADSVKG	250	HSWLDYDY	333
57G08	GITMG	167	TIDIHNSTKYADSVKG	251	IPTFGRY	334
57H08	TKNVG	168	QQRYDGSTNYADSLQG	252	NRGFISY	335

Again, such VHHs may be derived in any suitable manner and from any suitable source, and may for example be naturally occurring  $V_{HH}$  sequences (i.e. from a suitable species of Camelid) or synthetic or semi-synthetic heavy-chain variable domains, including but not limited to “camelized” immunoglobulin sequences (and in particular camelized heavy chain variable domain sequences), as well as those that have been obtained by techniques such as affinity maturation (for example, starting from synthetic, random or naturally occurring immunoglobulin sequences), CDR grafting, veneering, combining fragments derived from different immunoglobulin sequences, PCR assembly using overlapping primers, and similar techniques for engineering immunoglobulin sequences well known to the skilled person; or any suitable combination of any of the foregoing as further described herein.

The present invention also encompasses parts, fragments, analogs, mutants, variants, and/or derivatives of the VHHs as disclosed herein and/or polypeptides comprising or essentially consisting of one or more of such parts, fragments, analogs, mutants, variants, and/or derivatives, as long as these parts,

fragments, analogs, mutants, variants, and/or derivatives are suitable for the purposes envisaged herein. Such parts, fragments, analogs, mutants, variants, and/or derivatives according to the invention are still capable of specifically binding to the sphingolipid target.

### TARGETS

5 In certain embodiments, the VHH as taught herein are obtained by affinity selection against a particular pest target. Obtaining suitable polypeptides by affinity selection against a particular pest target may for example be performed by screening a set, collection or library of cells that express polypeptides on their surface (e.g. bacteriophages) for binding against a pest target molecule, which molecule is known in the art to be a target for a pesticide; all of which may be performed in a manner known per se, essentially  
10 comprising the following non-limiting steps: a) obtaining an isolated solution or suspension of a pest target molecule, which molecule is known to be a target for a pesticide; b) bio-panning phages or other cells from a polypeptide library against said target molecule; c) isolating the phages or other cells binding to the target molecule; d) determining the nucleotide sequence encoding the polypeptide insert from individual binding phages or other cells; e) producing an amount of polypeptide according to this  
15 sequence using recombinant protein expression and f) determining the affinity of said polypeptide for said pest target and optionally g) testing the pesticidal activity of said polypeptide in a bio-assay for said pest. Various methods may be used to determine the affinity between the polypeptide and the pest target molecule, including for example, enzyme linked immunosorbent assays (ELISA) or Surface Plasmon Resonance (SPR) assays, which are common practice in the art, for example, as described in Sambrook  
20 et al. (2001), *Molecular Cloning, A Laboratory Manual*. Third Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. The dissociation constant is commonly used to describe the affinity between a polypeptide and its pest target molecule. Typically, the dissociation constant of the binding between the polypeptide and its pest target molecule is lower than  $10^{-5}$  M, more preferably, the dissociation constant is lower than  $10^{-6}$  M, even more preferably, the dissociation constant is lower than  
25  $10^{-7}$  M, most preferably, the dissociation constant is lower than  $10^{-8}$  M.

Pest target molecules as disclosed herein are molecules occurring in or on pest organisms and which, when bound and/or inhibited, kill or arrest, inhibit or reduce the growth or pesticidal activity of said pest organism. Such suitable target molecules are readily available from existing literature or patent databases for the skilled person and include, without limitation secreted parasitism proteins such as 16D10 as  
30 suitable pest target molecules for root knot nematodes (Huang et al (2006) PNAS 103: 14302-14306), the V-ATPase proton pump as suitable pest target molecule for coleopteran, hemipteran, dipteran insect species and nematodes (Knight AJ and Behm CA (2011) Ex. Parasitol. Sept 19), the tetraspanin PLS1 as suitable fungal pest target molecule for *B. cinerea* and *M. grisea* (Gourgues et al (2002) Biochem. Biophys. Res. Commun. 297: 1197) or the proton-pumping-ATPase as antifungal target (Manavathu EK  
35 et al (1999) Antimicrob Agents and Chemotherapy, Dec p. 2950). It is understood that preferred pest target molecules are accessible in the extra-cellular space (as opposed to intracellular pest targets).

More particularly, the sphingolipid targets to which the VHHs as disclosed herein bind, constitute a distinctive group of membrane lipids characterized by a long-chain (monounsaturated), di-hydroxy amine structure (sphingosine). Sphingolipids are essential components of the plasma membrane of cells where

they are typically found in the outer leaflet. They are membrane constituents of some bacterial groups, particularly anaerobes. These groups include *Bacteroides*, *Prevotella*, *Porphyromonas*, *Fusobacterium*, *Sphingomonas*, *Sphingobacterium*, *Bdellovibrio*, *Cystobacter*, *Mycoplasma*, *Flectobacillus*, and possibly *Acetobacter*. Fungi in which sphingolipids have been found comprise *Saccharomyces*, *Candida*,  
 5 *Histoplasma*, *Phytophthora*, *Cryptococcus*, *Aspergillus*, *Neurospora*, *Schizosaccharomyces*, *Fusicoccum*, *Shizophyllum*, *Amanita*, *Hansenula*, *Lactarius*, *Lentinus*, *Penicillium*, *Clitocybe*, *Paracoccidioides*, *Agaricus*, *Sporothrix*, and oomycete plant pathogens.

The basic building block of fungal sphingolipids is sphinganine, which can be converted either to ceramide and finally to ceramide monohexosides (CMH; cerebroside), or to phytoceramide and finally to  
 10 ceramide dihexosides (CDH) or to glycoinositol phosphorylceramides (GIPCs). Non-limiting examples of sphingolipids against which the VHH as disclosed herein are directed include for instance 9-methyl 4,8-sphingadienine, glycosylceramides, glucosylceramide, monoglucosylceramides, oligoglucosylceramides, gangliosides, sulfatides, ceramides, sphingosine-1-phosphate, ceramide-1-phosphate, galactosylceramide, inositol-phosphorylceramide (IPC), mannosyl-inositol-phosphorylceramide (MIPC),  
 15 galactosyl-inositol-phosphorylceramide, mannosyl-(inositol-phosphoryl)<sub>2</sub>-ceramide (M(IP)<sub>2</sub>C), dimannosyl-inositol-phosphorylceramide (M2IPC), galactosyl-dimannosyl-inositol-phosphorylceramide (GalM2IPC), mannosyl-di-inositol-diphosphorylceramide, di-inositol-diphosphorylceramide, trigalactosyl-glycosylceramide.

Non-limiting examples of sphingolipids against which the VHH as disclosed herein are directed include for  
 20 instance glycosylceramides, glucosylceramide, sphingomyelin, monoglucosylceramides, oligoglucosylceramides, gangliosides, sulfatides, ceramides, sphingosine-1-phosphate and ceramide-1-phosphate.


In certain preferred embodiments of the transgenic plant or plant tissue or plant cell, methods, or uses, as taught herein, the sphingolipid is a ceramide. In a further preferred embodiment, the sphingolipid is a  
 25 glycosphingolipid. In a further preferred embodiment, the sphingolipid is a cerebroside (i.e. monoglucosylceramide). In a further preferred embodiment, the sphingolipid is a glucocerebroside (i.e. glucosylceramide).

In certain preferred embodiments of the transgenic plant or plant tissue or plant cell, methods, or uses, as taught herein, the fungal sphingolipid is a fungal ceramide. In a further preferred embodiment, the fungal  
 30 sphingolipid is a fungal glycosphingolipid. In a further preferred embodiment, the fungal sphingolipid is a fungal cerebroside (i.e. monoglucosylceramide). In a further preferred embodiment, the fungal sphingolipid is a fungal glucocerebroside (i.e. glucosylceramide).


In certain embodiments, the sphingolipid as described herein is glucosylceramide (glucocerebroside) from *Pleurotus citrinopileatus*.

35 In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the sphingolipid may comprise a C19 sphingoid base with a C-9 methyl group, and two double bonds ( $\Delta 4$ ,  $\Delta 8$ ).

In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the sphingolipid may have, may comprise, consist of, or be represented by any of the following structures:



- 5 In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the sphingolipid as described herein may have, or comprise any of the following structures:



N-2'-hydroxyhexadecanoyl-1- $\beta$ -D-glucopyranosyl-9-methyl-4,8-sphingadienine.

- 10 In certain embodiments, the plant pathogen is a fungus, such as a plant pathogenic fungus, as defined before. Fungi can be highly detrimental for plants and can cause substantial harvest losses in crops. Plant pathogenic fungi include necrotrophic fungi and biotrophic fungi, and include ascomycetes, basidiomycetes and oomycetes.

- 15 Examples of plant pathogenic fungi are known in the art and include, but are not limited to, those selected from the group consisting of the Genera: *Alternaria*; *Ascochyta*; *Botrytis*; *Cercospora*; *Colletotrichum*; *Diplodia*; *Erysiphe*; *Fusarium*; *Leptosphaeria*; *Gaeumanomyces*; *Helminthosporium*; *Macrophomina*; *Nectria*; *Peronospora*; *Phoma*; *Phymatotrichum*; *Phytophthora*; *Plasmopara*; *Podosphaera*; *Puccinia*;

- Puthium; Pyrenophora; Pyricularia; Pythium; Rhizoctonia; Scerotium; Sclerotinia; Septoria; Thielaviopsis; Uncinula; Venturia; and Verticillium. Specific examples of plant pathogenic fungi which may be combated by the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein include Erysiphe graminis in cereals, Erysiphe cichoracearum and Sphaerotheca fuliginea in cucurbits,
- 5 Podosphaera leucotricha in apples, Uncinula necator in vines, Puccinia sp. in cereals, Rhizoctonia sp. in cotton, potatoes, rice and lawns, Ustilago sp. in cereals and sugarcane, Venturia inaequalis (scab) in apples, Helminthosporium sp. in cereals, Septoria nodorum in wheat, Septoria tritici in wheat, Rhynchosporium secalis on barley, Botrytis cinerea (gray mold) in strawberries, tomatoes and grapes, Cercospora arachidicola in groundnuts, Peronospora tabacina in tobacco, or other Peronospora in
- 10 various crops, Pseudocercospora herpotrichoides in wheat and barley, Pyrenophora teres in barley, Pyricularia oryzae in rice, Phytophthora infestans in potatoes and tomatoes, Fusarium sp. (such as Fusarium oxysporum) and Verticillium sp. in various plants, Plasmopara viticola in grapes, Alternaria sp. in fruit and vegetables, Pseudoperonospora cubensis in cucumbers, Mycosphaerella fijiensis in banana, Ascochyta sp. in chickpeas, Leptosphaeria sp. on canola, and Colleotrichum sp. in various crops.
- 15 In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the plant pathogenic fungus which may be combated by the transgenic plants or plant tissues or plant cells include the plant pathogenic fungi as defined in Table 3.

- In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the plant pathogenic fungus which may be combated by the transgenic plants or plant tissues or plant cells include the plant pathogenic fungi as defined in Table 3 in combination with the
- 20 transgenic plants or plant tissues or plant cells as defined in Table 3.

Table 3: List of plant pathogenic fungi and their combination with transgenic plants or plant tissues or plant cells, in particular crops

<b>Crop</b>	<b>Plant pathogenic fungus</b>	<b>Common name of fungal disease</b>
Banana	Mycosphaerella fijiensis	Black Sigatoka
Banana	Mycosphaerella musicola	Yellow Sigatoka
Barley oat rye	Alternaria spp.	Kernel blight
Barley oat rye	Puccinia hordei)	Leaf rust
Barley oat rye	Drechslera graminea = Pyrenophora graminea	Barley stripe
Barley oat rye	Pyrenophora teres	Net blotch
Barley oat rye	Erysiphe graminis f. sp. hordei	Powdery mildew
Barley oat rye	Stagonospora nodorum	Stagonospora blotch
Canola	Alternaria spp.	Alternaria blackspot
Canola	Leptosphaeria maculans	Blackleg
Canola	Sclerotinia sclerotiorum	Sclerotinia stem rot
Corn	Puccinia sorghi	Rust
Corn	Colletotrichum graminicola	Anthraco nose leaf blight
Corn	Aureobasidium zeae	Eye spot
Corn	Cercospora sorghi	Gray leaf spot
Corn	Setosphaeria turcica	Northern corn leaf blight
Corn	Cochliobolus carbonum	Northern corn leaf spot

<b>Crop</b>	<b>Plant pathogenic fungus</b>	<b>Common name of fungal disease</b>
Corn	<i>Cochliobolus heterostrophus</i>	Southern corn leaf blight
Corn	<i>Rhizoctonia solani</i>	Rhizoctonia root and stalk rot
Corn	<i>Helminthosporium</i> spp. ( <i>maydis</i> , <i>turcicum</i> , <i>carbonum</i> )	Leaf lights
Corn	<i>Puccinia</i> spp.	Rust
Corn	<i>Phytium</i> spp.	
Corn	<i>Cercospora zeae-maydis</i>	Gray Leaf Spot
Corn	<i>Physoderma maydis</i>	Physoderma Brown Spot
Corn	<i>Diplodia maydis</i>	Diplodia Ear Rot
Cotton	<i>Glomerella gossypii</i>	Anthraxnose
Cotton	<i>Ascochyta gossypii</i>	Ascochyta blight, Boll rot
Cotton	<i>Fusarium verticillioides</i>	Hardlock
Cotton	<i>Puccinia schedonnardi</i>	Cotton rust
Cotton	<i>Puccinia cacabata</i>	Southwestern cotton rust
Cotton	<i>Glomerella gossypii</i>	Anthraxnose
Cotton	<i>Puccinia cacabata</i>	Southwestern cotton rust
Cotton	<i>Pythium aphanidermatum</i>	Pythium seedling blight
Cotton	<i>Rhizoctonia solani</i>	Rhizoctonia seedling blight
Potato	<i>Colletotrichum coccodes</i>	Black dot
Potato	<i>Alternaria solani</i>	Early blight
Potato	<i>Phytophthora infestans</i>	Late blight
Potato	<i>Erysiphe cichoracearum</i>	Powdery mildew
Potato	<i>Rhizoctonia solani</i>	Black scurf
Potato	<i>Helminthosporium solani</i>	Silver scurf
Potato	<i>Sclerotinia sclerotiorum</i>	White Mold
Rice	<i>Rhizoctonia solani</i>	Sheath blight
Rice	<i>Ceratobasidium oryzae-sativae</i> = <i>Rhizoctonia oryzae-sativae</i>	Aggregate sheath spot
Rice	<i>Gaeumannomyces graminis</i> var. <i>graminis</i>	Black sheath rot
Rice	<i>Magnaporthe salvinii</i> = <i>Sclerotium oryzae</i> = <i>Nakateae sigmoidea</i>	Stem rot
Rice	<i>Cochliobolus miyabeanus</i>	Brown leaf spot
Rice	<i>Entyloma oryzae</i>	Leaf smut
Rice	<i>Cercospora janseana</i> = <i>Cercospora oryzae</i>	Narrow brown leaf spot
Rice	<i>Tilletia barclayana</i> = <i>Neovossia barclayana</i>	Kernel smut
Rice	<i>Pyricularia grisea</i>	Leaf/Panicle blast
Rice	<i>Ustilaginoidea virens</i>	False Smut
Soybean	<i>Rhizoctonia solani</i>	Aerial blight
Soybean	<i>Alternaria</i> spp.	Alternaria leaf spot
Soybean	<i>Colletotrichum truncatum</i>	Anthraxnose
Soybean	<i>Septoria glycines</i>	Brown spot
Soybean	<i>Cercospora kikuchii</i>	Cercospora blight and leaf spot
Soybean	<i>Cercospora sojina</i>	Frogeye leaf spot
Soybean	<i>Diaporthe phaseolorum</i>	Pod and stem blight
Soybean	<i>Phakopsora</i> spp.	Rust
Soybean	<i>Rhizoctonia solani</i>	Rhizoctonia solani

Crop	Plant pathogenic fungus	Common name of fungal disease
Soybean	<i>Sclerotium rolfsii</i>	Southern blight
Soybean	<i>Sclerotinia sclerotiorum</i>	White Mold
Tobacco	<i>Peronospora tabacina</i>	Blue mold
Tobacco	<i>Cercospora nicotianae</i>	Frogeye leaf spot
Tobacco	<i>Rhizoctonia solani</i>	Target spot
Wheat	<i>Puccinia triticina</i> = <i>Puccinia recondita</i> f.sp. <i>tritici</i>	Leaf rust
Wheat	<i>Septoria tritici</i> , <i>Septoria nodorum</i>	Septoria leaf and glume blotch
Wheat	<i>Puccinia graminis</i>	Stem rust
Wheat	<i>Puccinia striiformis</i>	Stripe rust
Wheat	<i>Pyrenophora tritici-repentis</i>	Tan spot
Wheat	<i>Erysiphe graminis</i>	Powdery mildew
Wheat	<i>Blumeria</i> spp., <i>Erysiphe</i> spp.	Powdery mildew
Wheat	<i>Stagonospora nordorum</i>	Glume Blotch
Wheat	<i>Blumeria</i> spp., <i>Erysiphe</i> spp.	Powdery mildew
Wheat	<i>Stagonospora nordorum</i>	Glume Blotch
Wheat	<i>Drechslera tritici-repentis</i>	Helminthosporium leaf blight
Wheat	<i>Bipolaris sorokiniana</i>	Spot Blotch
Wheat	<i>Tapesia</i> spp.	Foot Rot/Eyespot

- In certain embodiments of the transgenic plants or plant tissues or plant cells, methods, or uses, as taught herein, the plant pathogenic fungus may be a plant pathogenic fungus from the genus chosen from the group consisting of *Alternaria*, *Ascochyta*, *Botrytis*, *Cercospora*, *Colletotrichum*, *Diplodia*, *Erysiphe*, *Fusarium*, *Leptosphaeria*, *Gaeumanomyces*, *Helminthosporium*, *Macrophomina*, *Nectria*, *Penicillium*, *Peronospora*, *Phoma*, *Phymatotrichum*, *Phytophthora*, *Plasmopara*, *Podosphaera*, *Puccinia*, *Pyrenophora*, *Pyricularia*, *Pythium*, *Rhizoctonia*, *Scerotium*, *Sclerotinia*, *Septoria*, *Thielaviopsis*, *Uncinula*, *Venturia*, *Verticillium*, *Magnaporthe*, *Blumeria*, *Mycosphaerella*, *Ustilago*, *Melampsora*, *Phakospora*, *Monilinia*, *Mucor*, *Rhizopus*, and *Aspergillus*.
- 5
- 10 In certain embodiments, the transgenic plants or plant tissues or plant cells as taught herein may comprise at least one polynucleotide comprising at least one sequence encoding a VHH, which specifically binds to a sphingolipid of a fungus from the fungal species *Botrytis*, *Fusarium* or *Penicillium*. In further particular embodiments, the fungal sphingolipid is a ceramide, such as in particular glucosylceramide.
- 15 In particular embodiments, the present invention provides transgenic plants or plant tissues or plant cells as taught herein may comprise at least one polynucleotide comprising at least one sequence encoding VHHs that are specifically directed against a structural molecular component of the fungus, i.e. a fungal sphingolipid. The inventors have surprisingly succeeded in identifying such VHHs while it is generally described in the art that it is (technically) difficult to generate proteins or amino acid sequences having a
- 20 unique and specific interaction with non-protein molecular structures.

Based on the present teaching, further non-limiting examples of suitable fungal pest target molecules can be envisaged by the person skilled in the art and comprise for example chitin synthase,  $\beta$ -1,3-glucan synthase, succinate dehydrogenase, fungal glycosylceramides, or the tetraspanin PLS1.

Also disclosed herein are plant pathogenic bacteria including, but not limited to, *Acidovorax avenae* subsp. *avenae* (causing bacterial brown stripe of rice), *Acidovorax avenae* subsp. *cattleyae* (causing bacterial brown spot of cattleya), *Acidovorax konjaci* Konnyaku (causing bacterial leaf blight), *Agrobacterium rhizogenes* (causing hairy root of melon), *Agrobacterium tumefaciens* (causing crown gall), *Burkholderia andropogonis* (causing bacterial spot of carnation), *Burkholderia caryophylli* (causing bacterial wilt of carnation), *Burkholderia cepacia* (causing bacterial brown spot of cymbidium), *Burkholderia gladioli* pv. *gladioli* (causing neck rot of gladiolus), *Burkholderia glumae* (causing bacterial grain rot of rice), *Burkholderia plantarii* (causing bacterial seedling blight of rice), *Clavibacter michiganensis* subsp. *michiganensis* (causing bacterial canker of tomato), *Clavibacter michiganensis* subsp. *sepedonicus* (causing ring rot of potato), *Clostridium* spp. (causing slimy rot of potato), *Curtobacterium flaccumfaciens* (causing bacterial canker of onion), *Erwinia amylovora* (causing fire blight of pear), *Erwinia ananas* (causing bacterial palea browning of rice), *Erwinia carotovora* subsp. *atroseptica* (causing black leg of potato), *Erwinia carotovora* subsp. *carotovora* (causing bacterial soft rot of vegetables), *Erwinia chrysanthemi* (causing bacterial seedling blight of taro), *Erwinia chrysanthemi* pv. *zeae* (causing bacterial foot rot of rice), *Erwinia herbicola* pv. *milletiae* (causing bacterial gall of wisteria), *Pseudomonas cichorii* (causing bacterial spot of chrysanthemum), *Pseudomonas corrugate* Pith (causing necrosis of tomato), *Pseudomonas fuscovaginae* (causing sheath brown rot of rice), *Pseudomonas marginalis* pv. *marginalis* (causing soft rot of cabbage) *Pseudomonas rubrisubalbicans* (causing mottled stripe of sugar cane), *Pseudomonas syringae* pv. *aptata* (causing bacterial blight of sugar beet), *Pseudomonas syringae* pv. *atropurpurea* (causing halo blight of ryegrass), *Pseudomonas syringae* pv. *castaneae* (causing bacterial canker of chestnut), *Pseudomonas syringae* pv. *glycinea* (causing bacterial blight of soybean), *Pseudomonas syringae* pv. *lachrymans* (causing bacterial spot of cucumber), *Pseudomonas syringae* pv. *maculicola* (causing bacterial black spot of cabbage), *Pseudomonas syringae* pv. *mori* (causing bacterial blight of mulberry), *Pseudomonas syringae* pv. *morsprunorum* (causing bacterial canker of plums), *Pseudomonas syringae* pv. *oryzae* (causing halo blight of rice), *Pseudomonas syringae* pv. *phaseolicola* (causing halo blight of kidney bean), *Pseudomonas syringae* pv. *pisi* (causing bacterial blight of garden pea), *Pseudomonas syringae* pv. *sesame* (causing bacterial spot of sesame), *Pseudomonas syringae* pv. *striaefaciens* (causing bacterial stripe blight of oats), *Pseudomonas syringae* pv. *syringae* (causing bacterial brown spot of small red bead), *Pseudomonas syringae* pv. *tabaci* (causing wild fire of tobacco), *Pseudomonas syringae* pv. *theae* (causing bacterial shoot blight of tea), *Pseudomonas syringae* pv. *tomato* (causing bacterial leaf spot of tomato), *Pseudomonas viridiflava* (causing bacterial brown spot of kidney bean), *Ralstonia solanacearum* (causing bacterial wilt), *Rathayibacter rathayi* (causing bacterial head blight of orchardgrass), *Streptomyces scabies* (causing common scab of potato), *Streptomyces ipomoea* (causing soil rot of sweet potato), *Xanthomonas albilineans* (causing white streak of sugar cane), *Xanthomonas campestris* pv. *cerealis* (causing bacterial streak of rye), *Xanthomonas campestris* pv. *campestris* (causing black rot), *Xanthomonas campestris* pv. *citri* (causing canker of citrus), *Xanthomonas campestris* pv. *cucurbitae* (causing bacterial brown spot of

cucumber), *Xanthomonas campestris* pv. *glycines* (causing bacterial pastule of soybean), *Xanthomonas campestris* pv. *incanae* (causing black rot of stock), *Xanthomonas campestris* pv. (causing angular leaf spot of cotton malvacearum), *Xanthomonas campestris* pv. (causing bacterial canker of mango), *Mangiferaeindicae* *Xanthomonas campestris* pv. *mellea* (causing wisconsin bacterial leaf spot of tobacco), *Xanthomonas campestris* pv. (causing bacterial spot of great nigromaculans burdock), *Xanthomonas campestris* pv. *phaseoli* (causing bacterial pastule of kidney bean), *Xanthomonas campestris* pv. *pisi* (causing bacterial stem-rot of kidney bean), *Xanthomonas campestris* pv. *pruni* (causing bacterial shot hole of peach), *Xanthomonas campestris* pv. *raphani* (causing bacterial spot of Japanese radish), *Xanthomonas campestris* pv. *ricini* (causing bacterial spot of castor-oil plant), *Xanthomonas campestris* pv. *theicola* (causing canker of tea), *Xanthomonas campestris* pv. *translucens* (causing bacterial blight of orchardgrass), *Xanthomonas campestris* pv. *vesicatoria* (causing bacterial spot of tomato), *Xanthomonas oryzae* pv. *oryzae* (causing bacterial leaf blight of rice).

Also disclosed herein are plant pests such as insects, arachnids, helminths, viruses, nematodes and molluscs encountered in agriculture, in horticulture, in forests, in gardens and in leisure facilities. The transgenic plants or plant tissues or plant cells as taught herein are active against normally sensitive and resistant species and against all or some stages of development. These plant pests include: pests from the phylum: Arthropoda, in particular from the class of the arachnids, for example *Acarus* spp., *Aceria sheldoni*, *Aculops* spp., *Aculus* spp., *Amblyomma* spp., *Amphitetranynchus viennensis*, *Argas* spp., *Boophilus* spp., *Brevipalpus* spp., *Bryobia praetiosa*, *Centruroides* spp., *Chorioptes* spp., *Dermanyssus gallinae*, *Dermatophagoides pteronyssius*, *Dermatophagoides farinae*, *Dermacentor* spp., *Eotetranychus* spp., *Epitrimerus pyri*, *Eutetranychus* spp., *Eriophyes* spp., *Halotydeus destructor*, *Hemitarsonemus* spp., *Hyalomma* spp., *Ixodes* spp., *Latrodectus* spp., *Loxosceles* spp., *Metatetranychus* spp., *Nuphessa* spp., *Oligonychus* spp., *Ornithodoros* spp., *Ornithonyssus* spp., *Panonychus* spp., *Phyllocoptruta oleivora*, *Polyphagotarsonemus latus*, *Psoroptes* spp., *Rhipicephalus* spp., *Rhizoglyphus* spp., *Sarcoptes* spp., *Scorpio maurus*, *Stenotarsonemus* spp., *Tarsonemus* spp., *Tetranychus* spp., *Vaejovis* spp., *Vasates lycopersici*.

Still other examples are from the order of the Anoplura (Phthiraptera), for example, *Damalinia* spp., *Haematopinus* spp., *Linognathus* spp., *Pediculus* spp., *Ptirus pubis*, *Trichodectes* spp.

Still other examples are from the order of the Chilopoda, for example, *Geophilus* spp., *Scutigera* spp.

Still other examples are from the order of the Coleoptera, for example, *Acalymma vittatum*, *Acanthoscelides obtectus*, *Adoretus* spp., *Agelastica alni*, *Agriotes* spp., *Alphitobius diaperinus*, *Amphimallon solstitialis*, *Anobium punctatum*, *Anoplophora* spp., *Anthonomus* spp., *Anthrenus* spp., *Apion* spp., *Apogonia* spp., *Atomaria* spp., *Attagenus* spp., *Bruchidius obtectus*, *Bruchus* spp., *Cassida* spp., *Cerotoma trifurcata*, *Ceutorrhynchus* spp., *Chaetocnema* spp., *Cleonus mendicus*, *Conoderus* spp., *Cosmopolites* spp., *Costelytra zealandica*, *Ctenicera* spp., *Curculio* spp., *Cryptorhynchus lapathi*, *Cylindrocopturus* spp., *Dermestes* spp., *Diabrotica* spp., *Dichocrocis* spp., *Diloboderus* spp., *Epilachna* spp., *Epitrix* spp., *Faustinus* spp., *Gibbium psylloides*, *Hellula undalis*, *Heteronychus arator*, *Heteronyx* spp., *Hylamorpha elegans*, *Hylotrupes bajulus*, *Hypera postica*, *Hypothenemus* spp., *Lachnosterna consanguinea*, *Lema* spp., *Leptinotarsa decemlineata*, *Leucoptera* spp., *Lissorhoptrus oryzophilus*, *Lixus*

spp., Luperodes spp., Lyctus spp., Megascelis spp., Melanotus spp., Meligethes aeneus, Melolontha spp., Migdolus spp., Monochamus spp., Naupactus xanthographus, Niptus hololeucus, Oryctes rhinoceros, Oryzaephilus surinamensis, Oryzaphagus oryzae, Otiorrhynchus spp., Oxycetonia jucunda, Phaedon cochleariae, Phyllophaga spp., Phyllotreta spp., Popillia japonica, Premnotrypes spp.,  
 5 Prostephanus truncatus, Psylliodes spp., Ptinus spp., Rhizobius ventralis, Rhizopertha dominica, Sitophilus spp., Sphenophorus spp., Stegobium paniceum, Sternechus spp., Symphyletes spp., Tanymericus spp., Tenebrio molitor, Tribolium spp., Trogoderma spp., Tychius spp., Xylotrechus spp., Zabrus spp.

Still other examples are from the order of the Collembola, for example, Onychiurus armatus.

10 Still other examples are from the order of the Diplopoda, for example, Blaniulus guttulatus.

Still other examples are from the order of the Diptera, for example, Aedes spp., Agromyza spp., Anastrepha spp., Anopheles spp., Asphondylia spp., Bactrocera spp., Bibio hortulanus, Calliphora erythrocephala, Ceratitis capitata, Chironomus spp., Chrysomyia spp., Chrysops spp., Cochliomyia spp., Contarinia spp., Cordylobia anthropophaga, Culex spp., Culicoides spp., Culiseta spp., Cuterebra spp.,  
 15 Dacus oleae, Dasyneura spp., Delia spp., Dermatobia hominis, Drosophila spp., Echinocnemus spp., Fannia spp., Gasterophilus spp., Glossina spp., Haematopota spp., Hydrellia spp., Hylemyia spp., Hyppobosca spp., Hypoderma spp., Liriomyza spp., Lucilia spp., Lutzomia spp., Mansonia spp., Musca spp., Nezara spp., Oestrus spp., Oscinella frit, Pegomyia spp., Phlebotomus spp., Phorbia spp., Phormia spp., Prodiplosis spp., Psila rosae, Rhagoletis spp., Sarcophaga spp., Simulium spp., Stomoxys spp.,  
 20 Tabanus spp., Tannia spp., Tetanops spp., Tipula spp.

Still other examples are from the order of the Heteroptera, for example, Anasa tristis, Antestiopsis spp., Boisea spp., Blissus spp., Calocoris spp., Campylomma livida, Cavalerius spp., Cimex spp., Collaria spp., Creontiades dilutus, Dasynus piperis, Dichelops furcatus, Diconocoris hewetti, Dysdercus spp., Euschistus spp., Eurygaster spp., Heliopeltis spp., Horcias nobilellus, Leptocoris spp., Leptoglossus  
 25 phyllopus, Lygus spp., Macropes excavatus, Miridae, Monalonion atratum, Nezara spp., Oebalus spp., Pentomidae, Piesma quadrata, Piezodorus spp., Psallus spp., Pseudacysta perseae, Rhodnius spp., Sahlbergella singularis, Scaptocoris castanea, Scotinophora spp., Stephanitis nashi, Tibraca spp., Triatoma spp.

Still other examples are from the order of the Homoptera, for example, Acyrthosipon spp., Acrogonia  
 30 spp., Aeneolamia spp., Agonosцена spp., Aleurodes spp., Aleurolobus barodensis, Aleurothrixus spp., Amrasca spp., Anuraphis cardui, Aonidiella spp., Aphanostigma pin, Aphis spp., Arboridia apicalis, Aspidiella spp., Aspidiotus spp., Atanus spp., Aulacorthum solani, Bemisia spp., Brachycaudus helichrysi, Brachycolus spp., Brevicoryne brassicae, Calligypona marginata, Carneocephala fulgida, Ceratovacuna lanigera, Cercopidae, Ceroplastes spp., Chaetosiphon fragaefolii, Chionaspis tegalensis,  
 35 Chlorita onukii, Chromaphis juglandicola, Chrysomphalus ficus, Cicadulina mbila, Cocomytilus halli, Coccus spp., Cryptomyzus ribis, Dalbulus spp., Dialeurodes spp., Diaphorina spp., Diaspis spp., Drosicha spp., Dysaphis spp., Dysmicoccus spp., Empoasca spp., Eriosoma spp., Erythroneura spp., Euscelis bilobatus, Ferrisia spp., Geococcus coffeae, Hieroglyphus spp., Homalodisca coagulata, Hyalopterus

arundinis, *Icerya* spp., *Idiocerus* spp., *Idioscopus* spp., *Laodelphax striatellus*, *Lecanium* spp., *Lepidosaphes* spp., *Lipaphis erysimi*, *Macrosiphum* spp., *Mahanarva* spp., *Melanaphis sacchari*, *Metcalfiella* spp., *Metopolophium dirhodum*, *Monellia costalis*, *Monelliopsis pecanis*, *Myzus* spp., *Nasonovia ribisnigri*, *Nephotettix* spp., *Nilaparvata lugens*, *Oncometopia* spp., *Orthezia praelonga*,  
 5 *Parabemisia myricae*, *Paratrioza* spp., *Parlatoria* spp., *Pemphigus* spp., *Peregrinus maidis*, *Phenacoccus* spp., *Phloeomyzus passerinii*, *Phorodon humuli*, *Phylloxera* spp., *Pinnaspis aspidistrae*, *Planococcus* spp., *Protopulvinaria pyriformis*, *Pseudaulacaspis pentagona*, *Pseudococcus* spp., *Psylla* spp., *Pteromalus* spp., *Pyrilla* spp., *Quadraspidotus* spp., *Quesada gigas*, *Rastrococcus* spp., *Rhopalosiphum* spp., *Saissetia* spp., *Scaphoides titanus*, *Schizaphis graminum*, *Selenaspidus articulatus*, *Sogata* spp.,  
 10 *Sogatella furcifera*, *Sogatodes* spp., *Stictocephala festina*, *Tenalaphara malayensis*, *Tinocallis caryaefoliae*, *Tomaspis* spp., *Toxoptera* spp., *Trialeurodes* spp., *Trioza* spp., *Typhlocyba* spp., *Unaspis* spp., *Viteus vitifolii*, *Zygina* spp.

Still other examples are from the order of the Hymenoptera, for example, *Acromyrmex* spp., *Athalia* spp., *Atta* spp., *Diprion* spp., *Hoplocampa* spp., *Lasius* spp., *Monomorium pharaonis*, *Solenopsis invicta*,  
 15 *Tapinoma* spp., *Vespa* spp.

Still other examples are from the order of the Isopoda, for example, *Armadillidium vulgare*, *Oniscus asellus*, *Porcellio scaber*.

Still other examples are from the order of the Isoptera, for example, *Coptotermes* spp., *Cornitermes cumulans*, *Cryptotermes* spp., *Incisitermes* spp., *Microtermes obesi*, *Odontotermes* spp., *Reticulitermes* spp.  
 20

Still other examples are from the order of the Lepidoptera, for example, *Acronicta major*, *Adoxophyes* spp., *Aedia leucomelas*, *Agrotis* spp., *Alabama* spp., *Amyelois transitella*, *Anarsia* spp., *Anticarsia* spp., *Argyroproce* spp., *Barathra brassicae*, *Borbo cinnara*, *Bucculatrix thurberiella*, *Bupalus piniarius*, *Busseola* spp., *Cacoecia* spp., *Caloptilia theivora*, *Capua reticulana*, *Carpocapsa pomonella*, *Carposina niponensis*,  
 25 *Chematobia brumata*, *Chilo* spp., *Choristoneura* spp., *Clysia ambiguella*, *Cnaphalocerus* spp., *Cnephasia* spp., *Conopomorpha* spp., *Conotrachelus* spp., *Copitarsia* spp., *Cydia* spp., *Dalaca noctuides*, *Diaphania* spp., *Diatraea saccharalis*, *Earias* spp., *Ecdytolopha aurantium*, *Elasmopalpus lignosellus*, *Eldana saccharina*, *Ephestia* spp., *Epinotia* spp., *Epiphyas postvittana*, *Etiella* spp., *Eulia* spp., *Eupoecilia ambiguella*, *Euproctis* spp., *Euxoa* spp., *Feltia* spp., *Galleria mellonella*, *Gracillaria* spp., *Grapholitha* spp.,  
 30 *Hedylepta* spp., *Helicoverpa* spp., *Heliopsis* spp., *Hofmannophila pseudospretella*, *Homoeosoma* spp., *Homona* spp., *Hyponomeuta padella*, *Kakivoria flavofasciata*, *Laphygma* spp., *Laspeyresia molesta*, *Leucinodes orbonalis*, *Leucoptera* spp., *Lithocolletis* spp., *Lithophane antennata*, *Lobesia* spp., *Loxagrotis albicosta*, *Lymantria* spp., *Lyonetia* spp., *Malacosoma neustria*, *Maruca testulalis*, *Mamestra brassicae*, *Mocis* spp., *Mythimna separata*, *Nymphula* spp., *Oiketeticus* spp., *Oria* spp., *Orthaga* spp., *Ostrinia* spp.,  
 35 *Oulema oryzae*, *Panolis flammea*, *Parnara* spp., *Pectinophora* spp., *Perileucoptera* spp., *Phthorimaea* spp., *Phyllocnistis citrella*, *Phyllonorycter* spp., *Pieris* spp., *Platynota stultana*, *Plodia interpunctella*, *Plusia* spp., *Plutella xylostella*, *Prays* spp., *Prodenia* spp., *Protoparce* spp., *Pseudaletia* spp., *Pseudoplusia includens*, *Pyrausta nubilalis*, *Rachiplusia nu*, *Schoenobius* spp., *Scirpophaga* spp., *Scotia segetum*, *Sesamia* spp., *Sparganothis* spp., *Spodoptera* spp., *Stathmopoda* spp., *Stomopteryx subsecivella*,

Synanthedon spp., Tecia solanivora, Thermesia gemmatalis, Tinea pellionella, Tineola bisselliella, Tortrix spp., Trichophaga tapetzella, Trichoplusia spp., Tuta absoluta, Virachola spp.

Still other examples are from the order of the Orthoptera, for example, Acheta domesticus, Blatta orientalis, Blattella germanica, Dichroplus spp., Gryllotalpa spp., Leucophaea maderae, Locusta spp.,  
5 Melanoplus spp., Periplaneta spp., Pulex irritans, Schistocerca gregaria, Supella longipalpa.

Still other examples are from the order of the Siphonaptera, for example, Ceratophyllus spp., Ctenocephalides spp., Tunga penetrans, Xenopsylla cheopis.

Still other examples are from the order of the Symphyla, for example, Scutigera spp.

Still other examples are from the order of the Thysanoptera, for example, Anaphothrips obscurus,  
10 Baliothrips biformis, Drepanothrips reuteri, Enneothrips flavens, Frankliniella spp., Heliothrips spp., Hercinothrips femoralis, Rhipiphorothrips cruentatus, Scirtothrips spp., Taeniothrips cardamoni, Thrips spp.

Still other examples are from the order of the Zygentoma (=Thysanura), for example, Lepisma saccharina, Thermobia domestica. for example Lepisma saccharina, Thermobia domestica.

15 In another embodiment pests of the phylum Mollusca, in particular from the class of the Bivalvia, for example Dreissena spp. are also important plant pests.

In another embodiment pests of the class of the Gastropoda are important plant pests, for example, Anion spp., Biomphalaria spp., Bulinus spp., Deroceras spp., Galba spp., Lymnaea spp., Oncomelania spp., Pomacea spp., Succinea spp.

20 In yet another embodiment, plant pests are from the phylum Nematoda are important plant pests, i.e. phytoparasitic nematodes, thus meaning plant parasitic nematodes that cause damage to plants. Plant nematodes encompass plant parasitic nematodes and nematodes living in the soil. Plant parasitic nematodes include, but are not limited to, ectoparasites such as Xiphinema spp., Longidorus spp., and Trichodorus spp.; semiparasites such as Tylenchulus spp.; migratory endoparasites such as Pratylenchus  
25 spp., Radopholus spp., and Scutellonema spp.; sedentary parasites such as Heterodera spp., Globodera spp., and Meloidogyne spp., and stem and leaf endoparasites such as Ditylenchus spp., Aphelenchoides spp., and Hirshmaniella spp. In addition, harmful root parasitic soil nematodes are cyst-forming nematodes of the genera Heterodera or Globodera, and/or root knot nematodes of the genus Meloidogyne. Harmful species of these genera are for example Meloidogyne incognata, Heterodera  
30 glycines (soybean cyst nematode), Globodera pallida and Globodera rostochiensis (potato cyst nematode). Still other important genera of importance as plant pests comprise Rotylenchulus spp., Paratrichodorus spp., Pratylenchus penetrans, Radolophus similis, Ditylenchus dispaci, Tylenchulus semipenetrans, Xiphinema spp., Bursaphelenchus spp., and the like. in particular Aphelenchoides spp., Bursaphelenchus spp., Ditylenchus spp., Globodera spp., Heterodera spp., Longidorus spp.,  
35 Meloidogyne spp., Pratylenchus spp., Radopholus similis, Trichodorus spp., Tylenchulus semipenetrans, Xiphinema spp.

Also disclosed herein as being plant pests are plant viruses selected from an alfamovirus, an allexivirus, an alphacryptovirus, an anulavirus, an apscaviroid, an aureusvirus, an avenavirus, an aysunviroid, a badnavirus, a begomovirus, a benyvirus, a betacryptovirus, a betaflexiviridae, a bromovirus, a bymovirus, a capillovirus, a carlavirus, a carmovirus, a caulimovirus, a cavemovirus, a cheravirus, a closterovirus, a cocadviroid, a coleviroid, a comovirus, a crinivirus, a cucumovirus, a curtovirus, a cytorhabdovirus, a dianthovirus, an enamovirus, an umbravirus & B-type satellite virus, a fabavirus, a fijivirus, a furovirus, a hordeivirus, a hostuviroid, an idaeovirus, an ilarvirus, an ipomovirus, a luteovirus, a machlomovirus, a macluravirus, a marafivirus, a mastrevirus, a nanovirus, a necrovirus, a nepovirus, a nucleorhabdovirus, an oleavirus, an ophiovirus, an oryzavirus, a panicovirus, a pecluvirus, a petuvirus, a phytoreovirus, a polerovirus, a pomovirus, a pospiviroid, a potexvirus, a potyvirus, a reovirus, a rhabdovirus, a rymovirus, a sadwavirus, a SbCMV-like virus, a sequivirus, a sobemovirus, a tenuivirus, a TNsatV-like satellite virus, a tobamovirus, a topocuvirus, a tospovirus, a trichovirus, a tritimovirus, a tungrovirus, a tymovirus, an umbravirus, a varicosavirus, a vitivirus, or a waikavirus.

In certain embodiments, the present invention provides a transgenic plant or plant tissue or plant cell resistant to a plant pathogenic fungus, wherein the transgenic plant or plant tissue or plant cell comprises at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a sphingolipid of a fungus.

In certain embodiments, the present invention provides a transgenic plant or plant tissue or plant cell resistant to an infection or other biological interaction with a plant pathogenic fungus, wherein the transgenic plant or plant tissue or plant cell comprises at least one polynucleotide comprising at least one sequence encoding a VHH specifically binding to a sphingolipid of a fungus.

#### METHODS AND USES

A further aspect provides a method for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide encoding a VHH specifically binding to a pathogen.

In certain embodiments, the present invention provides methods for protecting or treating a plant or a part of a plant from an infection or other biological interaction with a plant pathogen, at least comprising the step of expressing in the plant or plant tissue or plant cell or in at least part of the plant or plant tissue or plant cell (i.e., *in planta*) a polynucleotide comprising at least one sequence encoding a VHH specifically binding to a pathogen, in particular to a sphingolipid of a fungus. In certain embodiments, the polynucleotide may be expressed in the plant or plant tissue or plant cell or in at least part of the plant or plant tissue or plant cell (i.e., *in planta*) under conditions effective to protect or treat at least part of the plant or plant tissue or plant cell against that infection or biological interaction with the plant pathogen, in particular with a plant pathogenic fungus.

In certain particular embodiments, the present invention provides methods of inhibiting, preventing, reducing or controlling the growth of a plant pathogen, in particular a plant pathogenic fungus, comprising

at least the step of expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide encoding a VHH specifically binding to a pathogen, in particular to a sphingolipid of a fungus.

5 In certain other embodiments, the present invention provides methods for killing a plant pathogen, in particular a plant pathogenic fungus, comprising at least the step of expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide encoding a VHH specifically binding to a pathogen, in particular to a sphingolipid of a fungus.

10 In certain embodiments, the present invention provides the use of at least one variable domain of a heavy-chain antibody (VHH) specifically binding to a pathogen, as a antimicrobial agent, preferably as a microbiostatic agent, wherein the VHH is encoded by a polynucleotide which is expressed in at least part of the plant or plant tissue.

In certain embodiments, the present invention provides the use of the polynucleotides of SEQ ID NO: 336 and/or SEQ ID NO: 337 for protecting a transgenic plant or plant tissue or plant cell against a plant pathogen, preferably a plant pathogenic fungus.

15 In certain embodiments, the present invention provides the use of the polynucleotides of SEQ ID NO: 336 and/or SEQ ID NO: 337 for improving the yield of a transgenic plant or plant tissue.

The invention further provides methods for preparing or generating the VHH as taught herein, as well as methods for producing polynucleotides encoding these. Some preferred but non-limiting examples of such methods will become clear from the further description herein.

20 As will be clear to the skilled person, one particularly useful method for preparing VHH sequences as disclosed herein generally comprises the steps of:

a) expressing a nucleotide sequence encoding a heavy chain variable domain sequence as disclosed herein or a vector or genetic construct a nucleotide sequence encoding that heavy chain variable domain sequence; and

25 b) optionally isolating and/or purifying the VHH sequence.

In particular embodiments envisaged herein, the pest-specific a VHH sequences can be obtained by methods which involve generating a random library of amino acid sequences and screening this library for an amino acid sequence capable of specifically binding to a sphingolipid target.

30 Accordingly, in particular embodiments, methods for preparing a heavy chain variable domain sequence as disclosed herein comprise the steps of

a) providing a set, collection or library of amino acid sequences of a heavy chain variable domain sequences;

b) screening said set, collection or library of amino acid sequences for amino acid sequences that can bind to and/or have affinity for the sphingolipid target; and

35 c) isolating the amino acid sequence(s) that can bind to and/or have affinity for the sphingolipid target.

In such a method, the set, collection or library of amino acid sequences may be any suitable set, collection or library of amino acid sequences. For example, the set, collection or library of amino acid sequences may be a set, collection or library of immunoglobulin fragment sequences (as described herein), such as a naïve set, collection or library of immunoglobulin fragment sequences; a synthetic or semi-synthetic set, collection or library of immunoglobulin fragment sequences; and/or a set, collection or library of immunoglobulin fragment sequences that have been subjected to affinity maturation.

In particular embodiments of this method, the set, collection or library of amino acid sequences may be an immune set, collection or library of immunoglobulin fragment sequences, for example derived from a mammal that has been suitably immunized with a sphingolipid target or with a suitable antigenic determinant based thereon or derived therefrom, such as an antigenic part, fragment, region, domain, loop or other epitope thereof. In one particular aspect, said antigenic determinant may be an extracellular part, region, domain, loop or other extracellular epitope(s).

In the above methods, the set, collection or library of amino acid sequences may be displayed on a phage, phagemid, ribosome or suitable micro-organism (such as yeast), such as to facilitate screening. Suitable methods, techniques and host organisms for displaying and screening (a set, collection or library of) amino acid sequences will be clear to the person skilled in the art, for example on the basis of the further disclosure herein. Reference is also made to the review by Hoogenboom in Nature Biotechnology, 23, 9, 1105-1116 (2005).

In other embodiments, the methods for generating the VHH sequences as disclosed herein comprise at least the steps of:

- a) providing a collection or sample of cells expressing heavy chain variable domain amino acid sequences;
- b) screening said collection or sample of cells for cells that express an amino acid sequence that can bind to and/or have affinity for a sphingolipid target; and
- c) either (i) isolating said amino acid sequence; or (ii) isolating from said cell a nucleic acid sequence that encodes said amino acid sequence, followed by expressing said amino acid sequence.

The collection or sample of cells may for example be a collection or sample of B-cells. Also, in this method, the sample of cells may be derived from a mammal that has been suitably immunized with a fungal target or with a suitable antigenic determinant based thereon or derived therefrom, such as an antigenic part, fragment, region, domain, loop or other epitope thereof. In one particular embodiment, the antigenic determinant may be an extracellular part, region, domain, loop or other extracellular epitope(s).

In other embodiments, the method for generating a heavy chain variable domain sequence directed against a sphingolipid target may comprise at least the steps of:

- a) providing a set, collection or library of nucleic acid sequences encoding a heavy chain variable domain amino acid sequence;
- b) screening said set, collection or library of nucleic acid sequences for nucleic acid sequences that encode an amino acid sequence that can bind to and/or has affinity for the sphingolipid target; and

c) isolating said nucleic acid sequence, followed by expressing said amino acid sequence.

In the above methods, the set, collection or library of nucleic acid sequences encoding amino acid sequences may for example be a set, collection or library of nucleic acid sequences encoding a naïve set, collection or library of immunoglobulin fragment sequences; a set, collection or library of nucleic acid sequences encoding a synthetic or semi-synthetic set, collection or library of immunoglobulin fragment sequences; and/or a set, collection or library of nucleic acid sequences encoding a set, collection or library of immunoglobulin fragment sequences that have been subjected to affinity maturation.

In particular, in such a method, the set, collection or library of nucleic acid sequences encodes a set, collection, or library of VHs. For example, the set, collection or library of nucleic acid sequences may encode a set, collection or library of domain antibodies or single domain antibodies, or a set, collection or library of amino acid sequences that are capable of functioning as a domain antibody or single domain antibody. In specific embodiments, the set, collection or library of nucleotide sequences encodes a set, collection or library of VHH sequences.

In the above methods, the set, collection or library of nucleotide sequences may be displayed on a phage, phagemid, ribosome or suitable micro-organism (such as yeast), such as to facilitate screening. Suitable methods, techniques and host organisms for displaying and screening (a set, collection or library of) nucleotide sequences encoding amino acid sequences will be clear to the person skilled in the art, for example on the basis of the further disclosure herein. Reference is also made to the review by Hoogenboom in Nature Biotechnology, 23, 9, 1105-1116 (2005).

The invention also relates to amino acid sequences that are obtainable or obtained by the above methods, or alternatively by a method that comprises one of the above methods and in addition at least the steps of determining the nucleotide sequence or amino acid sequence of said immunoglobulin sequence; and of expressing or synthesizing said amino acid sequence in a manner known per se, such as by expression in a suitable host cell or host organism or by chemical synthesis.

In some cases, the methods for producing the amino acid sequences binding specifically to a fungal target as envisaged herein may further comprise the step of isolating from the amino acid sequence library at least one heavy chain variable domain having detectable binding affinity for, or detectable in vitro effect on a sphingolipid target.

These methods may further comprise the step of amplifying a sequence encoding at least one heavy chain variable domain having detectable binding affinity for, or detectable in vitro effect on the activity of a sphingolipid target. For example, a phage clone displaying a particular amino acid sequence, obtained from a selection step of a method described herein, may be amplified by reinfection of a host bacteria and incubation in a growth medium.

In particular embodiments, these methods may encompass determining the sequence of the one or more amino acid sequences capable of binding to a sphingolipid target.

Where a heavy chain variable domain sequence, comprised in a set, collection or library of amino acid sequences, is displayed on a suitable cell or phage or particle, it is possible to isolate from said cell or

phage or particle, the nucleotide sequence that encodes that amino acid sequence. In this way, the nucleotide sequence of the selected amino acid sequence library member(s) can be determined by a routine sequencing method.

5 In further particular embodiments, the methods for producing a heavy chain variable domain as envisaged herein comprise the step of expressing said nucleotide sequence(s) in a host organism under suitable conditions, so as to obtain the actual desired amino acid sequence. This step can be performed by methods known to the person skilled in the art.

10 In addition, the obtained heavy chain variable domain sequences having detectable binding affinity for, or detectable in vitro effect on the activity of a sphingolipid target, may be synthesized as soluble protein construct, optionally after their sequence has been identified.

For instance, the heavy chain variable domain sequences obtained, obtainable or selected by the above methods can be synthesized using recombinant or chemical synthesis methods known in the art. Also, the amino acid sequences obtained, obtainable or selected by the above methods can be produced by genetic engineering techniques. Thus, methods for synthesizing the heavy chain variable domain  
15 sequences obtained, obtainable or selected by the above methods may comprise transforming or infecting a host cell with a nucleic acid or a vector encoding an amino acid sequence having detectable binding affinity for, or detectable in vitro effect on the activity of a sphingolipid target. Accordingly, the amino acid sequences having detectable binding affinity for, or detectable in vitro effect on the activity of a sphingolipid target can be made by recombinant DNA methods. DNA encoding the amino acid  
20 sequences can be readily synthesized using conventional procedures. Once prepared, the DNA can be introduced into expression vectors, which can then be transformed or transfected into host cells such as *E. coli* or any suitable expression system, in order to obtain the expression of amino acid sequences in the recombinant host cells and/or in the medium in which these recombinant host cells reside.

25 It should be understood, as known by someone skilled in the art of protein expression and purification, that the VHH as taught herein produced from an expression vector using a suitable expression system may be tagged (typically at the N-terminal or C-terminal end of the amino acid sequence) with e.g. a His-tag or other sequence tag for easy purification.

Transformation or transfection of nucleic acids or vectors into host cells may be accomplished by a variety of means known to the person skilled in the art including calcium phosphate-DNA co-precipitation,  
30 DEAE-dextran-mediated transfection, polybrene-mediated transfection, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, retroviral infection, and biolistics.

Suitable host cells for the expression of the desired heavy chain variable domain sequences may be any eukaryotic or prokaryotic cell (e.g., bacterial cells such as *E. coli*, yeast cells, mammalian cells, avian cells, amphibian cells, plant cells, fish cells, and insect cells), whether located in vitro or in vivo. For  
35 example, host cells may be located in a transgenic plant.

Thus, the application also provides methods for the production of heavy chain variable domain sequences having detectable binding affinity for, or detectable in vitro effect on the activity of a sphingolipid target comprising transforming, transfecting or infecting a host cell with nucleic acid sequences or vectors

encoding such amino acid sequences and expressing the amino acid sequences under suitable conditions.

In other particular embodiments of these methods, the step of obtaining at least one heavy chain variable domain or functional fragment thereof, which specifically binds to a sphingolipid of a plant pathogen comprises:

- 5
- a) providing a set, collection or library of VHHs or functional variants thereof;
  - b) screening said set, collection or library of VHHs or functional variants thereof for sequences that specifically bind to and/or have affinity for a sphingolipid of a plant pathogen, and optionally
  - c) isolating the VHHs or functional variants thereof that specifically bind to and/or have affinity for a
- 10 sphingolipid of a plant pathogen.

The following non-limiting Examples describe methods and means according to the invention. Unless stated otherwise in the Examples, all techniques are carried out according to protocols standard in the art. The following examples are included to illustrate embodiments of the invention. Those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific

15 embodiments which are disclosed and still obtain a like or similar result without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to

20 those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

Thus, the Figures, Sequence Listing and the Experimental Part/Examples are only given to further illustrate the invention and should not be interpreted or construed as limiting the scope of the invention and/or of the appended claims in any way, unless explicitly indicated otherwise herein.

25 The above disclosure will now be further described by means of the following non-limiting Examples.

## EXAMPLES

### Example 1

#### **Isolation of nucleic acid sequences encoding peptides with affinity for fungal glucosylceramide**

Animal immunizations: VHH's were generated from llamas immunized with fungal glucosylceramide (GlcCer). Llamas were immunized according to standard protocols with 6 boosts of thin Layer Chromatography (TLC)-purified (99%) glucosylceramide (GlcCer) from *Pleurotus citrinopileatus* (Nacalai Tesque). Purified GlcCer was dissolved in a water:methanol:chloroform mixture and spotted on a TLC silica glass plate. Silica with adsorbed GlcCer was scraped from the plate and suspended in phosphate buffer. The suspension was sonicated, mixed with Freund incomplete adjuvant, and used for subcutaneous injections. VHH were also generated from llamas immunized with native germinated fungal or oomycete spores. Llamas were immunized according to standard protocols with 6 boosts of native germinated spores of *Botrytis cinerea* or *Phytophthora infestans* by subcutaneous injections. All llamas remained healthy throughout the immunization process and blood samples were taken before and after immunizations.

Library construction: A phage library of antibodies is a phage population in which each individual phage exposes a unique antigen-binding antibody domain on its surface as a part of a chimeric pIII protein. Peripheral blood mononuclear cells were prepared from blood samples of the immunized llamas using Ficoll-Hypaque according to the manufacturer's instructions. Total RNA was extracted from these cells and used as starting material for RT-PCR to amplify VHH encoding gene fragments. These fragments were cloned into phagemid vector pASF20. pASF20 is an expression vector that is derived from pUC119 which contains the lacZ promoter, a synthetic leader sequence, a multiple cloning site, a coliphage pIII protein coding sequence, a resistance gene for ampicillin, and an M13 phage origin for single strand production. In frame with the VHH coding sequence, the vector codes for a C-terminal (His)<sub>6</sub> peptide tag and c-myc peptide tag. Phages were prepared according to standard methods (Phage Display of Peptides and Proteins: A Laboratory Manual; Brian K. Kay, Jill Winter, Dr. John McCafferty). 4 libraries each with a clonal diversity equal to or greater than 1E+08 were obtained and phage were produced ensuring presentation of the antibody diversity.

VHH selections by phage display: Phage expressing antigen-binding antibody domains specific for a particular antigen were isolated by selecting the phage in the library for binding to the antigen. Fungal GlcCer were immobilized on polystyrene Maxisorp multiwell plates by dissolving fungal GlcCer in a water:methanol:chloroform mixture or methanol at different concentrations, adding dissolved fungal GlcCer to wells of the multiwell plate, and allowing to dry overnight at room temperature. Wells with coated fungal GlcCer were washed and blocked with 1 % fish gelatin in preparation of VHH selections by phage display. VHH library phages were allowed to bind for two hours at room temperature to wells of 96-well plate coated with fungal GlcCer. To specifically select for phage binding to fungal GlcCer phage were pre-incubated with 1% fish gelatin and/or BSA and/or skimmed milk and/or plant GlcCer and/or mammalian GlcCer. Non-bound phage were removed by extensive washing and bound phage were eluted by competitive elution with RsAFP2 (Osborn et al., 1995) or with trypsin. One to three consecutive

rounds of selection were performed, and the titers of phage from fungal GlcCer-coated wells were compared to titers of phage from blank wells and non-target pathogen sphingolipids for enrichment and specificity, respectively. Enrichments were observed in first and subsequent rounds of selection, and phage populations after one or more selection rounds already showed specificity for fungal GlcCer in ELISA (not shown). Individual clones were picked from first, second and/or third round selections for further characterization by sequence analysis and primary binding assays.

VHH characterization by sequencing and binding assays: The diversity of the obtained antibody or antibody domain population can be rapidly determined using high-throughput DNA sequencing and allows precise quantification of clonal diversity. Antibody or antibody domain binding and specificity of binding to an antigen can be analyzed in assays for binding to that antigen and compared to related and unrelated controls. Each antibody or antibody domain can bind to a specific antigen and possibly to antigenic variants of that antigen. Specificity is the degree to which the binding of an antibody or antibody domain discriminates between antigenic variants. From individual VHH clones that were picked from first, second or third round phage display selections the DNA was amplified in a colony PCR and PCR products were sequenced by Sanger-sequencing. After sequence analysis and based on sequence diversity, VHH were selected for further characterization. To check for species specificity, fungal and non-fungal GlcCer from target and non-target species were used in binding assays. Primary binding assays to identify which clones were functionally selected from the libraries were performed with TLC-purified (99%) GlcCer or GlcCer-enriched Glycosphingolipids (GSL) fractions from *A. brassicicola*, *B. cinerea*, *C. beticola*, *F. culmorum*, *F. graminearum*, *F. oxysporum*, *P. citrinopileatus*, *P. digitatum*, *P. expansum*, or *V. dahlia* (prepared as described in Ternes et al., 2011 JBC 286:11401-14). GlcCer from soybean and porcine GlcCer were purchased from Avanti Polar Lipids. VHH were produced in 96-well deep-well plates and the binding profile of diluted crude VHH-containing periplasmic extracts was assessed in ELISA format. In the same way, binding assays were performed with purified VHH.

From the primary binding assays 130 VHH-containing periplasmic extracts showed to bind fungal GlcCer with higher OD 405 nm values than the unrelated VHH\_A, unrelated VHH\_B and blank. OD 405 nm values demonstrating the specific binding of several of these fungal GlcCer binding VHH's are shown in Figure 1. Sequence analysis revealed 84 unique sequences from the identified set of anti-GlcCer VHH.

Further characterization by differential binding screens: For further characterization, VHH belonging to the abovementioned lead panel were produced in *E.coli* in culture flasks according to standard procedures. Hexahistidine-tagged VHH were purified from the periplasmic extract with TALON metal affinity resin (Clontech), according to the manufacturer's instructions. Purified VHH were concentrated and dialyzed to PBS. VHH were also purified using automated purification systems using a combination of immobilized Nickel IMAC and desalting columns. VHH of the lead panel that scored positively in primary binding assays, were subsequently tested for their specificity towards GlcCer or cell wall fractions from different fungal phytopathogens.

As demonstrated in Figures 2, 3A, 3B and 3C, GlcCer-specific VHH showed specific binding to fungal GlcCer (*Pleurotus citrinopileatus*, *Fusarium oxysporum*) and not to other non-fungal GlcCer or blank non-coated well.

- Surface plasmon resonance: Binding of VHH to fungal GlcCer was characterised by surface plasmon resonance in a Biacore 3000 instrument. Anti-GlcCer VHH 41D01 or unrelated VHH\_A were covalently bound to CM5 sensor chips surface via amine coupling until an increase of 1000 response units was reached. Remaining reactive groups were inactivated. A range of concentrations of in solution *Fusarium oxysporum* GlcCer prepared according to Salio et al., 2013 PNAS 110, E4753–E4761 was injected for 2 minutes at a flow rate of 30  $\mu$ l/min to allow for binding to chip-bound VHH. Running buffer without GlcCer was injected over the chip at the same flow rate to allow spontaneous dissociation of bound fungal GlcCer for 10 minutes. A  $K_{off}$ -value was calculated from the sensorgrams obtained for the different fungal GlcCer concentrations with 1:1 Langmuir dissociation global fitting model.
- 10 For anti-GlcCer VHH a slow off-rate of  $4.86 \times 10^{-4}$ /s was calculated. As shown in figure 4, an unrelated VHH did not bind fungal GlcCer.
- Plant (soy), mammalian (pork) and fungal (*Fusarium oxysporum*) GlcCer in solution were sequentially injected for 2 minutes at a flow rate of 30  $\mu$ l/min to allow for binding to chip-bound VHH (anti-GlcCer VHH 41D01 or unrelated VHH\_A). Running buffer without GlcCer was injected over the chip between each
- 15 injection at the same flow rate to allow spontaneous dissociation of bound GlcCer.
- No plant or mammalian GlcCer binding to anti-GlcCer VHH 41D01 or unrelated VHH\_A was observed. Specific binding of fungal GlcCer was observed for anti-GlcCer VHH 41D01 and not for unrelated VHH\_A.
- Differential binding to different fungal lipid extracts: The binding of anti-GlcCer VHH compositions to different fungal lipid extracts compared to unrelated compounds.
- 20 Fungal extracts were prepared according to Rodrigues et al. 2000 *Infection and Immunity* 68 (12): 7049–60. Briefly, mycelium from *Botrytis cinerea* B05-10, *Botrytis cinerea* MUCL401, *Botrytis cinerea* R16, *Botrytis cinerea* (own pear isolate), *Fusarium culmorum* MUCL555, *Fusarium graminearum* MUCL53451, *Penicillium digitatum* MUCL43-410, *Penicillium digitatum* (own lemon isolate) or *Penicillium expansum* CBS 146.45 were harvested from fungi grown in agar plates and lipids were extracted with
- 25 chloroform/methanol 2:1 (vol/vol) and 1:2 (vol/vol); crude lipid extract was partitioned according to Folch et al. 1957. *Journal of Biological Chemistry* 226 (1): 497–509. Fungal lipid extracts were recovered from Folch's lower phase. Binding of anti-GlcCer VHH 41D01 (0.1  $\mu$ g/ml) and anti-GlcCer VHH 56F11 (1  $\mu$ g/ml) was evaluated to wells coated with the extracted fungal lipids (each in 1/20 dilution), purified *Fusarium oxysporum* GlcCer, purified *Pleurotus citrinopileatus* GlcCer and unrelated compounds: apple pectin (Apple pectin high esterified 70-75%, Sigma, cat#: 76282), citrus pectin (Citrus pectin low esterified 20-34%, Sigma, cat# P9311) or potato lectin (*Solanum Tuberosum* Lectin, Vector labs, cat#: L-1160) or a blank non-coated well. Binding was measured after consecutive incubation with enzyme-conjugated detection antibodies, adding substrate, and measuring absorbance at 405nm. Bars represent average OD 405 nm values, error bars represent standard errors of the mean of  $n = 2$ .
- 35 As shown in Figure 5, anti-GlcCer VHH 41D01 and 56F11 specifically recognized all the fungi lipid extracts tested. Anti-GlcCer VHH 41D01 and 56F11 did not show binding to unrelated coated compounds or non-coated wells. The binding of the anti-GlcCer VHH compositions to a wide array of fungal lipids

extracts potentiates a variety of applications for the anti-GlcCer VHH compositions as disclosed herein against different fungi.

Binding of anti-GlcCer VHH to fungal GlcCer in different aqueous compositions:

Aqueous compositions containing anti-GlcCer VHH 41D01 and/or protease inhibitors and/or non-ionic surfactants and/or preservatives were prepared. Composition A1 (protease inhibitors: 0.06 µg/ml aprotinin (Roche, cat#: 10236624001), 0.5 µg/ml leupeptin (Roche, cat#: 11017101001), 24 µg/ml 4-benzenesulfonyl fluoride hydrochloride (Sigma, A8456), 1 mM EDTA (Carl-Roth, cat# 8040.1) and non-ionic surfactant: 0.00001% Polysorbate 20 (Tween<sup>20</sup>, Sigma, cat# P2287); Composition A2 (protease inhibitors: 1 µg/ml aprotinin, 2.5 µg/ml leupeptin, 100 µg/ml 4-benzenesulfonyl fluoride hydrochloride, 1 mM EDTA and non-ionic surfactant: 0.05% Polysorbate 20); Composition A3 (protease inhibitors: 2 µg/ml aprotinin, 5µg/ml leupeptin, 240 µg/ml 4-benzenesulfonyl fluoride hydrochloride, 1 mM EDTA and non-ionic surfactant: 5% Polysorbate 20), Composition B1 (non-ionic surfactant: 0.0001%% Polysorbate 20), Composition B2 (non-ionic surfactant: 0.05% Polysorbate 20), Composition B3 (non-ionic surfactant: 5% Polysorbate 20) and Composition C1 (preservative: 0.05% sodium benzoate (Sigma, cat# B3420)).

Binding of anti-GlcCer VHH (at 0.1µg/ml) to fungal GlcCer in different aqueous compositions was tested in ELISA with coated GlcCer from *F. oxysporum* and compared to blank non-coated wells. Binding was measured after consecutive incubation with enzyme-conjugated detection antibodies, adding substrate and measuring absorbance at 405nm.

In Figure 6, values of GlcCer-specific VHH 41D01 in the different compositions were compared with 41D01 in solution without other additives. It is shown in Figure 6 that GlcCer-specific VHH 41D01 was capable of specifically binding to fungal GlcCer in all tested compositions.

**Example 2**

**Generation of transgenic plants according to embodiments of the present invention**

Arabidopsis has been transformed with different vectors for the expression of polynucleotides encoding VHH specifically binding to a sphingolipid of a plant pathogenic fungus. The polynucleotides comprise at least one sequence encoding a targeting signal for secretion (e.g., 2S2), for localization to the cytoplasm (e.g., start codon), or for location to the endoplasmatic reticulum (e.g., KDEL), as schematically illustrated in Figure 7. The transgenic Arabidopsis plants are analyzed in bioassays with different plant pathogenic fungi.

Transgenic plants comprising a polynucleotide encoding VHH 41D01 were made. Also, transgenic plants comprising a polynucleotide encoding VHH 56F11 were made. The nucleotide sequence of the polynucleotides encoding VHH 41D01 and VHH 56F11 are respectively represented by SEQ ID NO: 336 and SEQ ID NO: 337.

Different chimeric constructs were made comprising each of the polynucleotides encoding VHH 41D01 and 56F11 and polynucleotides encoding various tag sequences, signal sequences, spacer sequences, hinge sequence, and/or Fc sequences. These different chimeric constructs are listed in Table 4.

Table 4: Chimeric constructs for generating transgenic plants according to embodiments of the present invention

Construct name	Targeting	SEQ ID NO
41D01_His_KDEL	ER	338
sec_41D01_hinge_Fc_His	secreted	339
sec_41D01-9GS-41D01_His	secreted	340
sec_41D01_His	secreted	341
cyto_41D01_His	cytoplasmatic	342
56F11_His_KDEL	ER	343
sec_56F11_hinge_Fc_His	secreted	344
sec_56F11-9GS-56F11_His	secreted	345
sec_56F11_His	secreted	346
cyto_56F11_His	cytoplasmatic	347

41D01: VHH1 (SEQ ID NO: 336); His: His6 tag, consists of 6 His repeats (SEQ ID NO: 348); KDEL: ER retention signal (SEQ ID NO: 349); sec: 2S2 seed storage protein gene signal peptide (SEQ ID NO: 350); Fc: Fc from mouse IgG3 (SEQ ID NO: 351); 9GS: spacer, consisting of GGGGSGGGS (SEQ ID NO: 352); hinge: mouse IgG3 hinge (SEQ ID NO: 353); cyto: addition of an ATG start codon; 56F11: VHH2 (SEQ ID NO: 337); ER: endoplasmatic reticulum.

- 5 Table 5 lists the protein sequence of the various tags, signal sequences, spacers, hinge regions, or Fc used to generate the different chimeric constructs.

Table 5: Protein sequence of the elements used to generate chimeric constructs

Sequence elements	SEQ ID NO
His6	348
ER retention signal	349
2S2 seed storage protein gene signal peptide	350
Fc of mouse IgG3	351
9GS	352
Mouse IgG3 hinge	353

- 10 The chimeric constructs of Table 4 were placed under transcriptional control of the 35S CaMV promoter (SEQ ID NO: 354) in the pK7WG2 destination vector (see further below).

### **Generation of entry vectors**

The vectors listed in Table 6 were ordered at GeneArt® Gene Synthesis (Life technologies).

Table 6: Vectors used to generate entry vectors

Vector number	Vector name
1	pMA_56F11-KDEL
2	pMA_sec-bi56F11
3	pMA_sec-56F11Fc
4	pMA_sec-56F11

Vector number	Vector name
5	pMA_41D01-KDEL
6	pMA_sec-bi41D01
7	pMA_sec-41D01Fc
8	pMA_sec-41D01

KDEL: 4 amino acid sequence (K, D, E, and L) to retain the expressed VHH in the endoplasmic reticulum (ER); sec: 2S2 signal peptide (to target the expressed VHH to the secretory pathway); bi: indicates that the VHH is expressed as a bivalent; Fc: 'fragment crystallizable' chain of the mouse IgG3 antibody

- 5 PCR amplification of these sequences was done using specific primers (pMA\_FW and pMA\_REV) to introduce restriction sites (EcoRI + BamHI). A second set of primers (pCYTO\_FW and pMA\_REV) was used to introduce a cytoplasmic targeting signal. For this, sequence 4 and 8 were used as a template. The sequences of pMA\_FW, pMA\_REV, and pCYTO\_FW are listed in Table 7.

Table 7: Nucleic acid sequences of the primers used for PCR amplification

Primer	Nucleic acid sequence	SEQ ID NO
pMA_FW	TTGTAAAACGACGGCCAG	355
pMA_REV	GGAAACAGCTATGACCATGT	356
pMA_CYTO	CCGGAATTCCCACCATGCAGGTTTCAGCTGCAGGAAT (underlined section overlaps with N-terminal VHH ends)	357

- 10 Restriction digest was performed on both amplified fragments and the entry vector E-IgG3-GmR. This vector introduces AttL1 and AttL2 sites for further downstream Gateway-compatible cloning. Digested sequence fragments and vector fragment were purified (using a purification kit for the sequence fragments and in-gel purification for the vector fragment).

Digested sequence fragments were ligated into the digested E-IgG3-GmR vector.

- 15 Next, the obtained entry clones (10 in total: 2x VHH-KDEL, 2x sec-VHH, 2x sec-biVHH, 2x sec-VHH-Fc and 2x cyto-VHH) were used for transformation of DH5α *E. coli* cells.

Per entry clone, 10 colonies were checked via colony-PCR. Of each construct, up to 4 positive clones were plated again, to screen for single colonies. Next, colony-PCR was performed on the generated single colonies using a high-fidelity polymerase (Phusion PCR, New England Biolabs).

- 20 The PCR products resulting from this Phusion PCR (35 in total) were sent to LGC Genomics for sequence analysis.

### **Generation of expression vectors**

- 25 All 35 entry vectors (representing 10 different entry vector constructs in total) that were sent for sequencing, were initially continued with. DNA was purified of each construct, and used for LR reaction (Gateway cloning) to the pK7WG2 destination vector (Plant Systems Biology (Karimi et al., "Gateway

vectors for Agrobacterium-mediated plant transformation". Trends Plant Sci. 2002 May;7(5): 193-195); SEQ ID NO: 358).

The obtained expression clones were used for transformation of DH5 $\alpha$  E.coli cells.

5 Based on the obtained sequencing results from the 35 entry clones, a positive candidate for each of the 10 different entry vector constructs was selected.

Per expression clone, 2 colonies were checked via colony-PCR. From 1 positive clone per expression clone, plasmid was prepared and sent for sequence analysis (VIB sequence service facility).

A glycerol bank of DH5 $\alpha$  *E. coli* cells containing each of the 10 entry clones and each of the 10 expression clones was established (20 entries in total). The 10 expression vectors are listed in Table 8.

10 Table 8: Expression vectors for generating plants according to embodiments of the present invention

Construct name	Targeting	SEQ ID NO
pK7WG2-41D01_His_KDEL	ER	359
pK7WG2-sec_41D01_hinge_Fc_His	secreted	360
pK7WG2-sec_41D01-9GS-41D01_His	secreted	361
pK7WG2-sec_41D01_His	secreted	362
pK7WG2-cyto_41D01_His	cytoplasmatic	363
pK7WG2-56F11_His_KDEL	ER	364
pK7WG2-sec_56F11_hinge_Fc_His	secreted	365
pK7WG2-sec_56F11-9GS-56F11_His	secreted	366
pK7WG2-sec_56F11_His	secreted	367
pK7WG2-cyto_56F11_His	cytoplasmatic	368

### **Transformation of expression vectors into Agrobacterium and Arabidopsis transformation**

15 Each of the 10 expression constructs (SEQ ID NOs: 359-368) was transformed into Agrobacterium strain C58C1 Rif<sup>R</sup>(pMP90); (Koncz and Schell (1986) Mol. Gen. Genet. 204, 383-396). Colonies were checked for the presence of the expression vector via colony-PCR. For each of the 10 expression constructs, a positive strain was identified.

Of these positive strains, a glycerol bank was established.

20 The same positive strains were used for the transformation of Arabidopsis Col-0 WT plants using floral dipping. Five plants were dipped per construct. The floral dip transformation protocol is described in Clough SJ, Bent AF (1998) Floral dip: a simplified method for Agrobacterium-mediated transformation of Arabidopsis thaliana. Plant J 16: 735-743.

Floral dip transformation of Arabidopsis generated T1 seeds after 6 weeks. Per construct, 300-400 mg of T1 seed was obtained.

T1 seeds were sterilized by bleach and ethanol, and sown on K1 medium, supplemented with kanamycin (50 mg/L), nystatin (50 mg/L) and vancomycin (750 mg/L). After sowing with 7 ml of 0.1% agarose, plates were first incubated for 4 nights at 4°C, then transferred to the growth chamber. For each construct, 30 kanamycin-resistant T1 plants were transferred to soil and further allowed to set seed .

5

### **VHH expression analysis**

*T1 plants - confirmation of VHH expression:*

#### **VHH expression analysis (protein level) in isolated leaves from T1 plants by Western blotting**

For each construct (10 in total), VHH protein expression analysis was performed for 30 T1 plants. From each T1 plant, 2 leaves were cut and harvested in 2-ml eppendorfs, cooled in liquid nitrogen and crushed for 2 min at 20 Hz with two steel, 4-mm balls. The powder was dissolved in 100 µl extraction buffer (20 mM Pi, 300 mM NaCl, 0.1% CHAPS, pH 7.8, cOmplete® protease inhibitor) and centrifuged (10min, max speed, 4 °C) to spin down the cell debris. The supernatant was transferred to a fresh eppendorf and centrifuged again (10min, max speed, 4 °C). Ninety µl of final supernatant was kept, 22.5 µl of glycerol was added and the extract was stored at -20 °C. Total protein content of each extract was determined by Bradford analysis. The total protein concentrations ranged from 0.5 to 4 mg/ml.

Protein extracts were analysed by SDS-PAGE (12% TGX gels; Bio-Rad) followed by Western blotting (WB). For SDS-PAGE analysis, a volume corresponding with 10µg of total protein content of each extract was loaded onto gel. WB detection was performed in 2 steps: the primary antibody was a mouse anti-His (Serotec; 1/1000 dilution). The secondary antibody comprised a mixture of 2 antibodies: sheep anti-mIgG-HRP (GE; 1/5000 dilution) and anti-IgG1-HRP (Sigma; 1/1000 dilution). For the constructs that contain the Fc fragment, detection was performed in a single step using goat anti-mouse IgG3-HRP (Sigma; 1/5000 dilution). All events for which a band appeared that corresponded with the appropriate size of the VHH-construct were considered as events in which the VHH-construct was expressed.

From the WB analysis, it became clear that expression was highest for VHHs fused to an Fc fragment. It was decided to continue analysis with the constructs `sec_41D01_hinge_Fc_HIS` and `sec_56F11_hinge_Fc_HIS`.

T1 plants that showed expression of VHH on WB were further allowed to set seed and T2 seed were harvested for segregation analysis.

30

#### *T2 plants - segregation analysis*

T2 seeds were sterilized by bleach and ethanol, and sown on K1 medium, supplemented with kanamycin (50 mg/L), nystatin (50 mg/L) and vancomycin (750 mg/L). After sowing with 7 ml of 0.1% agarose, plates were first incubated for 4 nights at 4°C, and then transferred to the growth chamber. To identify lines containing the expression construct at a single locus in the genome, plates were scored for the ratio of the number of kanamycin-sensitive to resistant seedlings, and plates for which this ratio diverged from 1:3

35

were discarded. For the single-copy lines which showed the highest VHH expression, 10 plants were transferred to soil and further allowed to set seed. T3 seed were harvested for zygosity analysis.

#### *T3 plants - zygosity analysis*

- 5 T3 seeds were sterilized by bleach and ethanol, and sown on K1 medium, supplemented with kanamycin (50 mg/L), nystatin (50 mg/L) and vancomycin (750 mg/L). After sowing with 7 ml of 0.1% agarose, plates were first incubated for 4 nights at 4°C, and then transferred to the growth chamber. Plates were scored for the number of kanamycin-resistant seedlings, and plates for which not all seedlings were resistant were discarded. For the remaining homozygous lines, plants were transferred to soil for seed  
10 propagation.

### **Example 3**

#### **Functional assays**

##### *Glucosylceramide binding assay*

- 15 Leaf extract from a homozygous single-copy event of *Arabidopsis* overexpressing sec\_56F11\_hinge\_Fc\_HIS was tested in an ELISA for binding of glucosylceramide (GlcCer). For this, wells of a multi-well plate (Greiner Bio-one, µClear, black, half area, high bind) was coated with 250 ng (50 µl of a 5 µg/ml solution) of GlcCer purified from *Fusarium oxysporum*. After coating, the plate was blocked with 1% gelatin in PBS for 1h. The blocking agent was removed and the plate incubated with 50  
20 µl of (diluted) leaf extract for 1h. Next, the plate is washed 3 times with PBS. The plate is incubated with mouse anti-His (Serotec) for 1h. After washing the plate 3 times with PBS, the plate was incubated with anti-mouse IgG/alkaline phosphatase antibody (Sigma) for 1h. After washing 3 times with PBS, the plate was developed by adding ELISA buffer (100mM Tris-HCl; 100mM NaCl; 5mM MgCl; pH 9,5; containing 2mg/ml PNPP ELISA substrate (Sigma)) in each well. After 5 min, the absorbance at 405 nm was  
25 measured. As a control, uncoated wells were used. Figure 8 shows the specific binding of sec\_56F11\_hinge\_Fc\_HIS in leaf extract to fungal GlcCer.

##### *Botrytis cinerea* infection assay

- 30 *A. thaliana* wild-type (Col-0) and plants overexpressing sec\_41D01\_hinge\_Fc\_HIS and sec\_56F11\_hinge\_Fc\_HIS were grown for five weeks in soil ("DCM potgrond voor Zaaïen en Stekken", DCM, Sint-Katelijne-Waver, Belgium) in a growth chamber with 21°C, 75% humidity and a 12-h day-light cycle with a light intensity of approximately 120 µmol/m<sup>2</sup>s. A 5 µL drop of a *B. cinerea* spore suspension (B05.10, 5 x 10<sup>4</sup>/mL in ½ PDB) was inoculated onto three leaves per plant. Plants were kept in transparent sealed boxes to retain almost 100 % humidity after inoculation. Disease symptoms were

scored by measuring the diameters of the necrotic lesions on 3, 4 and 7 days post inoculation (dpi). Twenty plants per line and condition, divided over 5 boxes, were analyzed.

Figure 9A shows increased resistance against *B. cinerea* in plants expressing VHH against fungal GlcCer as compared to wild-type plants.

- 5 A further infection assay was performed under identical conditions using twenty four plants per line and condition, divided over 6 boxes. A different line of plants overexpressing sec\_41D01\_hinge\_Fc\_HIS was used than in the first bioassay. Figure 9B confirms increased resistance against *B. cinerea* in plants expressing VHH against fungal GlcCer as compared to wild-type plants.

#### 10 **Example 4**

##### **In vitro evaluation of the antifungal activity of anti-GlcCer VHH-containing leaf extract**

From a homozygous single-copy event of Arabidopsis overexpressing anti-GlcCer VHH, 2 leaves are cut and harvested in 2-ml eppendorfs, cooled in liquid nitrogen and crushed for 2 min at 20 Hz with two steel, 4-mm balls. The powder is dissolved in 100 µl extraction buffer (20 mM Pi, 300 mM NaCl, 0.1% CHAPS, 15 pH 7.8, cOmplete® protease inhibitor) and centrifuged (10min, max speed, 4 °C) to spin down the cell debris. The supernatant is transferred to a fresh eppendorf and centrifuged again (10min, max speed, 4 °C). This final supernatant is used in the antifungal bioassay.

The antifungal activity of anti-GlcCer VHH-containing leaf extract is tested using antifungal assays in liquid media and on agar plates as described in Thevissen et al., 2011, Bioorg. Med. Chem. Lett. 21(12): 3686-92; François et al., 2009, J. Biol. Chem. 284(47): 32680-5; Aerts et al., 2009, FEBS Lett. 583(15): 25143-6. The inhibitory action is determined for the anti-GlcCer VHH-containing leaf extract on *in vitro* growth of *Botrytis cinerea* and *Phytophthora infestans*.

Two-fold dilutions of the anti-GlcCer VHH-containing leaf extract in water are prepared in 96-well microtiter plates. To 20 µl of these dilutions and to 20 µl of water as a control, 80 µl of fungal spores suspension (1E+05 spores/ml in half strength potato dextrose broth (PDB)) are added. The fungal test strains are *Alternaria brassicicola* MUCL20297, *Botrytis cinerea* R16, *Cercospora beticola* (own sugar beet isolate), *Fusarium culmorum* MUCL555 and *Verticillium dahliae* MUCL6963. The test plates are incubated for 72h at room temperature in the dark and the antifungal activity of the test compounds is scored microscopically and quantified based on photographic standards, whereby a score of 0 or 100 25 refers to no or maximal fungal growth, respectively. All tests are performed in at least 2 replicas.

The results of the antifungal activity assays, indicate a clear difference between the growth inhibition pattern, expressed as the % fungal growth in function of dilution of the anti-GlcCer VHH-containing leaf extract. This difference is clear irrespective of the species of the test fungus.

The results show the antifungal potency of anti-GlcCer VHH-containing leaf extract. Moreover, the results 35 reveal a broad-spectrum of antifungal activity of anti-GlcCer VHH-containing leaf extract towards at least 5 different fungal plant pathogens and indicate that the spectrum of antifungal activity of the selected anti-GlcCer VHH-containing leaf extract can be broadened to other plant pathogenic fungi.

**Example 5****In planta evaluation of the antifungal activity of leaf extracts containing anti-GlcCer VHH to protect crops against fungal infection**

- 5 Efficacy of leaf extracts containing anti-GlcCer VHH on tomato leaves inoculated with *Botrytis cinerea*: preventive treatment.

Leaf extract from homozygous single-copy event of *Arabidopsis* overexpressing anti-GlcCer VHH is tested in a *Botrytis cinerea* infection assay on tomato. The effect of a preventive treatment with plant extracts containing anti-GlcCer VHH on the disease severity of *Botrytis cinerea* B05-10 inoculated tomato leaves is evaluated and compared with the effect of water.

Leaves from greenhouse grown tomato plants are treated with 10 µl of VHH-containing leaf extract and water. Upon drying of the applied compositions, 10 µl drops of a *Botrytis cinerea* spores suspension (6E+06 spores/ml in 4-fold diluted PDB) are applied on the treated surfaces. Treated and inoculated leaves are incubated at high relative humidity and at room temperature in small plant propagators.

15 Disease severity is scored measuring the bidirectional diameter at 6 days post inoculation (dpi).

Preventive treatment with the anti-GlcCer VHH composition results in a smaller average lesion diameter than treatment with water. Preventive treatment of tomato leaves with the application of the anti-GlcCer VHH-containing leaf extract clearly results in a reduction of disease severity compared with the treatment with water. Therefore, anti-GlcCer VHH-containing leaf extracts show the potency to be used as

20 antifungal compounds to protect crops against fungal pathogens in agricultural applications.

**Efficacy of anti-GlcCer VHH compositions on tomato leaves inoculated with *Botrytis cinerea*: curative treatment.**

The effect of a curative treatment with anti-GlcCer VHH-containing leaf extract on the disease severity of *Botrytis cinerea* B05-10 inoculated tomato leaves is evaluated and compared with the effect of water.

Leaves from greenhouse-grown tomato plants are inoculated with 10 µl drops of a *Botrytis cinerea* spores suspension ((6E+06 spores / ml) in 4-fold diluted PDB). One hour after inoculation, the inoculated spots on the leaves are treated with 10 µl of VHH-containing leaf extract and water. Inoculated and treated leaves are incubated at high relative humidity and at room temperature in small plant propagators.

30 Disease severity is scored measuring the bidirectional diameter at 5 dpi.

Curative treatment with anti-GlcCer VHH-containing leaf extract results in a smaller average lesion diameter than treatment with water. Curative treatment of tomato leaves with the application of anti-GlcCer VHH-containing leaf extract clearly results in a reduction of disease severity compared with the

treatment with water Therefore, anti-GlcCer VHH-containing leaf extracts show the potency to be used as antifungal compounds to protect crops against fungal pathogens in agricultural applications.

**CLAIMS**

1. A transgenic plant or plant tissue or plant cell comprising at least one polynucleotide comprising at least one sequence encoding a variable domain of a heavy-chain antibody (VHH) specifically binding to a sphingolipid of a fungus, preferably to a ceramide of a fungus, more preferably to a glycosphingolipid of a fungus, even more preferably to a cerebroside of a fungus, yet more preferably to a glucocerebroside of a fungus.  
5
2. The transgenic plant or plant tissue or plant cell according to claim 1, wherein the expression of the polynucleotide in at least part of the transgenic plant or plant tissue or plant cell (i) protects at least part of the transgenic plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, (ii) inhibits the growth of a plant pathogenic fungus on at least part of the transgenic plant or plant tissue or plant cell, and/or (iii) increases the resistance of at least part of the transgenic plant or plant tissue or plant cell against a plant pathogenic fungus.  
10
3. The transgenic plant or plant tissue or plant cell according to claim 1 or 2, wherein the polynucleotide comprises a promoter suitable for expression in plants, a plant tissue or plant cell specific promoter, or an inducible promoter.  
15
4. The transgenic plant or plant tissue or plant cell according to any one of claims 1 to 3, wherein the polynucleotide comprises at least one sequence encoding a targeting signal for secretion, for location to the cytoplasm, or for location to cellular compartments or organelles, such as the endoplasmatic reticulum (ER) lumen, the apoplast, the vacuole, or intra- and/or exterior membranes.  
20
5. The transgenic plant or plant tissue or plant cell according to any one of claims 1 to 4, wherein the polynucleotide encodes the VHH as such, as a combination with one or more identical or different VHHs, or as a combination with one or more identical or different VHHs with a fragment crystallizable region (Fc region); optionally with a spacer.
- 25 6. The transgenic plant or plant tissue or plant cell according to any one of claims 1 to 5, wherein the plant is a plant selected from the group consisting of corn, rice, wheat, barley, sorghum, millet oats, rye, triticale or other cereals, soybean, alfalfa or other leguminous crops, sugar beet, fodder beet, papaya, banana and plantains or other fruits, grapevines, nuts, oilseed rape, sunflower or other oil crops, squash cucumber, melons or other cucurbits, cotton or other fiber plants, sugarcane, palm, jatropha or other fuel crops, cabbages, tomato, pepper or other vegetables, ornamentals, shrubs, poplar, eucalyptus or other trees, evergreens, grasses, coffee plants, tea plants, tobacco plants, hop plants, rubber plants, and latex plants.  
30
7. The transgenic plant or plant tissue or plant cell according to any one of claims 1 to 6, wherein the polynucleotide comprises a sequence encoding a VHH comprising:  
35 (i) any one or more of SEQ ID NO 1 to 84, preferably SEQ ID NO 1, 2, and/or 70, more preferably SEQ ID NO 1 and/or 2, and/or

(ii) a CDR1, CDR2, and CDR3 region, wherein (i) the CDR1 region is selected from the group of SEQ ID NOs 85-168, and/or (ii) the CDR2 region is selected from the group of SEQ ID NOs 169-252, and/or (iii) the CDR3 region is selected from the group of SEQ ID NOs 253-335, or the CDR3 region has the amino acid sequence NRY.

- 5 8. Harvestable parts and propagation materials of a transgenic plant or plant tissue or plant cell according to any one of claims 1 to 7, comprising at least one polynucleotide as defined in any one of claims 1 to 7.
9. The harvestable parts and propagation materials according to claim 8, wherein the harvestable parts and propagation materials of a transgenic plant or plant tissue or plant cell are selected from  
10 the group consisting of seeds, fruits, grains, bulbs, bolls, tubers, progeny, and hybrids.
10. A method for the production of a transgenic plant or plant tissue or plant cell comprising the introduction of at least one polynucleotide as defined in any one of claims 1 to 7 into the genome of a plant or plant tissue.
11. A method for protecting at least part of a plant or plant tissue or plant cell from an infection with a  
15 plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, comprising expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide encoding a variable domain of a heavy-chain antibody (VHH) specifically binding to a pathogen.
- 20 12. The method according to claim 11, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, for inhibiting the growth of a plant pathogenic fungus on at least part of a plant or plant tissue or plant cell, and/or for increasing resistance of at least part of a plant or plant tissue or plant cell against the plant pathogenic fungus, comprising  
25 expressing in at least part of the plant or plant tissue or plant cell at least one polynucleotide as defined any one of claims 1 to 7.
13. Use of at least one polynucleotide encoding a variable domain of a heavy-chain antibody (VHH) specifically binding to a pathogen, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a  
30 plant or plant tissue or plant cell, wherein the polynucleotide is expressed in at least part of the plant or plant tissue.
14. The use according to claim 13, for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogenic fungus, for inhibiting the growth of a plant pathogenic fungus on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of  
35 at least part of a plant or plant tissue or plant cell, wherein the polynucleotide is defined as in any one of claims 1 to 7.

15. An extract of a transgenic plant or plant tissue or plant cell according to any one of claims 1 to 7, said extract comprising said VHH.
16. A composition comprising the extract of claim 15.
- 5 17. A method for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell, comprising treating said at least part of a plant or plant tissue or plant cell with the extract of claim 15 or the composition of claim 16.
- 10 18. Use of the extract of claim 15 or the composition of claim 16 for protecting at least part of a plant or plant tissue or plant cell from an infection with a plant pathogen, for inhibiting the growth of a plant pathogen on at least part of a plant or plant tissue or plant cell, and/or for increasing pathogen resistance of at least part of a plant or plant tissue or plant cell.

Figure 1




Figure 2




Figure 3A




Figure 3B




Figure 3C




Figure 4




Figure 5





Figure 6




Figure 7




Figure 8




Figure 9A




Figure 9B

